预约演示
更新于：2025-12-04
Amino Acids
复方氨基酸
更新于：2025-12-04
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1971-09-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
74
项与 复方氨基酸 相关的临床试验NCT07030933
Amino Acid Infusion in Cardiac Surgery
The goal of this study is to see if an infusion of amino acids given to adult male and female patients during cardiac surgery can help prevent acute kidney injury that commonly occurs when patients undergo cardiac surgery needing cardiopulmonary bypass. The main question the study aims to answer is if a short infusion of amino acids given to study participants during their scheduled heart surgery can decrease rates of acute kidney injury - which will be measured by biological markers of kidney injury in the urine.
The study will be conducted in 2 phases. Participants in the first phase will receive the current standard of anesthetic care for patients having heart surgery and markers of acute kidney injury will be measured before and after their surgery. Participants in the second group will receive the anesthetic standard of care plus a short infusion of amino acids during their surgery. They will also have markers of kidney injury measured before and after their surgery. This study is based on prior studies that showed amino acid infusions are protective against kidney injury; however, these past studies did not look at markers of kidney injury in the urine.
The study will be conducted in 2 phases. Participants in the first phase will receive the current standard of anesthetic care for patients having heart surgery and markers of acute kidney injury will be measured before and after their surgery. Participants in the second group will receive the anesthetic standard of care plus a short infusion of amino acids during their surgery. They will also have markers of kidney injury measured before and after their surgery. This study is based on prior studies that showed amino acid infusions are protective against kidney injury; however, these past studies did not look at markers of kidney injury in the urine.
开始日期2025-11-01 |
申办/合作机构 |
NCT07212595
Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy
The goal of the BRAVE-HEART study is to learn if an amino acid infusion can reduce the risk of developing acute kidney injury after cardiac surgery in children. The main questions it aims to answer are:
1. Does an amino acid infusion decrease the number of participants with acute kidney injury?
2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?
Researchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.
Participants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.
1. Does an amino acid infusion decrease the number of participants with acute kidney injury?
2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?
Researchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.
Participants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.
开始日期2025-11-01 |
ChiCTR2500113364
A Multicenter, Prospective, Real-World Study to Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition
开始日期2025-09-23 |
申办/合作机构 |
100 项与 复方氨基酸 相关的临床结果
登录后查看更多信息
100 项与 复方氨基酸 相关的转化医学
登录后查看更多信息
100 项与 复方氨基酸 相关的专利（医药）
登录后查看更多信息
501
项与 复方氨基酸 相关的文献（医药）2025-12-01·Journal of Advanced Research
Factors affecting the intracytoplasmic sperm cell injection outcomes: A meta-analysis of porcine studies
Review
作者: Xu, Kaixiang ; Wei, Hong-Jiang ; Husnain, Ali ; Jamal, Muhammad Ameen
BACKGROUND:
Intracytoplasmic sperm cell injection (ICSI) has the potential to produce gene-edited (GE) pigs for biomedical research, but its success is limited. The factors impeding ICSI in pigs are impractical in-vivo oocyte production, incomplete cytoplasmic maturation of in-vitro matured (IVM) oocytes, inefficient methods for sperm selection and membrane removal, abnormal sperm nucleus decondensation, substandard protocols for oocyte stimulation, suboptimal in-vitro culture (IVC) systems, and high embryonic/fetal losses.
AIM OF REVIEW:
The aim of this review is to investigate the effects of interventions in ICSI on oocyte activation, fertilization, cleavage, blastocyst, blastomere count, and live birth by means of robust statistical meta-analytical methods.
KEY SCIENTIFIC CONCEPTS OF REVIEW:
A total of 61 studies published between 1905 ∼ 2024 met the inclusion criteria. The results of the meta-analysis suggested that manipulation in the IVM media did not improve oocyte developmental competency to blastocysts but increased the blastomere count, especially with the addition of thiol compounds. Consistently, manipulation with sperm was beneficial only for increasing the cleavage and blastomere count. Exogenous stimulation increased the relative risk (RR) for oocyte activation (10 %), fertilization (33 %), cleavage (18 %), and blastocyst formation (71 %) but did not affect the blastomere count. Chemical stimulation either pre- or post-ICSI was more beneficial than electrical stimulation. Manipulation of the culture increased the RR for oocyte activation (14 %) and fertilization (37 %) but did not benefit cleavage, blastocyst formation, or blastomere count. The subgroup analyses revealed that supplementation with thiol compounds was indeed beneficial. Our network meta-analysis also supported the findings of classical meta-analyses showing that cysteine, cysteamine, epidermal growth factor, amino acid supplementation in maturation and culture media, and Triton treatment of sperm improved blastocyst formation. The overall success rate of live births from total embryos transferred after ICSI was not greater than 2 %. Although, manipulations that were beneficial for ICSI outcomes were identified in this meta-analysis, however, areas where more robust data are needed to reach a conclusive decision are highlighted.
2025-12-01·CLINICAL NUCLEAR MEDICINE
Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor
Article
作者: Lu, Zhonglin ; Wong, Ka Kit ; Muhleman, Mitchel ; Patterson, Jasmine ; Scott, Peter J. H. ; Frey, Kirk A. ; Viglianti, Benjamin L. ; Akhavanallaf, Azadeh ; Roseland, Molly ; Wang, Ivan E. ; Dewaraja, Yuni K.
Approval of
177
Lu-DOTATATE for the treatment of neuroendocrine tumors (NETs) requires monitoring for therapeutic efficacy and safety. A retrospective review was conducted on 173 patients who received
177
Lu-DOTATATE at the University of Michigan to identify if posology changes would improve therapy tolerance and completion. Patients were followed up to 3 years following their last cycle of treatment to determine long-term adverse events. Dose reduction (from 7.4 GBq to 3.7 GBq) was used in 13 patients, and cycle delay (8±1 wk to >16-week gap) was used in 36 patients, leading to 82% completion of 4 cycles of therapy. Dose reduction led to higher rates for completing all 4 cycles of therapy, whereas cycle delay led to worsened outcomes. Amino acid infusions led to limited adverse events with nausea, vomiting, and fatigue, even with antiemetic prophylaxis. Carcinoid crisis was observed in 1.2% of patients, which was similar to the findings in the NETTER-1 trial. Acute decline in neutrophils and platelets was observed; however, these blood values rebounded. A decline in renal function (4.3 mL/min/1.73 m
2
over 4 years compared with untreated patients) suggests a potential long-term risk for renal toxicity; however, it could also be associated with changes in therapy. When adverse events were severe due to underlying disease, dose reduction, or cycle delay did not adequately impact therapy completion, and required further therapy monitoring. Long-term occurrence of myelodysplasia syndrome was 1.8%, comparable to reported occurrences requiring further monitoring. Our analysis reinforces that
177
Lu-DOTATATE is an effective, well-tolerated treatment for NETs with low incidences of long-term adverse events.
2025-09-30·Physical activity and nutrition
Effects of Amino Acid Supplementation on Muscle protein metabolism and adaptation: a narrative review of effects on muscle mass, strength, and sex differences
Article
作者: Park, Sok ; Noh, Ki-Woong
[Purpose] To review the effects of amino acid supplementation including essential, branched-chain, and non-essential amino acids on muscle mass, strength, and adaptation, with a focus on sex-specific differences.[Methods] PubMed, ScienceDirect, and Google Scholar databases were searched for clinical and nonclinical studies on the effects of supplementation in adults, published between 1990 and 2025.[Results] Essential amino acids and leucine showed the most consistent associations with increased MPS and, in older adults, improvements in strength/lean mass. Branched-chain amino acids supplementation generally attenuated muscle damage/DOMS and helped preserve performance, with benefits appearing context dependent (e.g., energy restriction, high training load). Evidence for non-essential amino acids is preliminary. Signals of greater strength oriented effects in men and greater recovery benefits in women are biologically plausible but largely hypothesis-generating due to single sex cohorts and indirect cross study contrasts.[Conclusion] Amino acid supplementation can support muscle anabolism and, in selected contexts, strength and recovery, best viewed as an adjunct to resistance training with individualized dosing/timing. Progress requires adequately powered, pre registered, sex comparative RCTs that standardize protocols and prespecify functional and structural endpoints to define dose response, timing, and durability across ages and training states.
366
项与 复方氨基酸 相关的新闻（医药）2025-12-03
·知芽汇
“炎症”通常意味着红肿热痛——比如喉咙发炎、皮肤感染，但你是否想过，大脑也可能“发炎”，这种看不见摸不着的“神经炎症”，可能正是自闭症、多动症、抽动症，甚至某些孩子突然出现的强迫行为、情绪崩溃、恐惧进食背后的共同推手。
过去几十年，医学界普遍将这些行为问题归为“心理障碍”或“教养问题”，然而，近年来越来越多的研究揭示：免疫系统不仅守护身体免受病毒细菌侵袭，也深度参与了大脑的发育与功能调节。当免疫反应失调，尤其在生命早期关键窗口期（如孕期或婴幼儿阶段）出现免疫异常激活，就可能干扰神经回路的正常构建，埋下神经发育障碍的种子。
2025年8月，一项发表于国际权威期刊《国际分子科学杂志》的重要综述研究（Gagliano et al., 2025）系统梳理了神经发育障碍（NDDs）与儿童急性发作神经精神综合征（PANS）之间免疫-炎症联系。
这项由意大利、美国等多国科学家合作完成的研究，整合了来自全球上百项高质量研究，提出一个颠覆性观点：这些看似不同的精神行为问题，可能共享一条“免疫-神经炎症”的致病通路。
一、免神经发育障碍(NDDs)：真的是“心理问题”吗？
▸ 神经发育障碍(NDDs)
根据《精神障碍诊断与统计手册》（DSM-5），神经发育障碍 （NDDs）是一大类在儿童期起病、影响大脑发育和功能的疾病统称，主要包括：
· 自闭症谱系障碍(ASD):社交沟通困难、重复刻板行为、兴趣狭窄
· 注意缺陷多动障碍(ADHD):注意力难以集中、坐不住、冲动行事
· 抽动障碍/图雷特综合征(TD/TS):不自主地眨眼、耸肩、清嗓子，甚至发出怪声
· 智力障碍(ID):学习能力、生活自理能力显著低于同龄人
· 特定学习障碍(SLDs):阅读、书写或数学能力严重落后,智力通常正常
长期以来，这些障碍主要依靠行为观察和临床评估来诊断，缺乏明确的生物学标志物，因此，社会上常存在误解：认为这些问题源于“父母管教不当”“孩子懒惰”或“性格古怪”，许多家庭因此承受巨大压力，甚至陷入自责。
▸ 神经发育障碍(NDDs)生理共患病
现代神经科学证实，这些障碍源于大脑结构与功能的生物学差异，更关键的是，大量研究发现，神经发育障碍（NDDs）患者常常伴随其他身体问题：
· 过敏、湿疹、哮喘
· 自身免疫病（如1型糖尿病、桥本甲状腺炎、银屑病）
· 胃肠道问题（如便秘、腹泻、食物不耐受）
· 睡眠障碍、免疫力低下等
这种“共病现象”强烈提示：问题可能不止在大脑，而涉及全身性的生理失衡——尤其是免疫系统的异常，换句话说，孩子的“行为问题”，可能是身体内部“炎症风暴”的外在表现。
二、免疫系统：不只是“卫士”，更是大脑“建筑师”
要理解这一点，我们必须更新对免疫系统的认知，传统观念认为，大脑是一个“免疫豁免”器官——血脑屏障像一道坚固的城墙，将多数免疫细胞和炎症因子挡在外面，确保大脑环境稳定，但近二十年的研究不断完善并修正了这一看法：血脑屏障并非绝对“不可逾越”。
▸ 小胶质细胞：大脑的“常驻免疫工程师”
大脑中有一种特殊的免疫细胞，叫小胶质细胞，它们从胎儿期就开始工作，不仅是“哨兵”，更是“建筑师”：
1. 在发育早期,它们帮助神经元迁移到正确位置
2. 在儿童期，它们“修剪”多余的突触连接,让神经网络更高效
3. 它们还参与髓鞘形成（神经信号的“绝缘层”）,星形胶质细胞调控等关键过程
可以说，没有小胶质细胞的精准调控，就无法形成健康的大脑网络，但如果小胶质细胞被过度激活（如感染或毒素刺激），它们就会从“建设者”变成“破坏者”，释放大量炎症因子，损伤神经元，干扰突触可塑性。
▸ 免疫-脑对话：细胞因子是“信使”
免疫系统通过释放细胞因子（如IL-6、TNF-α、IL-17）等信号分子，与神经元“对话”，这些细胞因子：
1. 影响多巴胺、血清素等神经递质的合成与释放
2. 调节情绪、注意力、冲动控制
3. 改变神经回路的兴奋性与连接强度
因此，免疫系统不仅是防御者，更是大脑发育“合作者”甚至“指挥者”之一。
▸ 关键窗口期：生命最初1000天
从怀孕到孩子2岁，被称为“生命最初1000天”，这一时期，大脑以惊人速度发育，每天生成数百万神经元，建立万亿级连接，而免疫系统与大脑的互动尤为密切。
任何干扰（如母亲感染、压力、营养不良、环境污染）都可能通过免疫机制“编程”胎儿的大脑，使其在出生后对压力、感染等刺激更为敏感，更容易出现神经精神症状。
三、母体免疫激活：孩子大脑健康的“第一道警报”
综述中最引人注目的发现之一，是母亲在怀孕期间的免疫状态对孩子神经发育具有决定性影响。
▸ 什么是“母体免疫激活”（Maternal Immune Activation, MIA）？
当孕妇遭遇以下情况时，免疫系统会被激活，释放大量促炎细胞因子（如IL-6、TNF-α）：
· 感染（如流感、尿路感染、新冠）
· 自身免疫病（如系统性红斑狼疮、桥本甲状腺炎）
· 慢性炎症状态（如肥胖、哮喘、过敏）
这些炎症因子虽不能直接穿过胎盘，却可以：
· 改变胎盘功能，影响营养和氧气供应
· 激活胎儿自身的免疫系统
· 通过表观遗传机制（如DNA甲基化、microRNA调控）“标记”胎儿基因，使其在出生后长期处于高敏状态
▸ 科学证据有多强？
动物实验：
给怀孕小鼠注射模拟病毒的物质，其后代会出现社交退缩、重复行为、注意力缺陷——酷似人类ASD和ADHD。
人群研究：
1. 孕期母体IL-6水平升高，与孩子日后患自闭症、多动症、精神分裂症的风险显著相关
2. 母亲患有哮喘+极度肥胖，女婴患自闭症的风险可增加近17倍
3. 孕期C反应蛋白（CRP，炎症标志物）水平高，孩子10岁时被诊断为ADHD的几率上升40%
这些发现指向一个核心机制：母体的炎症信号“编程”了胎儿的免疫系统和大脑，为其一生埋下神经发育脆弱性的种子。
这解释了为何许多神经发育障碍(NDDs)患者具有家族聚集性——并非单纯遗传“精神病基因”，而是遗传了对免疫失调的易感性。
四、PANS——神经炎症“急先锋”：从慢性波动到急性爆发
如果说自闭症、多动症等是“慢性神经炎症”的表现，那么儿童急性神经精神综合征（PANS）则是其“急性暴发”形式。
▸ PANS是什么？家长如何识别？
PANS是一种突然发作（通常在数小时至数天内）的综合征，表现为：
·强迫症状：如反复洗手、检查门窗、害怕污染
·严重进食障碍：拒绝进食，担心食物有毒、噎住或“不干净”
·同时伴随至少两种以下症状：
1. 极度焦虑、情绪失控、易怒、攻击行为
2. 行为退化(如婴儿式说话、粘人、尿床)
3. 注意力涣散、记忆力下降、学业骤降
4. 运动协调障碍、字迹变差、感觉异常
5. 睡眠紊乱(失眠或嗜睡)、噩梦
6. 尿频、遗尿、瞳孔散大、心跳过快等自主神经症状
很多PANS患儿在发病前有感染史（如链球菌咽炎、流感、新冠），但并非所有病例都能找到明确病原体，因此，PANS的诊断不依赖特定感染，而强调“急性发作+多系统症状”。
▸ PANS与免疫有何关系？
研究发现，PANS患儿普遍存在：
·血清和脑脊液中炎症因子升高（如IL-17、TNF-α、IL-1β）
·针对基底神经节（大脑控制运动、习惯、情绪的区域）的自身抗体
·补体系统激活（免疫清除机制过度活跃，产生C4a等炎症介质）
·低水平自身免疫证据（如抗核抗体阳性、甲状腺抗体升高、乳糜泻筛查阳性）
·家族中自身免疫病高发（如多发性硬化、类风湿关节炎、红斑狼疮）
特别值得注意的是，约22%-71%的PANS患儿本身就有ADHD、ASD等神经发育障碍背景，这提示：PANS并非孤立疾病，而可能是已有神经发育脆弱性的孩子，在感染或应激触发下，免疫系统“过激反应”导致的症状急性恶化。
科学家提出“双重打击”模型：
第一次打击（孕期MIA或遗传易感）→ 大脑发育基础薄弱
第二次打击（儿童期感染/应激）→ 免疫系统失控，攻击神经回路 →PANS急性发作
五、跨越诊断界限：一个共享的“免疫—神经炎症”谱系
通常，医生按症状将孩子分门别类：自闭症、多动症、强迫症等等……但新研究证据表明，这些障碍在免疫机制上高度重叠，综述通过系统分析发现，各类障碍在以下六个维度上存在共性：
1. 遗传免疫相关改变
多个调控免疫反应与突触形成的基因（如SHANK3、NLRC4、SYNGAP1、PPM1D）在ASD、ADHD、PANS中均被发现存在变异，这些基因如同“双面开关”，既影响免疫细胞功能，又调控神经连接。
2. 家族自身免疫病史
几乎所有NDDs和PANS患者的家庭中，自身免疫病（如甲状腺炎、1型糖尿病、银屑病）的患病率都显著高于普通人群，PANS尤为突出——70%有家族史，20%的母亲患有严重自身免疫病。
3. 母体免疫激活（MIA）
孕期感染、炎症或自身抗体，是ASD、ADHD、精神分裂症的共同风险因素，虽然PANS尚无直接证据，但其相关基因在胎盘和脑血管中表达，暗示MIA可能奠定易感基础。
4. 炎症生物标志物
患者血清或脑脊液中普遍存在促炎因子（IL-6、TNF-α等）升高，且水平常与症状严重程度相关，PANS患者还表现出独特的代谢谱（如甘氨酸、谷氨酰胺异常），反映神经炎症与氧化应激。
5. 小胶质细胞失调
尸检和影像学研究证实，ASD、精神分裂症患者大脑中存在持续性小胶质细胞激活，动物模型显示，PANS相关的Th17/IL-17通路可直接激活小胶质细胞，破坏突触。
6. 血脑屏障功能障碍
虽然证据强弱不一，但ADHD、ASD、PANS均提示血脑屏障可能存在“漏洞”，使外周炎症因子或自身抗体得以进入中枢神经系统，引发“低级别神经炎症”。
因此，这些障碍不是彼此割裂的疾病，而是一个“免疫-神经炎症”谱系的不同表现，未来的精神疾病分类或许不再以症状为主，而转向基于生物学机制的“维度模型”——正如美国国立精神卫生研究所（NIMH）倡导的“研究领域标准”（RDoC）。
六、治疗新思路：从“压制症状”到“调节免疫”
目前，NDDs和PANS的主流治疗仍以行为干预和药物（如兴奋剂、抗精神病药）为主，但效果有限，且部分患者对药物反应不佳，甚至出现副作用，全球多项研究提示：对于存在免疫炎症证据的亚群，免疫调节可能成为关键突破口。
▸ 已有探索：
·抗生素/抗感染治疗：针对链球菌感染相关的PANDAS（PANS的一个亚型），青霉素等可预防复发
·静脉注射免疫球蛋白（IVIG）：通过调节抗体和免疫细胞，已在部分PANS和自闭症患儿中显示疗效，改善强迫、焦虑和认知功能
·皮质类固醇激素：如甲泼尼龙短期使用可快速抑制炎症，缓解急性症状
·血浆置换（Plasmapheresis）：清除循环中的致病性自身抗体，用于重症PANS
·靶向细胞因子药物：如抗IL-6（托珠单抗）、抗TNF-α（英夫利昔单抗）等生物制剂，正在临床试验中
然而，目前缺乏大规模随机对照试验（RCT）验证这些疗法的有效性与安全性，原因在于：
1.患者异质性高：并非所有ADHD或ASD都由免疫驱动
2.缺乏可靠生物标志物：难以精准识别“免疫亚型”
3.血脑屏障限制：许多药物难以进入中枢神经系统
▸ 未来方向：
·开发多模态生物标志物组合（如细胞因子+自身抗体+脑成像+代谢组学）
·根据免疫表型分层治疗（如“高炎症型” vs “免疫缺陷型”）
·在生命早期窗口期进行预防性干预（如优化孕期营养、控制母体炎症、调节肠道菌群）
七、给家长启示：关注“身体健康”，而不是仅仅“特殊教育”
如果你的孩子被诊断为神经发育障碍（NDDs），或出现突发性行为改变，请记住：
1. 这不是你的错，也不是孩子的“不听话”
背后可能有复杂的生物学机制，责备自己或强迫孩子“坚强一点”往往适得其反。
2. 全面体检很重要
建议排查：
·过敏原、食物不耐受
·自身免疫指标（如抗核抗体ANA、甲状腺抗体TPO-Ab）
·炎症标志物（C反应蛋白CRP、血沉ESR）
·维生素D、铁、锌等营养素水平
·肠道健康（如肠道菌群检测、乳糜泻筛查）
3. 记录症状与感染/应激事件的关系
如果每次感冒后抽动加重，或发烧后出现强迫行为，务必详细记录并告知医生，这可能是识别“免疫亚型”的关键线索。
4. 不要盲目尝试“消炎”
阿司匹林、布洛芬等非处方药对神经炎症作用有限，且可能有副作用，应在专业医生（如儿科神经免疫专家）指导下评估免疫干预的必要性。
5. 重视“生命最初1000天”
计划怀孕的女性建议如下：
·管理好慢性病（如哮喘、甲状腺疾病）
·保持健康体重，避免肥胖
·均衡饮食，补充叶酸、Omega-3
·减少压力，保证睡眠
·避免不必要的抗生素和环境毒素暴露
结语：“免疫神经精神病学”时代
长期以来，受身心二元论的影响，人们习惯于将“心理”与“生理”视为彼此分离的领域，然而，当代科学研究正不断打破这一传统界限，大脑并非孤立运作的器官，而是持续与免疫、代谢以及肠道微生态等系统进行复杂的动态的交互，共同构成一个高度整合的身心整体。
神经发育障碍（NNDs）和儿童急性神经精神综合征（PANS）的研究，不仅揭示了免疫炎症的核心作用，更呼吁我们要采用跨学科、多视角来看待儿童神经发育障碍，未来的诊疗，或将从“你是哪种病？”转向“你的免疫-神经网络发生了什么？”
正如该综述所言：“我们需要一场范式转变——承认大脑如同心脏、肝脏一样，也会因炎症而“生病”，并值得同样严谨的医学对待”。
这条路还很长——目前仍缺乏大规模的临床实验，免疫治疗也尚未成为标准方案，但每一步进展，都在为千万家庭带来新的希望！
参考文献：（向上滑动阅览）
向上滑动阅览
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Publishing: Arlington, VA, USA, 2013.
2. Mullin, A.P.; Gokhale, A.; Moreno–De–Luca, A.; Sanyal, S.; Waddington, J.L.; Faundez, V. Neurodevelopmental Disorders: Mechanisms and Boundary Definitions from Genomes, Interactomes and Proteomes. Transl. Psychiatry 2013, 3, e329. [CrossRef]
3. Parenti, I.; Rabaneda, L.G.; Schoen, H.; Novarino, G. Neurodevelopmental Disorders: From Genetics to Functional Pathways. Trends Neurosci. 2020, 43, 608–621. [CrossRef]
4. Mottahedin, A.; Ardalan, M.; Chumak, T.; Riebe, I.; Ek, J.; Mallard, C. Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for Neurodevelopmental and Neurodegenerative Disorders. Front. Cell. Neurosci. 2017, 11, 190. [CrossRef] [PubMed]
5. Martino, D.; Johnson, I.; Leckman, J.F. What Does Immunology Have to Do with Normal Brain Development and the Patho– physiology Underlying Tourette Syndrome and Related Neuropsychiatric Disorders? Front. Neurol. 2020, 11, 567407. [CrossRef] [PubMed]
6. Shohat, S.; Amelan, A.; Shifman, S. Convergence and Divergence in the Genetics of Psychiatric Disorders from Pathways to Developmental Stages. Biol. Psychiatry 2021, 89, 32–40. [CrossRef]
7. Smoller, J.W.; Andreassen, O.A.; Edenberg, H.J.; Faraone, S.V.; Glatt, S.J.; Kendler, K.S. Psychiatric Genetics and the Structure of Psychopathology. Mol. Psychiatry 2019, 24, 409–420. [CrossRef] [PubMed]
8. Azevedo, F.A.C.; Carvalho, L.R.B.; Grinberg, L.T.; Farfel, J.M.; Ferretti, R.E.L.; Leite, R.E.P.; Filho, W.J.; Lent, R.; Herculano–Houzel, S. Equal Numbers of Neuronal and Nonneuronal Cells Make the Human Brain an Isometrically Scaled–Up Primate Brain. J. Comp. Neurol. 2009, 513, 532–541. [CrossRef]
9. Mondelli, V.; Dazzan, P.; Pariante, C.M. Immune Abnormalities Across Psychiatric Disorders: Clinical Relevance; Cambridge University Press: Cambridge, UK, 2015.
10. Pape, K.; Tamouza, R.; Leboyer, M.; Zipp, F. Immunoneuropsychiatry—Novel Perspectives on Brain Disorders. Nat. Rev. Neurol. 2019, 15, 317–328. [CrossRef]
11. Carvalho, A.F.; Solmi, M.; Sanches, M.; Machado, M.O.; Stubbs, B.; Ajnakina, O.; Sherman, C.; Sun, Y.R.; Liu, C.S.; Brunoni, A.R.; et al. Evidence–Based Umbrella Review of 162 Peripheral Biomarkers for Major Mental Disorders. Transl. Psychiatry 2020, 10, 152. [CrossRef]
12. Goldsmith, D.R.; Bekhbat, M.; Mehta, N.D.; Felger, J.C. Inflammation–Related Functional and Structural Dysconnectivity as a Pathway to Psychopathology. Biol. Psychiatry 2023, 93, 405–418. [CrossRef]
13. Merzon, E.; Israel, A.; Ashkenazi, S.; Rotem, A.; Schneider, T.; Faraone, S.V.; Biederman, J.; Green, I.; Golan–Cohen, A.; Vinker, S.; et al. Attention–Deficit/Hyperactivity Disorder Is Associated with Increased Rates of Childhood Infectious Diseases: A Population–Based Case–Control Study. J. Am. Acad. Child Adolesc. Psychiatry 2023, 62, 253–260.e1. [CrossRef]
14. Lydholm, C.N.; Köhler–Forsberg, O.; Nordentoft, M.; Yolken, R.H.; Mortensen, P.B.; Petersen, L.; Benros, M.E. Parental Infections before, during, and after Pregnancy as Risk Factors for Mental Disorders in Childhood and Adolescence: A Nationwide Danish Study. Biol. Psychiatry 2019, 85, 317–325. [CrossRef]
15. Black, M.M.; Walker, S.P.; Fernald, L.C.H.; Andersen, C.T.; DiGirolamo, A.M.; Lu, C.; McCoy, D.C.; Fink, G.; Shawar, Y.R.; Shiffman, J.; et al. Early Childhood Development Coming of Age: Science through the Life Course. Lancet 2017, 389, 77–90. [CrossRef]
16. Tioleco, N.; Silberman, A.E.; Stratigos, K.; Banerjee–Basu, S.; Spann, M.N.; Whitaker, A.H.; Turner, J.B. Prenatal Maternal Infection and Risk for Autism in Offspring: A Meta–Analysis. Autism Res. 2021, 14, 1296–1316. [CrossRef] [PubMed]
17. Walle, K.M.; Askeland, R.B.; Gustavson, K.; Mjaaland, S.; Ystrom, E.; Lipkin, W.I.; Magnus, P.; Stoltenberg, C.; Susser, E.; Bresnahan, M.; et al. Risk of Attention–Deficit Hyperactivity Disorder in Offspring of Mothers with Infections during Pregnancy. JCPP Adv. 2022, 2, e12070. [CrossRef]
18. Brown, A.S.; Derkits, E.J. Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies. Am. J. Psychiatry 2010, 167, 261–280. [CrossRef]
19. Jones, H.F.; Han, V.X.; Patel, S.; Gloss, B.S.; Soler, N.; Ho, A.; Sharma, S.; Kothur, K.; Nosadini, M.; Wienholt, L.; et al. Maternal autoimmunity and inflammation are associated with childhood tics and obsessive–compulsive disorder: Transcriptomic data show common enriched innate immune pathways. Brain Behav. Immun. 2021, 94, 308–317. [CrossRef]
20. Sotgiu, S.; Manca, S.; Gagliano, A.; Minutolo, A.; Melis, M.C.; Pisuttu, G.; Scoppola, C.; Bolognesi, E.; Clerici, M.; Guerini, F.R.; et al. Immune Regulation of Neurodevelopment at the Mother–Foetus Interface: The Case of Autism. Clin. Transl. Immunol. 2020, 9, e1211. [CrossRef] [PubMed]
21. Choudhury, Z.; Lennox, B. Maternal Immune Activation and Schizophrenia—Evidence for an Immune Priming Disorder. Front. Psychiatry 2021, 12, 585742. [CrossRef] [PubMed]
22. Gilmore, J.H.; Jarskog, L.F. Exposure to infection and brain development: Cytokines in the pathogenesis of schizophrenia. Schizophr. Res. 1997, 24, 365–367. [CrossRef]
23. Estes, M.L.; McAllister, A.K. Maternal Immune Activation: Implications for Neuropsychiatric Disorders. Science 2016, 353, 772–777. [CrossRef]
24. Weber–Stadlbauer, U. Epigenetic and Transgenerational Mechanisms in Infection–Mediated Neurodevelopmental Disorders. Transl. Psychiatry 2017, 7, e1113. [CrossRef]
25. Graus, F.; Titulaer, M.J.; Balu, R.; Benseler, S.; Bien, C.G.; Cellucci, T.; Cortese, I.; Dale, R.C.; Gelfand, J.M.; Geschwind, M.; et al. A Clinical Approach to Diagnosis of Autoimmune Encephalitis. Lancet Neurol. 2016, 15, 391–404. [CrossRef] [PubMed] [PubMed Central]
26. Dalmau, J.; Graus, F. Antibody–Mediated Encephalitis. N. Engl. J. Med. 2018, 378, 840–851. [CrossRef]
27. Cellucci, T.; Van Mater, H.; Graus, F.; Muscal, E.; Gallentine, W.; Klein–Gitelman, M.S.; Benseler, S.M.; Frankovich, J.; Gorman, M.P.; Van Haren, K.; et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol. Neuroimmunol. Neuroinflammation 2020, 7, e663, Erratum in Neurol Neuroimmunol. Neuroinflamm. 2020, 7, e730. [CrossRef] [PubMed] [PubMed Central]
28. Armangue, T.; Spatola, M.; Vlagea, A.; Mattozzi, S.; Cárceles–Cordon, M.; Martinez–Heras, E.; Llufriu, S.; Muchart, J.; Erro, M.E.; Abraira, L.; et al. Frequency, Symptoms, Risk Factors, and Outcomes of Autoimmune Encephalitis after Herpes Simplex Encephalitis: A Prospective Observational Study and Retrospective Analysis. Lancet Neurol. 2018, 17, 760–772. [CrossRef]
29. Uy, C.E.; Binks, S.; Irani, S.R. Autoimmune Encephalitis: Clinical Spectrum and Management. Pract. Neurol. 2021, 21, 412–423. [CrossRef] [PubMed]
30. Bien, C.G.; Vincent, A.; Barnett, M.H.; Becker, A.J.; Blümcke, I.; Graus, F.; Jellinger, K.A.; Reuss, D.E.; Ribalta, T.; Schlegel, J.; et al. Immunopathology of Autoantibody–Associated Encephalitides: Clues for Pathogenesis. Brain 2012, 135, 1622–1638. [CrossRef]
31. Ehrenreich, H. Autoantibodies against the N–Methyl–d–Aspartate Receptor Subunit NR1: Untangling Apparent Inconsistencies for Clinical Practice. Front. Immunol. 2017, 8, 181. [CrossRef]
32. Makrides, V.; Dolgodilina, E.; Virgintino, D. Blood–Brain Barrier Transporters and Neuroinflammation: Partners in Neuro– protection and in Pathology. In The Blood Brain Barrier and Inflammation; Springer: Cham, Switzerland, 2017; pp. 103–151. [CrossRef]
33. Dileepan, T.; Smith, E.D.; Knowland, D.; Hsu, M.; Platt, M.; Bittner–Eddy, P.; Cohen, B.; Southern, P.; Latimer, E.; Harley, E.; et al. Group A Streptococcus Intranasal Infection Promotes CNS Infiltration by Streptococcal–Specific Th17 Cells. J. Clin. Investig. 2016, 126, 303–317. [CrossRef]
34. Liebner, S.; Dijkhuizen, R.M.; Reiss, Y.; Plate, K.H.; Agalliu, D.; Constantin, G. Functional Morphology of the Blood–Brain Barrier in Health and Disease. Acta Neuropathol. 2018, 135, 311–336. [CrossRef]
35. Platt, M.P.; Agalliu, D.; Cutforth, T. Hello from the Other Side: How Autoantibodies Circumvent the Blood–Brain Barrier in Autoimmune Encephalitis. Front. Immunol. 2017, 8, 442. [CrossRef]
36. Paolicelli, R.C.; Ferretti, M.T. Function and Dysfunction of Microglia during Brain Development: Consequences for Synapses and Neural Circuits. Front. Synaptic Neurosci. 2017, 9, 9. [CrossRef] [PubMed]
37. Mehl, L.C.; Manjally, A.V.; Bouadi, O.; Gibson, E.M.; Tay, T.L. Microglia in Brain Development and Regeneration. Development 2022, 149, dev200425. [CrossRef] [PubMed]
38. Komada, M.; Nishimura, Y. Epigenetics and Neuroinflammation Associated with Neurodevelopmental Disorders: A Microglial Perspective. Front. Cell Dev. Biol. 2022, 10, 852752. [CrossRef] [PubMed]
39. Gagliano, A.; Carta, A.; Tanca, M.G.; Sotgiu, S. Pediatric Acute–Onset Neuropsychiatric Syndrome: Current Perspectives. Neuropsychiatr. Dis. Treat. 2023, 19, 1221–1250. [CrossRef]
40. Kreutzberg, G.W. Microglia: A Sensor for Pathological Events in the CNS. Trends Neurosci. 1996, 19, 312–318. [CrossRef]
41. Chakraborty, S.; Kaushik, D.K.; Gupta, M.; Basu, A. Inflammasome Signaling at the Heart of Central Nervous System Pathology.
J. Neurosci. Res. 2010, 88, 1615–1631. [CrossRef]
42. Singhal, G.; Jaehne, E.J.; Corrigan, F.; Toben, C.; Baune, B.T. Inflammasomes in Neuroinflammation and Changes in Brain Function: A Focused Review. Front. Neurosci. 2014, 8, 315. [CrossRef]
43. Heneka, M.T.; McManus, R.M.; Latz, E. Inflammasome Signalling in Brain Function and Neurodegenerative Disease. Nat. Rev. Neurosci. 2018, 19, 610–621. [CrossRef]
44. Orihuela, R.; McPherson, C.A.; Harry, G.J. Microglial M1/M2 Polarization and Metabolic States. Br. J. Pharmacol. 2016, 173, 649–665. [CrossRef]
45. Prinz, M.; Jung, S.; Priller, J. Microglia Biology: One Century of Evolving Concepts. Cell 2019, 179, 292–311. [CrossRef] [PubMed]
46. Stratoulias, V.; Venero, J.L.; Tremblay, M.È.; Joseph, B. Microglial Subtypes: Diversity within the Microglial Community. EMBO J. 2019, 38, e101997. [CrossRef]
47. Thion, M.S.; Garel, S. Microglial Ontogeny, Diversity and Neurodevelopmental Functions. Curr. Opin. Genet. Dev. 2020, 65, 186–194. [CrossRef] [PubMed]
48. Glatt, S.J.; Faraone, S.V.; Tsuang, M.T. Is Schizophrenia a Neurodevelopmental Disorder? In Schizophrenia; Oxford University Press: Oxford, UK, 2019. [CrossRef]
49. Burchi, E.; Pallanti, S. Diagnostic Issues in Early–Onset Obsessive–Compulsive Disorder and Their Treatment Implications. Curr. Neuropharmacol. 2019, 17, 672–680. [CrossRef]
50. Gagliano, A.; Galati, C.; Ingrassia, M.; Ciuffo, M.; Alquino, M.A.; Tanca, M.G.; Carucci, S.; Zuddas, A.; Grossi, E. Pediatric Acute–Onset Neuropsychiatric Syndrome: A Data Mining Approach to a Very Specific Constellation of Clinical Variables. J. Child Adolesc. Psychopharmacol. 2020, 30, 495–511. [CrossRef]
51. Tricco, A.C.; Lillie, E.; Zarin, W.; O’Brien, K.K.; Colquhoun, H.; Levac, D.; Moher, D.; Peters, M.D.J.; Horsley, T.; Weeks, L.; et al. PRISMA Extension for Scoping Reviews (PRISMA–ScR): Checklist and Explanation. Ann. Intern. Med. 2018, 169, 467–473. [CrossRef]
52. Buske–Kirschbaum, A.; Schmitt, J.; Plessow, F.; Romanos, M.; Weidinger, S.; Roessner, V. Psychoendocrine and Psychoneu– roimmunological Mechanisms in the Comorbidity of Atopic Eczema and ADHD. Psychoneuroendocrinology 2013, 38, 12–23. [CrossRef]
53. Hegvik, T.A.; Chen, Q.; Kuja–Halkola, R.; Klungsøyr, K.; Butwicka, A.; Lichtenstein, P.; Almqvist, C.; Faraone, S.V.; Haavik, J.; Larsson, H. Familial co–aggregation of attention–deficit/hyperactivity disorder and autoimmune diseases: A cohort study based on Swedish population–wide registers. Int. J. Epidemiol. 2022, 51, 898–909. [CrossRef]
54. Liao, T.C.; Lien, Y.T.; Wang, S.; Huang, S.L.; Chen, C.Y. Comorbidity of atopic disorders with autism spectrum disorder and attention deficit/hyperactivity disorder. J. Pediatr. 2016, 171, 248–255. [CrossRef] [PubMed]
55. Lin, Y.T.; Chen, Y.C.; Gau, S.S.; Yeh, T.H.; Fan, H.Y.; Hwang, Y.Y.; Lee, Y.L. Associations between allergic diseases and attention deficit hyperactivity/oppositional defiant disorders in children. Pediatr. Res. 2016, 80, 480–485. [CrossRef]
56. Fasmer, O.B.; Halmøy, A.; Eagan, T.M.; Oedegaard, K.J.; Haavik, J. Adult attention deficit hyperactivity disorder is associated with asthma. BMC Psychiatry 2011, 11, 128. [CrossRef]
57. Hegvik, T.A.; Instanes, J.T.; Haavik, J.; Klungsøyr, K.; Engeland, A. Associations between attention–deficit/hyperactivity disorder and autoimmune diseases are modified by sex: A population–based cross–sectional study. Eur. Child Adolesc. Psychiatry 2018, 27, 663–675. [CrossRef]
58. Segman, R.H.; Meltzer, A.; Gross–Tsur, V.; Kosov, A.; Frisch, A.; Inbar, E.; Darvasi, A.; Levy, S.; Goltser, T.; Weizman, A.; et al. Preferential transmission of interleukin–1 receptor antagonist alleles in attention deficit hyperactivity disorder. Mol. Psychiatry 2002, 7, 72–74. [CrossRef] [PubMed]
59. Giana, G.; Romano, E.; Porfirio, M.C.; D’Ambrosio, R.; Giovinazzo, S.; Troianiello, M.; Barlocci, E.; Travaglini, D.; Granstrem, O.; Pascale, E.; et al. Detection of auto–antibodies to DAT in the serum: Interactions with DAT genotype and psycho–stimulant therapy for ADHD. J. Neuroimmunol. 2015, 278, 212–222. [CrossRef] [PubMed]
60. Toto, M.; Margari, F.; Simone, M.; Craig, F.; Petruzzelli, M.G.; Tafuri, S.; Margari, L. Antibasal Ganglia Antibodies and Antistrep– tolysin O in Noncomorbid ADHD. J. Atten. Disord. 2015, 19, 935–942. [CrossRef] [PubMed]
61. Instanes, J.T.; Halmøy, A.; Engeland, A.; Haavik, J.; Furu, K.; Klungsøyr, K. Attention–Deficit/Hyperactivity Disorder in Offspring of Mothers With Inflammatory and Immune System Diseases. Biol. Psychiatry 2017, 81, 452–459. [CrossRef]
62. Leffa, D.T.; Torres, I.L.S.; Rohde, L.A. A review on the role of inflammation in attention–deficit/hyperactivity disorder. Neuroim- munomodulation 2019, 25, 328–333. [CrossRef]
63. Zayats, T.; Athanasiu, L.; Sonderby, I.; Djurovic, S.; Westlye, L.T.; Tamnes, C.K.; Fladby, T.; Aase, H.; Zeiner, P.; Reichborn– Kjennerud, T.; et al. Genome–Wide Analysis of Attention Deficit Hyperactivity Disorder in Norway. PLoS ONE 2015, 10, e0122501. [CrossRef]
64. Faraone, S.V.; Asherson, P.; Banaschewski, T.; Biederman, J.; Buitelaar, J.K.; Ramos–Quiroga, J.A.; Rohde, L.A.; Sonuga–Barke, E.J.; Tannock, R.; Franke, B. Attention–Deficit/Hyperactivity Disorder. Nat. Rev. Dis. Primers 2015, 1, 15020. [CrossRef]
65. Li, D.J.; Tsai, C.S.; Hsiao, R.C.; Chen, Y.L.; Yen, C.F. Associations between allergic and autoimmune diseases with autism spectrum disorder and attention–deficit/hyperactivity disorder within families: A population–based cohort study. Int. J. Environ. Res. Public Health 2022, 19, 4503. [CrossRef]
66. Dunn, G.; Nigg, J.; Sontag–Padilla, L.; Seligman, M. Neuroinflammation as a Risk Factor for Attention Deficit Hyperactivity Disorder. Physiol. Behav. 2019, 198, 112–120. [CrossRef]
67. Aguilar–Valles, A.; Rodrigue, B.; Matta–Camacho, E. Maternal Immune Activation and the Development of Dopaminergic Neurotransmission of the Offspring: Relevance for Schizophrenia and Other Psychoses. Front. Psychiatry 2020, 11, 852. [CrossRef]
68. Rosenberg, J.B.; Jepsen, J.R.M.; Mohammadzadeh, P.; Sevelsted, A.; Vinding, R.; Sørensen, M.E.; Horner, D.; Aagaard, K.; Fagerlund, B.; Brix, S.; et al. Maternal Inflammation during Pregnancy Is Associated with Risk of ADHD in Children at Age 10. Brain Behav. Immun. 2024, 115, 450–457. [CrossRef]
69. Anand, D.; Colpo, G.D.; Zeni, G.; Zeni, C.P.; Teixeira, A.L. Attention–Deficit/Hyperactivity Disorder and Inflammation: What Does Current Knowledge Tell Us? A Systematic Review. Front. Psychiatry 2017, 8, 228. [CrossRef]
70. Donfrancesco, R.; Nativio, P.; Di Benedetto, A.; Villa, M.P.; Andriola, E.; Melegari, M.G.; Cipriano, E.; Di Trani, M. Anti–Yo Antibodies in Children with ADHD: First Results about Serum Cytokines. J. Atten. Disord. 2020, 24, 1497–1502. [CrossRef] [PubMed]
71. Oades, R.D.; Dauvermann, M.R.; Schimmelmann, B.G.; Schwarz, M.J.; Myint, A.M. Attention–Deficit Hyperactivity Disorder (ADHD) and Glial Integrity: S100B, Cytokines and Kynurenine Metabolism—Effects of Medication. Behav. Brain Funct. 2010, 6, 29. [CrossRef] [PubMed]
72. Corona, J.C. Role of Oxidative Stress and Neuroinflammation in Attention–Deficit/Hyperactivity Disorder. Antioxidants 2020, 9, 1039. [CrossRef] [PubMed]
73. Vázquez–González, D.; Carreón–Trujillo, S.; Alvarez–Arellano, L.; Abarca–Merlin, D.M.; Domínguez–López, P.; Salazar–García, M.; Corona, J.C. A Potential Role for Neuroinflammation in ADHD. In Neuroinflammation, Gut–Brain Axis and Immunity in Neuropsychiatric Disorders; Springer: Singapore, 2023; pp. 327–356. [CrossRef]
74. Lai, M.–C.; Kassee, C.; Besney, R.; Bonato, S.; Hull, L.; Mandy, W.; Szatmari, P.; Ameis, S.H. Prevalence of Co–Occurring Mental Health Diagnoses in the Autism Population: A Systematic Review and Meta–Analysis. Lancet Psychiatry 2019, 6, 819–829. [CrossRef]
75. Genovese, A.; Butler, M.G. The Autism Spectrum: Behavioral, Psychiatric and Genetic Associations. Genes 2023, 14, 677. [CrossRef]
76. Wiznitzer, M. Autism and Tuberous Sclerosis. J. Child Neurol. 2004, 19, 675–679. [CrossRef] [PubMed]
77. Bergbaum, A.; Ogilvie, C.M. Autism and Chromosome Abnormalities—A Review. Clin. Anat. 2016, 29, 620–627. [CrossRef]
78. Keski–Rahkonen, A.; Ruusunen, A. Avoidant–Restrictive Food Intake Disorder and Autism: Epidemiology, Etiology, Complica– tions, Treatment, and Outcome. Curr. Opin. Psychiatry 2023, 36, 438–442. [CrossRef]
79. Madra, M.; Ringel, R.; Margolis, K.G. Gastrointestinal Issues and Autism Spectrum Disorder. Child Adolesc. Psychiatr. Clin. N. Am. 2020, 29, 501–513. [CrossRef]
80. Capal, J.K.; Jeste, S.S. Autism and Epilepsy. Pediatr. Clin. N. Am. 2024, 71, 241–252. [CrossRef]
81. Johnson, K.P.; Zarrinnegar, P. Autism Spectrum Disorder and Sleep. Child Adolesc. Psychiatr. Clin. N. Am. 2021, 30, 195–208. [CrossRef] [PubMed]
82. Voineagu, I.; Wang, X.; Johnston, P.; Lowe, J.K.; Tian, Y.; Horvath, S.; Mill, J.; Cantor, R.M.; Blencowe, B.J.; Geschwind, D.H.
Transcriptomic Analysis of Autistic Brain Reveals Convergent Molecular Pathology. Nature 2011, 474, 380–384. [CrossRef]
83. Gładysz, D.; Krzywdzi ´nska, A.; Hozyasz, K.K. Immune Abnormalities in Autism Spectrum Disorder—Could They Hold Promise for Causative Treatment? Mol. Neurobiol. 2018, 55, 6387–6435. [CrossRef]
84. Hughes, H.K.; Moreno, R.J.; Ashwood, P. Innate Immune Dysfunction and Neuroinflammation in Autism Spectrum Disorder (ASD). Brain Behav. Immun. 2023, 108, 245–254. [CrossRef] [PubMed]
85. Usui, N.; Kobayashi, H.; Shimada, S. Neuroinflammation and Oxidative Stress in the Pathogenesis of Autism Spectrum Disorder. Int. J. Mol. Sci. 2023, 24, 5487. [CrossRef]
86. Villarreal, V.R.; Katusic, M.Z.; Myers, S.M.; Weaver, A.L.; Nocton, J.J.; Voigt, R.G. Risk of Autoimmune Disease in Research– Identified Cases of Autism Spectrum Disorder: A Longitudinal, Population–Based Birth Cohort Study. J. Dev. Behav. Pediatr. 2024, 45, E46–E53. [CrossRef]
87. Zerbo, O.; Leong, A.; Barcellos, L.; Bernal, P.; Fireman, B.; Croen, L.A. Immune Mediated Conditions in Autism Spectrum Disorders. Brain Behav. Immun. 2015, 46, 232–236. [CrossRef] [PubMed]
88. Al–Haddad, B.J.S.; Jacobsson, B.; Chabra, S.; Modzelewska, D.; Olson, E.M.; Bernier, R.; Enquobahrie, D.A.; Hagberg, H.; Östling, S.; Rajagopal, L.; et al. Long–term risk of neuropsychiatric disease after exposure to infection in utero. JAMA Psychiatry 2019, 76, 594–602. [CrossRef]
89. Croen, L.A.; Ames, J.L.; Qian, Y.; Alexeeff, S.; Ashwood, P.; Gunderson, E.P.; Wu, Y.W.; Boghossian, A.S.; Yolken, R.; Van de Water, J.; et al. Inflammatory conditions during pregnancy and risk of autism and other neurodevelopmental disorders. Biol. Psychiatry Glob. Open Sci. 2024, 4, 39–50. [CrossRef]
90. Brown, A.S.; Surcel, H.M.; Hinkka–Yli–Salomäki, S.; Cheslack–Postava, K.; Bao, Y.; Sourander, A. Maternal Thyroid Autoantibody and Elevated Risk of Autism in a National Birth Cohort. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 57, 86–92. [CrossRef]
91. Nielsen, T.C.; Nassar, N.; Shand, A.W.; Jones, H.F.; Han, V.X.; Patel, S.; Guastella, A.J.; Dale, R.C.; Lain, S.J. Association of Maternal Autoimmune Disease and Early Childhood Infections with Offspring Autism Spectrum Disorder: A Population–Based Cohort Study. Autism Res. 2022, 15, 2371–2380. [CrossRef] [PubMed]
92. Jones, K.L.; Croen, L.A.; Yoshida, C.K.; Heuer, L.S.; Hansen, R.L.; Zerbo, O.; DeLorenze, G.N.; Kharrazi, M.; Yolken, R.; Ashwood, P.; et al. Autism with Intellectual Disability Is Associated with Increased Levels of Maternal Cytokines and Chemokines during Gestation. Mol. Psychiatry 2017, 22, 273–279. [CrossRef]
93. Abdallah, M.W.; Larsen, N.; Grove, J.; Nørgaard–Pedersen, B.; Thorsen, P.; Mortensen, E.L.; Hougaard, D.M. Amniotic fluid chemokines and autism spectrum disorders: An exploratory study utilizing a Danish Historic Birth Cohort. Brain Behav. Immun. 2012, 26, 170–176. [CrossRef] [PubMed]
94. Rudolph, M.D.; Graham, A.M.; Feczko, E.; Miranda–Dominguez, O.; Rasmussen, J.M.; Nardos, R.; Entringer, S.; Wadhwa, P.D.; Buss, C.; Fair, D.A. Maternal IL–6 during Pregnancy Can Be Estimated from Newborn Brain Connectivity and Predicts Future Working Memory in Offspring. Nat. Neurosci. 2018, 21, 765–772. [CrossRef]
95. Graham, A.M.; Rasmussen, J.M.; Rudolph, M.D.; Heim, C.M.; Gilmore, J.H.; Styner, M.; Potkin, S.G.; Entringer, S.; Wadhwa, P.D.; Fair, D.A.; et al. Maternal Systemic Interleukin–6 During Pregnancy Is Associated with Newborn Amygdala Phenotypes and Subsequent Behavior at 2–Years–of–Age. Biol. Psychiatry 2018, 83, 109–119. [CrossRef]
96. Abdallah, M.W.; Larsen, N.; Grove, J.; Bonefeld–Jørgensen, E.C.; Nørgaard–Pedersen, B.; Hougaard, D.M.; Mortensen, E.L. Neonatal Chemokine Levels and Risk of Autism Spectrum Disorders: Findings from a Danish Historic Birth Cohort Follow–up Study. Cytokine 2013, 61, 370–376. [CrossRef] [PubMed]
97. Krakowiak, P.; Goines, P.E.; Tancredi, D.J.; Ashwood, P.; Hansen, R.L.; Hertz–Picciotto, I.; Van de Water, J. Neonatal Cytokine Profiles Associated with Autism Spectrum Disorder. Biol. Psychiatry 2017, 81, 442–451. [CrossRef] [PubMed]
98. Heuer, L.S.; Croen, L.A.; Jones, K.L.; Yoshida, C.K.; Hansen, R.L.; Yolken, R.; Zerbo, O.; DeLorenze, G.; Kharrazi, M.; Ashwood, P.; et al. An Exploratory Examination of Neonatal Cytokines and Chemokines as Predictors of Autism Risk: The Early Markers for Autism Study. Biol. Psychiatry 2019, 86, 255–264. [CrossRef] [PubMed]
99. Oskvig, D.B.; Elkahloun, A.G.; Johnson, K.R.; Phillips, T.M.; Herkenham, M. Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response. Brain Behav. Immun. 2012, 26, 623–634. [CrossRef]
100. O’Loughlin, E.; Pakan, J.M.P.; Yilmazer–Hanke, D.; McDermott, K.W. Acute in Utero Exposure to Lipopolysaccharide Induces In– flammation in the Pre– and Postnatal Brain and Alters the Glial Cytoarchitecture in the Developing Amygdala. J. Neuroinflammation 2017, 14, 212. [CrossRef]
101. Cie´slik, M.; Ga˛ssowska–Dobrowolska, M.; J˛e´sko, H.; Czapski, G.A.; Wilkaniec, A.; Zawadzka, A.; Dominiak, A.; Polowy, R.; Filipkowski, R.K.; Boguszewski, P.M.; et al. Maternal Immune Activation Induces Neuroinflammation and Cortical Synaptic Deficits in the Adolescent Rat Offspring. Int. J. Mol. Sci. 2020, 21, 4097. [CrossRef]
102. Han, V.X.; Patel, S.; Jones, H.F.; Dale, R.C. Maternal Immune Activation and Neuroinflammation in Human Neurodevelopmental Disorders. Nat. Rev. Neurol. 2021, 17, 564–579. [CrossRef]
103. Xiong, Y.; Chen, J.; Li, Y. Microglia and Astrocytes Underlie Neuroinflammation and Synaptic Susceptibility in Autism Spectrum Disorder. Front. Neurosci. 2023, 17, 1125428. [CrossRef]
104. Lampiasi, N.; Bonaventura, R.; Deidda, I.; Zito, F.; Russo, R. Inflammation and the Potential Implication of Macrophage–Microglia Polarization in Human ASD: An Overview. Int. J. Mol. Sci. 2023, 24, 2703. [CrossRef]
105. Rodriguez, J.I.; Kern, J.K. Evidence of Microglial Activation in Autism and Its Possible Role in Brain Underconnectivity. Neuron Glia Biol. 2011, 7, 205–213. [CrossRef]
106. Hu, C.; Li, H.; Li, J.; Luo, X.; Hao, Y. Microglia: Synaptic Modulator in Autism Spectrum Disorder. Front. Psychiatry 2022, 13, 958661. [CrossRef]
107. Vargas, D.L.; Nascimbene, C.; Krishnan, C.; Zimmerman, A.W.; Pardo, C.A. Neuroglial Activation and Neuroinflammation in the Brain of Patients with Autism. Ann. Neurol. 2005, 57, 67–81. [CrossRef] [PubMed]
108. Than, U.T.T.; Nguyen, L.T.; Nguyen, P.H.; Nguyen, X.H.; Trinh, D.P.; Hoang, D.H.; Nguyen, P.A.T.; Dang, V.D. Inflammatory Mediators Drive Neuroinflammation in Autism Spectrum Disorder and Cerebral Palsy. Sci. Rep. 2023, 13, 22587. [CrossRef]
109. De Giacomo, A.; Gargano, C.D.; Simone, M.; Petruzzelli, M.G.; Pedaci, C.; Giambersio, D.; Margari, L.; Ruggieri, M. B and T Immunoregulation: A New Insight of B Regulatory Lymphocytes in Autism Spectrum Disorder. Front. Neurosci. 2021, 15, 732611. [CrossRef]
110. Geller, H.; Williams, K.A. 6.34 Comparison of Primary Humoral Immunodeficiencies in Autism Spectrum Disorder (ASD) and Other Pediatric–Onset Psychiatric Disorders. J. Am. Acad. Child Adolesc. Psychiatry 2021, 60, S169. [CrossRef]
111. Bjørklund, G.; Saad, K.; Chirumbolo, S.; Kern, J.K.; Geier, D.A.; Geier, M.R.; Urbina, M.A. Immune Dysfunction and Neuroinflam– mation in Autism Spectrum Disorder. Acta Neurobiol. Exp. 2016, 76, 257–268. [CrossRef] [PubMed]
112. Robertson, M.M.; Eapen, V.; Singer, H.S.; Martino, D.; Scharf, J.M.; Paschou, P.; Roessner, V.; Woods, D.W.; Hariz, M.; Mathews, C.A.; et al. Gilles de la Tourette Syndrome. Nat. Rev. Dis. Primers 2017, 3, 16097. [CrossRef] [PubMed]
113. Knight, T.; Steeves, T.; Day, L.; Lowerison, M.; Jette, N.; Pringsheim, T. Prevalence of Tic Disorders: A Systematic Review and Meta–Analysis. Pediatr. Neurol. 2012, 47, 77–90. [CrossRef]
114. Jellinger, K.A. Neuropathology and Pathogenesis of Extrapyramidal Movement Disorders: A Critical Update. II. Hyperkinetic Disorders. J. Neural Transm. 2019, 126, 997–1027. [CrossRef]
115. Swedo, S.E.; Leonard, H.L.; Garvey, M.; Mittleman, B.; Allen, A.J.; Perlmutter, S.; Lougee, L.; Dow, S.; Zamkoff, J.; Dubbert, B.K. Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections: Clinical Description of the First 50 Cases. In Obsessive-Compulsive Disorder and Tourette’s Syndrome; Routledge: Oxfordshire, UK, 1998; Volume 155, pp. 264–271. [CrossRef]
116. Mataix–Cols, D.; Frans, E.; Pérez–Vigil, A.; Kuja–Halkola, R.; Gromark, C.; Isomura, K.; Fernández de la Cruz, L.; Serlachius, E.; Leckman, J.F.; Crowley, J.J.; et al. A Total–Population Multigenerational Family Clustering Study of Autoimmune Diseases in Obsessive–Compulsive Disorder and Tourette’s/Chronic Tic Disorders. Mol. Psychiatry 2018, 23, 1652–1658. [CrossRef]
117. Keszler, G.; Kruk, E.; Kenezloi, E.; Tarnok, Z.; Sasvari–Szekely, M.; Nemoda, Z. Association of the Tumor Necrosis Factor –308 A/G Promoter Polymorphism with Tourette Syndrome. Int. J. Immunogenet. 2014, 41, 493–498. [CrossRef]
118. Tylee, D.S.; Sun, J.; Hess, J.L.; Tahir, M.A.; Sharma, E.; Malik, R.; Worrall, B.B.; Levine, A.J.; Martinson, J.J.; Nejentsev, S.; et al. Genetic Correlations among Psychiatric and Immune–related Phenotypes Based on Genome–wide Association Data. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2018, 177, 641–657. [CrossRef]
119. Tsetsos, F.; Yu, D.; Sul, J.H.; Huang, A.Y.; Illmann, C.; Osiecki, L.; Darrow, S.M.; Hirschtritt, M.E.; Greenberg, E.; Muller–Vahl, K.R.; et al. Synaptic Processes and Immune–Related Pathways Implicated in Tourette Syndrome. Transl. Psychiatry 2021, 11, 56. [CrossRef]
120. Elamin, I.; Edwards, M.J.; Martino, D. Immune Dysfunction in Tourette Syndrome. Behav. Neurol. 2013, 27, 23–32. [CrossRef]
121. Martino, D.; Zis, P.; Buttiglione, M. The Role of Immune Mechanisms in Tourette Syndrome. Brain Res. 2015, 1617, 126–143. [CrossRef] [PubMed]
122. Leckman, J.F.; Katsovich, L.; Kawikova, I.; Lin, H.; Zhang, H.; Krönig, H.; Morshed, S.; Parveen, S.; Grantz, H.; Lombroso, P.J.; et al. Increased Serum Levels of Interleukin–12 and Tumor Necrosis Factor–Alpha in Tourette’s Syndrome. Biol. Psychiatry 2005, 57, 667–673. [CrossRef] [PubMed]
123. Chi, S.; Mok, Y.E.; Kang, J.; Gim, J.A.; Han, C.; Lee, M.S. Cytokine Levels Reflect Tic Symptoms More Prominently during Mild Phases. BMC Neurosci. 2023, 24, 14. [CrossRef]
124. Tao, Y.; Xu, P.; Zhu, W.; Chen, Z.; Tao, X.; Liu, J.; Xue, Z.; Zhu, T.; Jiang, P. Changes of Cytokines in Children With Tic Disorder. Front. Neurol. 2022, 12, 800189. [CrossRef]
125. Li, Y.; Wang, X.; Yang, H.; Li, Y.; Gui, J.; Cui, Y. Profiles of Proinflammatory Cytokines and T Cells in Patients With Tourette Syndrome: A Meta–Analysis. Front. Immunol. 2022, 13, 843247. [CrossRef] [PubMed]
126. Weidinger, E.; Krause, D.; Wildenauer, A.; Meyer, S.; Gruber, R.; Schwarz, M.J.; Müller, N. Impaired Activation of the Innate Immune Response to Bacterial Challenge in Tourette Syndrome. World J. Biol. Psychiatry 2014, 15, 453–458. [CrossRef]
127. Kawikova, I.; Leckman, J.F.; Kronig, H.; Katsovich, L.; Bessen, D.E.; Ghebremichael, M.; Bothwell, A.L. Decreased Numbers of Regulatory T Cells Suggest Impaired Immune Tolerance in Children with Tourette Syndrome: A Preliminary Study. Biol. Psychiatry 2007, 61, 273–278. [CrossRef] [PubMed]
128. Dale, R.C.; Merheb, V.; Pillai, S.; Wang, D.; Cantrill, L.; Murphy, T.K.; Ben–Pazi, H.; Varadkar, S.; Aumann, T.D.; Horne, M.K.; et al. Antibodies to Surface Dopamine–2 Receptor in Autoimmune Movement and Psychiatric Disorders. Brain 2012, 135, 3453–3468. [CrossRef]
129. Addabbo, F.; Baglioni, V.; Schrag, A.; Schwarz, M.J.; Dietrich, A.; Hoekstra, P.J.; Martino, D.; Buttiglione, M.; Emtics Collaborative Group. Anti–dopamine D2 Receptor Antibodies in Chronic Tic Disorders. Dev. Med. Child Neurol. 2020, 62, 1205–1212. [CrossRef]
130. Bos–Veneman, N.G.; Olieman, R.; Tobiasova, Z.; Hoekstra, P.J.; Katsovich, L.; Bothwell, A.L.; Leckman, J.F.; Kawikova, I. Altered Immunoglobulin Profiles in Children with Tourette Syndrome. Brain Behav. Immun. 2011, 25, 532–538. [CrossRef]
131. Harris, J. Intellectual Disability: Understanding Its Development, Causes, Classification, Evaluation, and Treatment; Oxford University Press: Oxford, UK, 2006.
132. Brynge, M.; Sjöqvist, H.; Gardner, R.M.; Lee, B.K.; Dalman, C.; Karlsson, H. Maternal Infection during Pregnancy and Likelihood of Autism and Intellectual Disability in Children in Sweden: A Negative Control and Sibling Comparison Cohort Study. Lancet Psychiatry 2022, 9, 782–791. [CrossRef] [PubMed]
133. Rezaeinejad, M.; Riahi, S.M.; Moghadam, K.B.; Tadi, M.J.; Geraili, Z.; Parsa, H.; Marhoommirzabak, E.; Nourollahpour Shiadeh, M.; Khatir, A.A. The Association between Maternal Infection and Intellectual Disability in Children: A Systematic Review and Meta–Analysis. PLoS ONE 2023, 18, e0292226. [CrossRef]
134. Benmakhlouf, Y.; Zian, Z.; Nourouti, N.G.; Barakat, A.; Mechita, M.B. Potential Cytokine Biomarkers in Intellectual Disability. Endocr. Metab. Immune Disord.—Drug Targets 2020, 21, 569–576. [CrossRef]
135. Mekori–Domachevsky, E.; Taler, M.; Shoenfeld, Y.; Gurevich, M.; Sonis, P.; Weisman, O.; Weizman, A.; Gothelf, D. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated with Psychosis and Cognitive Deficits. J. Clin. Psychiatry 2017, 78, e1219–e1225. [CrossRef]
136. Fan, X.Y.; Shi, G.; Zhao, P. Neonatal Sevoflurane Exposure Impairs Learning and Memory by the Hypermethylation of Hippocam– pal Synaptic Genes. Mol. Neurobiol. 2021, 58, 895–904. [CrossRef] [PubMed]
137. Huang, X.; Hussain, B.; Chang, J. Peripheral Inflammation and Blood–Brain Barrier Disruption: Effects and Mechanisms. CNS Neurosci. Ther. 2021, 27, 36–47. [CrossRef]
138. Zhang, F.; Zhang, J.; Wang, X.; Han, M.; Fei, Y.; Wang, J. Blood–Brain Barrier Disruption in Schizophrenia: Insights, Mechanisms, and Future Directions. Int. J. Mol. Sci. 2025, 26, 873. [CrossRef]
139. Al–Diwani, A.; Handel, A.; Townsend, L.; Pollak, T.; Leite, M.I.; Harrison, P.J.; Lennox, B.R.; Okai, D.; Manohar, S.G.; Irani, S.R. The psychopathology of NMDAR–antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019, 6, 235–246. [CrossRef] [PubMed]
140. Najjar, S.; Steiner, J.; Najjar, A.; Bechter, K. A clinical approach to new–onset psychosis associated with immune dysregulation: The concept of autoimmune psychosis. J. Neuroinflammation 2018, 15, 40. [CrossRef] [PubMed]
141. McKeon, A.; Dubey, D.; Flanagan, E.; Pittock, S.; Zekeridou, A. Autoimmune psychosis. Lancet Psychiatry 2020, 7, 122. [CrossRef] [PubMed]
142. Goldsmith, D.R.; Rapaport, M.H.; Miller, B.J. A meta–analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 2016, 21, 1696–1709. [CrossRef]
143. Bechter, K.; Reiber, H.; Herzog, S.; Fuchs, D.; Tumani, H.; Maxeiner, H.G. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood–CSF barrier dysfunction. J. Psychiatr. Res. 2010, 44, 321–330. [CrossRef]
144. Endres, D.; Perlov, E.; Baumgartner, A.; Hottenrott, T.; Dersch, R.; Stich, O.; Tebartz van Elst, L. Immunological findings in psychotic syndromes: A tertiary care hospital’s CSF sample of 180 patients. Front. Hum. Neurosci. 2015, 9, 476. [CrossRef]
145. Upthegrove, R.; Manzanares–Teson, N.; Barnes, N.M. Cytokine function in medication–naive first–episode psychosis: A systematic review and meta–analysis. Schizophr Res. 2014, 155, 101–108. [CrossRef]
146. Nayak, U.; Manikkath, J.; Arora, D.; Mudgal, J. Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: An update. Metab. Brain Dis. 2025, 40, 119. [CrossRef]
147. Miller, B.J.; Buckley, P.; Seabolt, W.; Mellor, A.; Kirkpatrick, B. Meta–Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol. Psychiatry 2011, 70, 663–671. [CrossRef]
148. Gallego, J.A.; Blanco, E.A.; Husain–Krautter, S.; Fagen, E.M.; Moreno–Merino, P.; del Ojo–Jiménez, J.A.; Ahmed, A.; Rothstein, T.L.; Lencz, T.; Malhotra, A.K. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta–analysis. Schizophr Res. 2018, 202, 64–71. [CrossRef] [PubMed]
149. Khandaker, G.M.; Pearson, R.M.; Zammit, S.; Lewis, G.; Jones, P.B. Association of serum interleukin 6 and C–reactive protein in childhood with depression and psychosis in young adult life: A population–based longitudinal study. JAMA Psychiatry 2014, 71, 1121–1128. [CrossRef]
150. Metcalf, S.A.; Jones, P.B.; Nordstrom, T.; Timonen, M.; Mäki, P.; Miettunen, J.; Jääskeläinen, E.; Järvelin, M.R.; Stochl, J.; Murray, G.K.; et al. Serum C–reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study. Brain Behav. Immun. 2017, 59, 253–259. [CrossRef]
151. Dunleavy, C.; Elsworthy, R.J.; Upthegrove, R.; Wood, S.J.; Aldred, S. Inflammation in first–episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta–analysis. Acta Psychiatr. Scand. 2022, 146, 6–20. [CrossRef] [PubMed]
152. Pollak, T.A.; Lennox, B.R.; Müller, S.; Benros, M.E.; Prüss, H.; Tebartz van Elst, L.; Klein, H.; Steiner, J.; Frodl, T.; Bogerts, B.; et al. Autoimmune psychosis: An international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020, 7, 93–108. [CrossRef]
153. Pollak, T.; Drndarski, S.; Stone, J.M.; David, A.S.; McGuire, P.K.; Abbott, N.J. The blood–brain barrier in psychosis. Lancet Psychiatry 2018, 5, 79–92. [CrossRef]
154. Trépanier, M.O.; Hopperton, K.E.; Mizrahi, R.; Mechawar, N.; Bazinet, R.P. Postmortem evidence of cerebral inflammation in schizophrenia: A systematic review. Mol. Psychiatry 2016, 21, 1009–1026. [CrossRef]
155. van Kesteren, C.F.M.G.; Gremmels, H.; de Witte, L.D.; Hol, E.M.; Van Gool, A.R.; Falkai, P.G.; Kahn, R.S.; Sommer, I.E.C. Immune involvement in the pathogenesis of schizophrenia: A meta–analysis on postmortem brain studies. Transl. Psychiatry 2017, 7, e1075. [CrossRef]
156. Kayser, M.S.; Dalmau, J. Anti–NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr. Res. 2016, 176, 36–40. [CrossRef]
157. Subeh, G.K.; Lajber, M.; Patel, T.; Mostafa, J.A. Anti–N–methyl–D–aspartate receptor encephalitis: A detailed review of the different psychiatric presentations and red flags to look for in suspected cases. Cureus 2021, 13, e15188. [CrossRef] [PubMed]
158. Hardy, D. Autoimmune encephalitis in children. Pediatr. Neurol. 2022, 132, 56–66. [CrossRef]
159. Giri, Y.R.; Parrill, A.; Damodar, S.; Fogel, J.; Ayed, N.; Syed, M.; Korie, I.; Ayyanar, S.; Typhair, C.; Hashmi, S. Anti–N–methyl–D– aspartate receptor (NMDAR) encephalitis in children and adolescents: A systematic review and quantitative analysis of reported cases. J. Can. Acad. Child Adolesc. Psychiatry 2021, 30, 236–248. [PubMed]
160. Ahmad, S.A.; Archer, H.A.; Rice, C.M.; Gerhand, S.; Bradley, M.; Wilkins, A. Seronegative limbic encephalitis: Case report, literature review and proposed treatment algorithm. Pract. Neurol. 2011, 11, 355–361. [CrossRef]
161. Shah, K.; Iloh, N.; Tabares, P.; Nnadi, C.; Sharif, Z.; Macaluso, C. Limbic encephalitis and psychosis. Gen. Hosp. Psychiatry 2013, 35, 682.e1–682.e2. [CrossRef]
162. Eaton, W.W.; Byrne, M.; Ewald, H.; Mors, O.; Chen, C.Y.; Agerbo, E.; Mortensen, P.B. Association of schizophrenia and autoimmune diseases: Linkage of Danish national registers. Am. J. Psychiatry 2006, 163, 521–528. [CrossRef] [PubMed]
163. Benros, M.E.; Pedersen, M.G.; Rasmussen, H.; Eaton, W.W.; Nordentoft, M.; Mortensen, P.B. A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. Am. J. Psychiatry 2014, 171, 218–226. [CrossRef] [PubMed]
164. Benros, M.E.; Nielsen, P.R.; Nordentoft, M.; Eaton, W.W.; Dalton, S.O.; Mortensen, P.B. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30–year population–based register study. Am. J. Psychiatry 2011, 168, 1303–1310. [CrossRef] [PubMed]
165. Yolken, R.H.; Torrey, E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol. Psychiatry 2008, 13, 470–479. [CrossRef]
166. Benros, M.E.; Waltoft, B.L.; Nordentoft, M.; Ostergaard, S.D.; Eaton, W.W.; Krogh, J.; Mortensen, P.B. Autoimmune diseases and severe infections as risk factors for mood disorders: A nationwide study. JAMA Psychiatry 2013, 70, 812–820. [CrossRef]
167. Girgis, R.R.; Ciarleglio, A.; Choo, T.; Haynes, G.; Bathon, J.M.; Cremers, S.; Kantrowitz, J.T.; Lieberman, J.A.; Brown, A.S. A randomized, double–blind, placebo–controlled clinical trial of tocilizumab, an interleukin–6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 2018, 43, 1317–1323. [CrossRef]
168. Ruscio, A.M.; Stein, D.J.; Chiu, W.T.; Kessler, R.C. The epidemiology of obsessive–compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry 2010, 15, 53–63. [CrossRef] [PubMed]
169. Robbins, T.W.; Vaghi, M.M.; Banca, P. Obsessive–compulsive disorder: Puzzles and prospects. Neuron 2019, 102, 27–47. [CrossRef] [PubMed]
170. Frick, L.; Pittenger, C. Microglial dysregulation in OCD, Tourette syndrome, and PANDAS. J. Immunol. Res. 2016, 2016, 8606057. [CrossRef]
171. Gerentes, M.; Pelissolo, A.; Rajagopal, K.; Tamouza, R.; Hamdani, N. Obsessive–compulsive disorder: Autoimmunity and neuroinflammation. Curr. Psychiatry Rep. 2019, 21, 78. [CrossRef]
172. Snider, L.A.; Swedo, S.E. PANDAS: Current status and directions for research. Mol. Psychiatry 2004, 9, 900–907. [CrossRef]
173. Orlovska, S.; Vestergaard, C.H.; Bech, B.H.; Nordentoft, M.; Vestergaard, M.; Benros, M.E. Association of Streptococcal Throat Infection With Mental Disorders: Testing Key Aspects of the PANDAS Hypothesis in a Nationwide Study. JAMA Psychiatry 2017, 74, 740–746. [CrossRef] [PubMed]
174. Xu, J.; Liu, R.J.; Fahey, S.; Frick, L.; Leckman, J.; Vaccarino, F.; Duman, R.S.; Williams, K.; Swedo, S.; Pittenger, C. Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity. Am. J. Psychiatry 2021, 178, 48–64. [CrossRef]
175. Xu, M.; Kobets, A.; Du, J.C.; Lennington, J.; Li, L.; Banasr, M.; Duman, R.S.; Vaccarino, F.M.; DiLeone, R.J.; Pittenger, C. Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome. Proc. Natl. Acad. Sci. USA 2015, 112, 893–898. [CrossRef]
176. Zhang, T.; Brander, G.; Isung, J.; Isomura, K.; Sidorchuk, A.; Larsson, H.; Chang, Z.; Mataix–Cols, D.; Fernández de la Cruz, L. Prenatal and early childhood infections and subsequent risk of obsessive–compulsive disorder and tic disorders: A nationwide, sibling–controlled study. Biol. Psychiatry 2023, 93, 1023–1030. [CrossRef]
177. Cainelli, E.; Nosadini, M.; Sartori, S.; Suppiej, A. Neuropsychological and psychopathological profile of anti–NMDAR encephalitis: A possible pathophysiological model for pediatric neuropsychiatric disorders. Arch. Clin. Neuropsychol. 2019, 34, 1309–1319. [CrossRef]
178. Foroughipour, M.; Behdani, F.; Hebrani, P.; Marvast, M.N.; Esmatinia, F.; Akhavanrezayat, A. Frequency of obsessive–compulsive disorder in patients with multiple sclerosis: A cross–sectional study. J. Res. Med. Sci. 2012, 17, 248–253.
179. Wang, L.Y.; Chen, S.F.; Chiang, J.H.; Hsu, C.Y.; Shen, Y.C. Systemic autoimmune diseases are associated with an increased risk of obsessive–compulsive disorder: A nationwide population–based cohort study. Soc. Psychiatry Psychiatr. Epidemiol. 2019, 54, 507–516. [CrossRef] [PubMed]
180. Lüngen, E.M.; Maier, V.; Venhoff, N.; Salzer, U.; Dersch, R.; Berger, B.; Riering, A.N.; Nickel, K.; Fiebich, B.L.; Süß, P.; et al. Systemic lupus erythematosus with isolated psychiatric symptoms and antinuclear antibody detection in the cerebrospinal fluid. Front. Psychiatry 2019, 10, 226. [CrossRef] [PubMed]
181. De Carvalho, J.F.; Ribeiro, F.M. Sjögren syndrome associated with obsessive–compulsive disorder. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 11801–11803.
182. Endres, D.; Pollak, T.A.; Bechter, K.; Denzel, D.; Pitsch, K.; Nickel, K.; Runge, K.; Pankratz, B.; Klatzmann, D.; Tamouza, R.; et al. Immunological causes of obsessive–compulsive disorder: Is it time for the concept of an “autoimmune OCD” subtype? Transl Psychiatry 2022, 12, 5. [CrossRef]
183. Pearlman, D.M.; Vora, H.S.; Marquis, B.G.; Najjar, S.; Dudley, L.A. Anti–basal ganglia antibodies in primary obsessive–compulsive disorder: Systematic review and meta–analysis. Br. J. Psychiatry 2014, 205, 8–16. [CrossRef]
184. Gray, S.M.; Bloch, M.H. Systematic review of proinflammatory cytokines in obsessive–compulsive disorder. Curr. Psychiatry Rep. 2012, 14, 220–228. [CrossRef]
185. Tamouza, R.; Krishnamoorthy, R.; Leboyer, M. Understanding the genetic contribution of the human leukocyte antigen system to common major psychiatric disorders in a world pandemic context. Brain Behav. Immun. 2021, 91, 731–739. [CrossRef]
186. Costas, J.; Carrera, N.; Alonso, P.; Gurriarán, X.; Segalàs, C.; Real, E.; López–Solà, C.; Mas, S.; Gassó, P.; Domènech, L.; et al. Exon–focused genome–wide association study of obsessive–compulsive disorder and shared polygenic risk with schizophrenia. Transl. Psychiatry 2016, 6, e768. [CrossRef] [PubMed]
187. Rodriguez, N.; Morer, A.; González–Navarro, E.A.; Gassó, P.; Boloc, D.; Serra–Pagès, C.; Lafuente, A.; Lazaro, L.; Mas, S. Human–leukocyte antigen class II genes in early–onset obsessive–compulsive disorder. World J. Biol. Psychiatry 2019, 20, 352–358. [CrossRef]
188. Noble, J.A. Immunogenetics of type 1 diabetes: A comprehensive review. J. Autoimmun. 2015, 64, 101–112. [CrossRef]
189. Jiang, C.; Ma, X.; Qi, S.; Han, G.; Li, Y.; Liu, Y.; Liu, L. Association between TNF–α–238G/A gene polymorphism and OCD susceptibility: A meta–analysis. Medicine 2018, 97, e9769. [CrossRef]
190. Wang, P.; Zhao, Q.; Xu, T.; Gu, Q.; Liu, Q.; Wang, Y.; Lin, G.N.; Wang, Z. Interaction between PGRN gene and the early trauma on clinical characteristics in patients with obsessive–compulsive disorder. J. Affect. Disord. 2020, 263, 134–140. [CrossRef] [PubMed]
191. Swedo, S.E.; Leckman, J.F.; Rose, N.R. From research subgroup to clinical syndrome: Modifying the PANDAS criteria to describe PANS (Pediatric Acute–Onset Neuropsychiatric Syndrome). Pediatr. Ther. 2012, 2, 1000113. [CrossRef]
192. Chang, K.; Frankovich, J.; Cooperstock, M.; Cunningham, M.W.; Latimer, M.E.; Murphy, T.K.; Pasternack, M.; Thienemann, M.; Williams, K.; Walter, J.; et al. Clinical evaluation of youth with pediatric acute–onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference. J. Child Adolesc. Psychopharmacol. 2015, 25, 3–13. [CrossRef]
193. Frankovich, J.; Thienemann, M.; Pearlstein, J.; Crable, A.; Brown, K.; Chang, K. Multidisciplinary clinic dedicated to treating youth with pediatric acute–onset neuropsychiatric syndrome: Presenting characteristics of the first 47 consecutive patients. J. Child Adolesc. Psychopharmacol. 2015, 25, 38–47. [CrossRef]
194. Gagliano, A.; Puligheddu, M.; Ronzano, N.; Congiu, P.; Tanca, M.G.; Cursio, I.; Carucci, S.; Sotgiu, S.; Grossi, E.; Zuddas, A. Artificial neural networks analysis of polysomnographic and clinical features in pediatric acute–onset neuropsychiatric syndrome (PANS): From sleep alteration to “Brain Fog”. Nat. Sci. Sleep. 2021, 13, 1209–1224. [CrossRef]
195. Chan, A.; Gao, J.; Houston, M.; Willett, T.; Farhadian, B.; Silverman, M.; Tran, P.; Jaradeh, S.; Thienemann, M.; Frankovich, J. Children With PANS May Manifest POTS. Front. Neurol. 2022, 13, 819636. [CrossRef] [PubMed] [PubMed Central]
196. Santoro, J.D.; Frankovich, J.; Bhargava, S. Continued Presence of Period Limb Movements During REM Sleep in Patients With Chronic Static Pediatric Acute–Onset Neuropsychiatric Syndrome (PANS). J. Clin. Sleep Med. 2018, 14, 1187–1192. [CrossRef]
197. Gaughan, T.; Buckley, A.; Hommer, R.; Grant, P.; Williams, K.; Leckman, J.F.; Swedo, S.E. Rapid Eye Movement Sleep Abnor– malities in Children with Pediatric Acute–Onset Neuropsychiatric Syndrome (PANS). J. Clin. Sleep Med. 2016, 12, 1027–1032. [CrossRef] [PubMed] [PubMed Central]
198. Calaprice, D.; Tona, J.; Parker–Athill, E.C.; Murphy, T.K. A survey of pediatric acute–onset neuropsychiatric syndrome characteris– tics and course. J. Child Adolesc. Psychopharmacol. 2017, 27, 607–618. [CrossRef]
199. Pavone, P.; Parano, E.; Battaglia, C.; Marino, S.; Trifiletti, R.R.; Marino, S.D.; Falsaperla, R. Severe psychotic symptoms in youth with PANS/PANDAS: Case–series. J. Child Adolesc. Psychopharmacol. 2020, 30, 567–571. [CrossRef]
200. Silverman, M.; Frankovich, J.; Nguyen, E.; Leibold, C.; Yoon, J.; Mark Freeman, G., Jr.; Karpel, H.; Thienemann, M. Psychotic symp– toms in youth with Pediatric Acute–onset Neuropsychiatric Syndrome (PANS) may reflect syndrome severity and heterogeneity.
J. Psychiatr. Res. 2019, 110, 93–102. [CrossRef]
201. Kalinowski, A.; Tian, L.; Pattni, R.; Ollila, H.; Khan, M.; Manko, C.; Silverman, M.; Ma, M.; Columbo, L.; Farhadian, B.; et al. Evaluation of C4 gene copy number in Pediatric Acute Neuropsychiatric Syndrome. Dev. Neurosci. 2023, 45, 315–324. [CrossRef] [PubMed]
202. Xu, J.; Frankovich, J.; Liu, R.J.; Thienemann, M.; Silverman, M.; Farhadian, B.; Willett, T.; Manko, C.; Columbo, L.; Leibold, C.; et al. Elevated antibody binding to striatal cholinergic interneurons in patients with pediatric acute–onset neuropsychiatric syndrome. Brain Behav. Immun. 2024, 122, 241–255. [CrossRef] [PubMed] [PubMed Central]
203. Ma, M.; Masterson, E.E.; Gao, J.; Karpel, H.; Chan, A.; Pooni, R.; Sandberg, J.; Rubesova, E.; Farhadian, B.; Willet, T.; et al. Development of Autoimmune Diseases Among Children With Pediatric Acute–Onset Neuropsychiatric Syndrome. JAMA Netw. Open. 2024, 7, e2421688. [CrossRef] [PubMed] [PubMed Central]
204. Melamed, I.; Rahman, S.; Pein, H.; Heffron, M.; Frankovich, J.; Kreuwel, H.; Mellins, E.D. IVIG response in pediatric acute–onset neuropsychiatric syndrome correlates with reduction in pro–inflammatory monocytes and neuropsychiatric measures. Front. Immunol. 2024, 15, 1383973. [CrossRef] [PubMed]
205. Murphy, T.K.; Storch, E.A.; Lewin, A.B.; Edge, P.J.; Goodman, W.K. Clinical factors associated with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Pediatr. 2012, 160, 314–319. [CrossRef]
206. Pavone, P.; Ceccarelli, M.; Marino, S.; Caruso, D.; Falsaperla, R.; Berretta, M.; Rullo, E.V.; Nunnari, G. SARS–CoV–2 related paediatric acute–onset neuropsychiatric syndrome. Lancet Child Adolesc. Health 2021, 5, e19–e21. [CrossRef]
207. Berloffa, S.; Salvati, A.; Pantalone, G.; Falcioni, L.; Rizzi, M.M.; Naldini, F.; Masi, G.; Gagliano, A. Steroid treatment response to post SARS–CoV–2 PANS symptoms: Case series. Front. Neurol. 2023, 14, 1085948. [CrossRef]
208. Saini, T.; Ma, M.; Sandberg, J.; Farhadian, B.; Manko, C.; Xie, Y.; Madan, J.; Bauer, K.; Tran, P.; Frankovich, J. New–onset OCD and juvenile enthesitis–related arthritis after COVID–19 (Three Cases). Dev. Neurosci. 2025, 303–315. [CrossRef] [PubMed]
209. Pallanti, S.; Di Ponzio, M. PANDAS/PANS in the COVID–19 age: Autoimmunity and Epstein–Barr virus reactivation as trigger agents? Children 2023, 10, 648. [CrossRef]
210. Zheng, J.; Frankovich, J.; McKenna, E.; Rowe, N.; MacEachern, S.; Ng, N.; Tam, L.; Moon, P.; Gao, J.; Thienemann, M.; et al. Association of Pediatric Acute–Onset Neuropsychiatric Syndrome With Microstructural Differences in Brain Regions Detected via Diffusion–Weighted Magnetic Resonance Imaging. J. Am. Med. Assoc. (JAMA) Netw. Open 2020, 3, e204063. [CrossRef]
211. Cabrera, B.; Romero–Rebollar, C.; Jiménez–Ángeles, L.; Genis–Mendoza, A.D.; Flores, J.; Lanzagorta, N.; Arroyo, M.; de la Fuente–Sandoval, C.; Santana, D.; Medina–Bañuelos, V.; et al. Neuroanatomical features and its usefulness in classification of patients with PANDAS. CNS Spectr. 2019, 24, 533–543. [CrossRef] [PubMed]
212. Kumar, A.; Williams, M.T.; Chugani, H.T. Evaluation of Basal Ganglia and Thalamic Inflammation in Children With Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infection and Tourette Syndrome: A Positron Emission Tomographic (PET) Study Using 11C–[R]–PK11195. J. Child Neurol. 2015, 30, 749–756. [CrossRef] [PubMed]
213. Giedd, J.N.; Rapoport, J.L.; Garvey, M.A.; Perlmutter, S.; Swedo, S.E. MRI assessment of children with obsessive–compulsive disorder or tics associated with streptococcal infection. Am. J. Psychiatry 2000, 157, 281–283. [CrossRef] [PubMed]
214. Congiu, P.; Gagliano, A.; Carucci, S.; Lanza, G.; Ferri, R.; Puligheddu, M. REM sleep atonia in patients with pediatric acute–onset neuropsychiatric syndrome: Implications for pathophysiology. J. Clin. Sleep Med. 2025, 21, 757–764. [CrossRef] [PubMed]
215. Zebrack, J.E.; Gao, J.; Verhey, B.; Tian, L.; Stave, C.; Farhadian, B.; Ma, M.; Silverman, M.; Xie, Y.; Tran, P.; et al. Neurological Soft Signs at Presentation in Patients With Pediatric Acute–Onset Neuropsychiatric Syndrome. JAMA Netw. Open. 2025, 8, e250314. [CrossRef] [PubMed] [PubMed Central]
216. Frick, L.R.; Rapanelli, M.; Jindachomthong, K.; Grant, P.; Leckman, J.F.; Swedo, S.; Williams, K.; Pittenger, C. Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. Brain Behav. Immun. 2018, 69, 304–311. [CrossRef]
217. Chain, J.L.; Alvarez, K.; Mascaro–Blanco, A.; Reim, S.; Bentley, R.; Hommer, R.; Grant, P.; Leckman, J.F.; Kawikova, I.; Williams, K.; et al. Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea and Pediatric Autoimmune Neuropsychi– atric Disorder Associated With Streptococcal Infections. Front. Psychiatry 2020, 11, 564. [CrossRef]
218. Foiadelli, T.; Loddo, N.; Sacchi, L.; Santi, V.; D’Imporzano, G.; Spreafico, E.; Orsini, A.; Ferretti, A.; De Amici, M.; Testa, G.; et al. IL–17 in serum and cerebrospinal fluid of pediatric patients with acute neuropsychiatric disorders: Implications for PANDAS and PANS. Eur. J. Paediatr. Neurol. 2025, 54, 1–7. [CrossRef] [PubMed]
219. Leonardi, L.; Perna, C.; Bernabei, I.; Fiore, M.; Ma, M.; Frankovich, J.; Tarani, L.; Spalice, A. Pediatric acute–onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS): Immunological Features Underpinning Controversial Entities. Children 2024, 11, 1043. [CrossRef]
220. Gromark, C.; Hesselmark, E.; Djupedal, I.G.; Silverberg, M.; Horne, A.; Harris, R.A.; Serlachius, E.; Mataix–Cols, D. A two–to–five year follow–up of a pediatric acute–onset neuropsychiatric syndrome cohort. Child Psychiatry Hum. Dev. 2022, 53, 354–364. [CrossRef] [PubMed]
221. Murphy, T.K.; Lewin, A.B.; Parker–Athill, E.C.; Storch, E.A.; Mutch, P.J. Tonsillectomies and adenoidectomies do not prevent the onset of pediatric autoimmune neuropsychiatric disorder associated with group A streptococcus. Pediatr. Infect. Dis. J. 2013, 32, 834–838. [CrossRef]
222. Gromark, C.; Harris, R.A.; Wickström, R.; Horne, A.; Silverberg–Mörse, M.; Serlachius, E.; Mataix–Cols, D. Establishing a pediatric acute–onset neuropsychiatric syndrome clinic: Baseline clinical features of the pediatric acute–onset neuropsychiatric syndrome cohort at Karolinska Institutet. J. Child Adolesc. Psychopharmacol. 2019, 29, 625–633. [CrossRef] [PubMed]
223. Stagi, S.; Rigante, D.; Lepri, G.; Bertini, F.; Matucci–Cerinic, M.; Falcini, F. Evaluation of autoimmune phenomena in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Autoimmun. Rev. 2014, 13, 1236–1240. [CrossRef]
224. Williams, K.A.; Swedo, S.E.; Farmer, C.A.; Grantz, H.; Grant, P.J.; D’Souza, P.; Hommer, R.; Katsovich, L.; King, R.A.; Leckman, J.F. Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J. Am. Acad. Child Adolesc. Psychiatry 2016, 55, 860–867.e2. [CrossRef]
225. Johnson, M.; Fernell, E.; Preda, I.; Wallin, L.; Fasth, A.; Gillberg, C.; Gillberg, C. Paediatric acute–onset neuropsychiatric syndrome in children and adolescents: An observational cohort study. Lancet Child Adolesc. Health 2019, 3, 175–180. [CrossRef]
226. Pohlman, D. PANDAS Network: PN 2018 State of Our Children SURVEY 2018 [Internet]. PANDAS Network; Downloaded by East Carolina University. 2018. Available online: https://pandasnetwork.org/wp–content/uploads/2018/10/PN–SOOC– SURVEY_2018.pdf(accessed on 5 August 2025).
227. Chan, A.; Phu, T.; Farhadian, B.; Willett, T.; Thienemann, M.; Frankovich, J. Familial Clustering of Immune–Mediated Diseases in Children with Abrupt–Onset Obsessive Compulsive Disorder. J. Child Adolesc. Psychopharmacol. 2020, 30, 345–346. [CrossRef]
228. Trifiletti, R.; Lachman, H.M.; Manusama, O.; Zheng, D.; Spalice, A.; Chiurazzi, P.; Schornagel, A.; Serban, A.M.; Van Wijck, R.; Cunningham, J.L.; et al. Identification of Ultra–Rare Genetic Variants in Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) by Exome and Whole Genome Sequencing. Sci. Rep. 2022, 12, 11106. [CrossRef]
229. Wang, Y.; Du, W.; Hu, X.; Yu, X.; Guo, C.; Jin, X.; Wang, W. Targeting the blood–brain barrier to delay aging–accompanied neurological diseases by modulating gut microbiota, circadian rhythms, and their interplays. Acta Pharm. Sin. B 2023, 13, 4667–4687. [CrossRef] [PubMed]
230. Tărlungeanu, D.C.; Deliu, E.; Dotter, C.P.; Kara, M.; Janiesch, P.C.; Scalise, M.; Galluccio, M.; Tesulov, M.; Morelli, E.; Sonmez, F.M.; et al. Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder. Cell 2016, 167, 1481–1494.e18. [CrossRef]
231. Xiu, Z.; Sun, L.; Liu, K.; Cao, H.; Qu, H.Q.; Glessner, J.T.; Ding, Z.; Zheng, G.; Wang, N.; Xia, Q.; et al. Shared Molecular Mechanisms and Transdiagnostic Potential of Neurodevelopmental Disorders and Immune Disorders. Brain Behav. Immun. 2024, 119, 767–780. [CrossRef] [PubMed]
232. Chiu, H.–J.; Sun, C.–K.; Tsai, S.–J.; Bai, Y.–M.; Hung, K.–C.; Hsu, J.–W.; Huang, K.–L.; Su, T.–P.; Chen, T.–J.; Sun, A.; et al. A Nationwide Study of the Risks of Major Mental Disorders among the Offspring of Parents with Rheumatoid Arthritis. Sci. Rep. 2022, 12, 4962. [CrossRef]
233. Arrondo, G.; Solmi, M.; Dragioti, E.; Eudave, L.; Ruiz–Goikoetxea, M.; Ciaurriz–Larraz, A.M.; Magallon, S.; Carvalho, A.F.; Cipriani, A.; Fusar–Poli, P.; et al. Associations between Mental and Physical Conditions in Children and Adolescents: An Umbrella Review. Neurosci. Biobehav. Rev. 2022, 137, 104662. [CrossRef]
234. Li, Q.; Barres, B.A. Microglia and Macrophages in Brain Homeostasis and Disease. Nat. Rev. Immunol. 2018, 18, 225–242. [CrossRef]
235. Lenz, K.M.; Nelson, L.H. Microglia and Beyond: Innate Immune Cells as Regulators of Brain Development and Behavioral Function. Front. Immunol. 2018, 9, 698. [CrossRef]
236. Lussier, A.A.; Bodnar, T.S.; Weinberg, J. Intersection of Epigenetic and Immune Alterations: Implications for Fetal Alcohol Spectrum Disorder and Mental Health. Front. Neurosci. 2021, 15, 788630. [CrossRef]
237. Asslih, S.; Damri, O.; Agam, G. Neuroinflammation as a Common Denominator of Complex Diseases (Cancer, Diabetes Type 2, and Neuropsychiatric Disorders). Int. J. Mol. Sci. 2021, 22, 6138. [CrossRef]
238. Masterson, E.E.; Miles, K.; Schlenk, N.; Manko, C.; Ma, M.; Farhadian, B.; Chang, K.; Silverman, M.; Thienemann, M.; Frankovich, J. Defining Clinical Course of Patients Evaluated for Pediatric Acute–Onset Neuropsychiatric Syndrome: Phenotypic Classification Based on 10 Years of Clinical Data. Dev. Neurosci. 2025, 270–286. [CrossRef] [PubMed]
239. Maser, J.D.; Akiskal, H.S. Spectrum concepts in major mental disorders. Psychiatr. Clin. N. Am. 2002, 25, xi–xiii. [CrossRef]
240. Hopwood, C.J.; Morey, L.C.; Markon, K.E. What is a psychopathology dimension? Clin. Psychol. Rev. 2023, 106, 102356. [CrossRef] [PubMed]
241. Pacheco, J.; Garvey, M.A.; Sarampote, C.S.; Cohen, E.D.; Murphy, E.R.; Friedman–Hill, S.R. Annual Research Review: The contributions of the RDoC research framework on understanding the neurodevelopmental origins, progression and treatment of mental illnesses. J. Child Psychol. Psychiatry 2022, 63, 360–376. [CrossRef]
242. Arnsten, A.F.; Rubia, K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: Disruptions in neurodevelopmental psychiatric disorders. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51, 356–367. [CrossRef] [PubMed]
243. Vreeland, A.; Calaprice, D.; Or–Geva, N.; Frye, R.E.; Agalliu, D.; Lachman, H.M.; Pittenger, C.; Pallanti, S.; Williams, K.; Ma, M.; et al. Postinfectious Inflammation, Autoimmunity, and Obsessive–Compulsive Disorder: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection, and Pediatric Acute–Onset Neuropsychiatric Disorder. Dev. Neurosci. 2023, 45, 361–374. [CrossRef]
244. Karakochuk, C.; Whitfield, K.; Green, T.; Kraemer, K. The Biology of the First 1000 Days; CRC Press: Boca Raton, FL, USA, 2018.
245. Wang, Q.; Yang, Q.; Liu, X. The Microbiota–Gut–Brain Axis and Neurodevelopmental Disorders. Protein Cell 2023, 14, 762–775. [CrossRef]
246. Murgia, F.; Gagliano, A.; Tanca, M.G.; Or–Geva, N.; Hendren, A.; Carucci, S.; Pintor, M.; Cera, F.; Cossu, F.; Sotgiu, S.; et al. Metabolomic Characterization of Pediatric Acute–Onset Neuropsychiatric Syndrome (PANS). Front. Neurosci. 2021, 15, 645267. [CrossRef]
247. Likhitweerawong, N.; Thonusin, C.; Boonchooduang, N.; Louthrenoo, O.; Nookaew, I.; Chattipakorn, N.; Chattipakorn, S.C. Profiles of Urine and Blood Metabolomics in Autism Spectrum Disorders. Metab. Brain Dis. 2021, 36, 1641–1671. [CrossRef]
248. Gagliano, A.; Murgia, F.; Capodiferro, A.M.; Tanca, M.G.; Hendren, A.; Falqui, S.G.; Aresti, M.; Comini, M.; Carucci, S.; Cocco, E.; et al. 1H–NMR–Based Metabolomics in Autism Spectrum Disorder and Pediatric Acute–Onset Neuropsychiatric Syndrome. J. Clin. Med. 2022, 11, 6493. [CrossRef]
249. Gagliano, A., Cucinotta, F., Giunta, I., et al. (2025). The Immune/Inflammatory Basis of Neurodevelopmental Disorders and Pediatric Acute-Onset Neuropsychiatric Syndrome: A Scoping Review. International Journal of Molecular Sciences, 26(16), 7767. https://doi.org/10.3390/ijms26167767
免责声明：本文中所有内容仅供读者交流学习，不能代替专业建议和诊疗，如有任何问题或疑虑，请务必咨询医生或者专业人士，图文转自网络，著作权属归原创者所有，如有侵权请在后台留言联系我们进行删除！
2025-12-02
Cancer Res[Jour] AND 85[volume] AND 13[issue]
癌症研究 85卷 13期
https://aacrjournals.org/cancerres/issue/
Editorial(社论)
1
Cancer Research in the Age of Big Data
大数据时代的癌症研究
Christine A. Iacobuzio-Donahue
Cancer Res (2025) 85 (13): 2347
In the Spotlight(焦点)
2
Leveraging Whole-Exome Sequencing and Mutational Signatures to Detect Homologous Recombination Deficiency in Cancer
利用全外显子组测序和突变特征检测癌症同源重组缺陷
Joonoh Lim; Young Seok Ju
Cancer Res (2025) 85 (13): 2348–2350
3
Cells Keep Diverse Company in Diseased Tissues
细胞在疾病组织中保持多样性
Kieran R. Campbell; Aleksandrina Goeva
Cancer Res (2025) 85 (13): 2351–2352
Cancer Research Landmarks(癌症研究里程碑)
4
Paving a Path to Clinical Impact with Radiomics: Enabling Reproducibility and Reach
为放射组学的临床影响铺平道路：实现可重复性和可及性
Mohamad El-Jammal; Caroline Chung
Cancer Res (2025) 85 (13): 2353–2355
Reviews(综述)
5
Artificial Intelligence–Driven Cancer Diagnostics: Enhancing Radiology and Pathology through Reproducibility, Explainability, and Multimodality
人工智能驱动的癌症诊断：通过可再现性、可解释性和多模态增强放射学和病理学
Pegah Khosravi; Thomas J. Fuchs; David Joon Ho
Cancer Res (2025) 85 (13): 2356–2367
6
Illuminating the Noncoding Genome in Cancer Using Artificial Intelligence
利用人工智能阐明癌症中的非编码基因组
Maria del Mar Alvarez-Torres; Xi Fu; Raul Rabadan
Cancer Res (2025) 85 (13): 2368–2375
7
Leveraging Artificial Intelligence for Neoantigen Prediction
利用人工智能进行新抗原预测
Jing Zeng; Zhengjun Lin; Xianghong Zhang; Tao Zheng; Haodong Xu; Tang Liu
Cancer Res (2025) 85 (13): 2376–2387
Cancer Biology(癌症生物学)
8
Dissecting FAP+ Cell Diversity in Pancreatic Cancer Uncovers an Interferon-Response Subtype of Cancer-Associated Fibroblasts with Tumor-Restraining Properties
剖析胰腺癌中FAP+细胞多样性揭示具有肿瘤抑制特性的癌症相关成纤维细胞干扰素应答亚型
Joshua Cumming; Parniyan Maneshi; Mitesh Dongre; Tala Alsaed; Mohammad Javad Dehghan-Nayeri; Agnes Ling; Kristian Pietras; Cedric Patthey; Daniel Öhlund
Cancer Res (2025) 85 (13): 2388–2411
9
Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy
靶向来自癌症相关成纤维细胞的LTBP2使食管鳞状细胞癌对化疗敏感
Jiarong Zhan; Mengqing Li; Lei Li; Ting-Ting Zeng; Jun Liu; Qingyun Chen; Chen Jiang; Xin Wang; Dan Xie; Xin-Yuan Guan; Ying-Hui Zhu
Cancer Res (2025) 85 (13): 2412–2428
10
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression
慢性应激刺激前体巨噬细胞极化促进肺癌进展
Cuilan Liu; Hengwei Du; Guoxing Yu; Jingjing Qi; Hongliang Dong; Ruiqi Hu; Fei Wang; Bingjie Cui; Weiwei Chen; Qian Zhang; Chen Li; Ran Gao; Clemens A. Schmitt; Jiong Deng; Yong Yu; Jing Du
Chronic stress facilitates lung cancer immune evasion by inducing M2-like macrophage polarization, supporting the potential of combination therapies targeting both tumor cells and the immune microenvironment for treating stress-related cancers.
Cancer Res (2025) 85 (13): 2429–2447
Cancer Immunology(癌症免疫学)
11
Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin
氨通过降低成熟穿孔素抑制自然杀伤细胞和T细胞的抗肿瘤活性
Joanna Domagala; Tomasz M. Grzywa; Iwona Baranowska; Magdalena Justyniarska; Ryan Tannir; Agnieszka Graczyk-Jarzynka; Aleksandra Kusowska; Maria Lecka; Marcin Poreba; Klaudyna Fidyt; Katsiaryna Marhelava; Zofia Pilch; Lea K. Picard; Tomasz Wegierski; Kamil Jastrzebski; Marta Krawczyk; Marta Klopotowska; Monika Granica; Doris Urlaub; Szymon Hajduk; Alexandra Neeser; Spencer Moros; Pawel Kozlowski; Malgorzata Bobrowicz; Marta Miaczynska; Leyuan Ma; Carsten Watzl; Magdalena Winiarska
Cancer Res (2025) 85 (13): 2448–2467
12
Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites
甘露糖通过调节肠道微生物代谢物提高卵巢癌免疫治疗效果
Chen Zhang; Yiying Wang; Mengdi He; Chenyang Wang; Kankan Cao; Yujing Zhong; Xueling Wang; Moran Yang; Guodong Zhang; Jiaqi Lu; Huan Yi; Haiou Liu; Congjian Xu
Cancer Res (2025) 85 (13): 2468–2484
Translational Cancer Biology(癌症转化生物学)
13
SCD1 Inhibition Blocks the AKT–NRF2–SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma
SCD1抑制阻断AKT-NRF2-SLC7A11通路诱导肺腺癌脂质代谢重塑和铁蛋白沉积
Utsav Sen; Charles Coleman; Nishant Gandhi; Vrinda Jethalia; Deniz Demircioglu; Andrew Elliott; Ari M. Vanderwalde; Omar Hayatt; Elisa de Stanchina; Balazs Halmos; Patrick C. Ma; Mirela Berisa; Dan Hasson; Triparna Sen
Cancer Res (2025) 85 (13): 2485–2503
Computational Cancer Biology and Technology(癌症计算生物学与技术)
14
HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data
HRProfiler使用全基因组和全外显子组测序数据检测乳腺癌和卵巢癌的同源重组缺陷
Ammal Abbasi; Christopher D. Steele; Erik N. Bergstrom; Azhar Khandekar; Akanksha Farswan; Rana R. McKay; Nischalan Pillay; Ludmil B. Alexandrov
Cancer Res (2025) 85 (13): 2504–2513
15
Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer
将空间转录组学、伪时间和机器学习相结合，有助于发现癌症前列腺生物标志物
Martin Smelik; Daniel Diaz-Roncero Gonzalez; Xiaojing An; Rakesh Heer; Lars Henningsohn; Xinxiu Li; Hui Wang; Yelin Zhao; Mikael Benson
Cancer Res (2025) 85 (13): 2514–2526
16
Multitask Deep Learning Based on Longitudinal CT Images Facilitates Prediction of Lymph Node Metastasis and Survival in Chemotherapy-Treated Gastric Cancer
基于纵向CT图像的多任务深度学习有助于预测癌症化疗后淋巴结转移和存活率
Bingjiang Qiu; Yunlin Zheng; Shunli Liu; Ruirui Song; Lei Wu; Cheng Lu; Xianqi Yang; Wei Wang; Zaiyi Liu; Yanfen Cui
Cancer Res (2025) 85 (13): 2527–2536
Convergence Science(融合医学)
17
Eco-Evolutionary Guided Pathomic Analysis Detects Biomarkers to Predict Ductal Carcinoma In Situ Upstaging
生态进化指导的病理分析检测生物标志物以预测导管癌原位升级
Yujie Xiao; Manal Elmasry; Ji Dong K. Bai; Andrew Chen; Yuzhu Chen; Brooke Jackson; Joseph O. Johnson; Prateek Prasanna; Chao Chen; Mehdi Damaghi
Evolutionary dynamics of the various niches composing the tumor ecosystem can be harnessed for predicting cancer progression, demonstrating how eco-evolutionary–designed approaches can guide biomarkers discovery studies in the era of digital pathology
Cancer Res (2025) 85 (13): 2537–2547
Cancer Res[Jour] AND 85[volume] AND 14[issue]
癌症研究85卷 14期
https://aacrjournals.org/cancerres/issue/
In the Spotlight(焦点)
1
Pan-Cancer Spatial Profiling Reveals Conserved Subtypes and Niches of Cancer-Associated Fibroblasts
泛癌症空间谱揭示了癌症相关成纤维细胞的保守亚型和生态位
Hani Jieun Kim; Travis Ruan; Alexander Swarbrick
Cancer Res (2025) 85 (14): 2555–2557
In Focus(焦点)
2
Bacterial Therapeutics: Addressing the Affordability Gap in Cancer Therapy
细菌疗法：解决癌症治疗的可负担性差距
Kejsi Prifti; Chiswili Yves Chabu; Koichi S. Kobayashi; Jianxun Song; Arum Han; Paul de Figueiredo
Cancer Res (2025) 85 (14): 2558–2560
Review(综述)
3
AXL Tyrosine Kinases: A Growing Isoform Family That Promotes Cancer Pathogenesis
AXL酪氨酸激酶：促进癌症发病的一个不断增长的异构体家族
May Eriksen Gjerstad; Pia Aehnlich; Pascal Gelebart; Emmet Mc Cormack
Cancer Res (2025) 85 (14): 2561–2573
Cancer Biology(癌症生物学)
4
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer
综合应激反应途径协调肺癌中多个免疫检查点的转化控制
Shayna Thomas-Jardin; Shruthy Suresh; Ariana Arce; Nicole Novaresi; Qing Deng; Emily Stein; Lisa Thomas; Cheryl Lewis; Chul Ahn; Bret M. Evers; Esra A. Akbay; Maria E. Salvatierra; Wei Lu; Khaja Khan; Luisa M. Solis Soto; Ignacio I. Wistuba; John D. Minna; Kathryn A. O’Donnell
Cancer Res (2025) 85 (14): 2574–2590
5
Cis-Regulatory Alterations in FOXP4 Modulate Esophageal Cancer Susceptibility Induced by Chronic Alcohol Exposure
FOXP4顺式调控改变可调节慢性酒精暴露诱导的食管癌易感性
Siyuan Niu; Jialing Ma; Shasha Liu; Yueping Li; Xinying Yue; Miaoxin Pan; Lina Song; Yutong Wu; Zifei Yang; Yuqian Tan; Linglong Gu; Chaolong Wang; Jiang Chang
Cancer Res (2025) 85 (14): 2591–2607
6
Large-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness
原位细胞系来源的异种移植物的大规模表征鉴定TGFβ信号作为乳腺癌形态和侵袭性的关键调节因子
Catrin Lutz; Xue Chao; Bim de Klein; Jinhyuk Bhin; Madelon Badoux; Timo Eijkman; Apostolos P. Nikolakopoulos; Stefan J. Hutten; Natalie Proost; Bjørn Siteur; Marieke van de Ven; Ji-Ying Song; Jacco van Rheenen; Jessica Morgner; Stefan Prekovic; Jos Jonkers
Cancer Res (2025) 85 (14): 2608–2625
7
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
SMARCA4的缺失导致高钙血症型卵巢小细胞癌内含子保留和肿瘤相关抗原的产生
Elizabeth A. Raupach; Apurva M. Hegde; Krystine Garcia-Mansfield; Marice Alcantara; David L. Rose; Rebecca F. Halperin; Krystal A. Orlando; Jessica D. Lang; Ritin Sharma; Victoria David-Dirgo; Salvatore J. Facista; Rayvon Moore; Rochelle Kofman; Zoe N. Jensen; Victoria L. Zismann; Anthony N. Karnezis; Yemin Wang; Lynda B. Bennett; Timothy G. Whitsett; Marcin Kortylewski; William P.D. Hendricks; David G. Huntsman; Lorna Rodriguez-Rodriguez; Bernard E. Weissman; Jeffrey M. Trent; Patrick Pirrotte
Cancer Res (2025) 85 (14): 2626–2642
Cancer Immunology(癌症免疫学)
8
Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
缺铁性巨噬细胞激活CD8+T细胞以刺激抗肿瘤免疫并提高免疫治疗效果
Brian J. Laight; Danielle Harper; Natasha Dmytryk; Connie S. Zhang; Changnian Shi; Andrew Garven; Richard W. Nauman; Jacob Kment; Faizah Alotaibi; Ivan Shapovalov; Victoria Hoskin; Yan Gao; Jeffery Mewburn; Caitlyn Vlasschaert; Ami Wang; Julian Simonetti; David LeBrun; Kathrin Tyryshkin; David M. Berman; Amber L. Simpson; Charles H. Graham; Andrew W. Craig; Sameh Basta; Madhuri Koti; Peter A. Greer
Cancer Res (2025) 85 (14): 2643–2658
9
Antigen Cross-Presentation by Type-2 Innate Lymphoid Cells Facilitates the Activation of Antitumor CD8+ T Cells
2型先天淋巴细胞的抗原交叉呈递促进了抗肿瘤CD8+ T细胞的激活
Jihyun Kim; Seung Geun Song; Suhyun Park; Young Gyun Ko; Jongho Ham; TaeSoo Kim; Sang-Jun Ha; Yong-Soo Bae; Doo Hyun Chung; Hye Young Kim
Cancer Res (2025) 85 (14): 2659–2678
10
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors
靶向细胞内天然RNA传感系统克服实体瘤对CAR-T细胞治疗的耐药性
Nardine Soliman; Tatiana Nedelko; Giada Mandracci; Stefan Enssle; Vincent Grass; Julius C. Fischer; Florian Bassermann; Hendrik Poeck; Sebastian Kobold; Nadia El Khawanky; Simon Heidegger
Cancer Res (2025) 85 (14): 2679–2693
Cancer Metabolism and Molecular Mechanisms(癌症代谢与分子机制)
11
Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation
异常CircTMEM45A通过m5c介导的NLRP3激活促进食管鳞状细胞癌的炎症进展
Lingjiao Meng; Haotian Wu; Jiaxiang Wu; Ping’an Ding; Jinchen He; Tongkun Li; Xiaoman Niu; Meixiang Sang; Lihua Liu
Cancer Res (2025) 85 (14): 2694–2713
Therapeutic Development and Chemical Biology(治疗学发展和生物化学)
12
A Cyanobacteria-Derived RNA Aptamer Resensitizes Prostate Cancer to Hormone Therapy
蓝藻衍生的RNA适体使前列腺癌对激素治疗重新敏感
Carlos D. Cruz-Hernández; Bethany Smith; Sandrine Billet; Manish Thiruvalluvan; Gabrielle Gonzales; David M. Underhill; Ekihiro Seki; Shelly C. Lu; Neil A. Bhowmick
Cancer Res (2025) 85 (14): 2714–2725
Translational Cancer Biology(癌症转化生物学)
13
Genomic and Single-Cell Analyses Characterize Patient-Derived Tumor Organoids to Enable Personalized Therapy for Head and Neck Squamous Cell Carcinoma
基因组和单细胞分析表征患者来源的肿瘤类器官，以实现头颈部鳞状细胞癌的个性化治疗
Jung Hyun Um; Yueyuan Zheng; Qiong Mao; Chehyun Nam; Hua Zhao; Yoon Woo Koh; Su-Jin Shin; Young Min Park; De-Chen Lin
Cancer Res (2025) 85 (14): 2726–2742
14
Integration of Germline and Somatic Variation Improves Chronic Lymphocytic Leukemia Risk Stratification
种系和体细胞变异的整合提高了慢性淋巴细胞白血病的风险分层
Aubrey K. Hubbard; Derek W. Brown; Jie Liu; Irenaeus C. Chan; Weiyin Zhou; Giulio Genovese; Alexander DePaulis; Sruthi Srinivasan; Shu-Hong Lin; Batel Blechter; Ian D. Buller; Qinglin Zeng; Yin Cao; Wen-Yi Huang; Neal D. Freedman; Haoyu Zhang; Diptavo Dutta; Stephen J. Chanock; Kelly L. Bolton; Mitchell J. Machiela
Cancer Res (2025) 85 (14): 2743–2752
Computational Cancer Biology and Technology(癌症计算生物学与技术)
15
A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia
基于机器学习的策略预测复发急性髓性白血病的选择性和协同药物组合
Yingjia Chen; Liye He; Aleksandr Ianevski; Kristen Nader; Tanja Ruokoranta; Nora Linnavirta; Juho J. Miettinen; Markus Vähä-Koskela; Ida Vänttinen; Heikki Kuusanmäki; Mika Kontro; Kimmo Porkka; Krister Wennerberg; Caroline A. Heckman; Anil K. Giri; Tero Aittokallio
Cancer Res (2025) 85 (14): 2753–2768
Cancer Res[Jour] AND 85[volume] AND 15[issue]
癌症研究85卷 15期
https://aacrjournals.org/cancerres/issue/
In the Spotlight(焦点)
1
Ferreting Out Ferroptosis: Extending the Mechanism of Action of RSL3 to the Selenoproteome in Colorectal Cancer
摆脱脱铁症：将RSL3的作用机制扩展到结直肠癌的硒蛋白组
Sarah P. Short
Cancer Res (2025) 85 (15): 2775–2777
2
Unlocking the Therapeutic Potential of the cGAS–STING Pathway through TREX1 Targeting
通过TREX1靶向释放cGAS-STING通路的治疗潜力
Brent A. Hanks
Cancer Res (2025) 85 (15): 2778–2780
3
The Genetic Footprint of Tobacco Smoking: Unraveling the Mutational Signatures in Head and Neck Cancer
吸烟的遗传足迹：揭示头颈癌的突变特征
Kaito Mimura; Kenichi Yoshida
Cancer Res (2025) 85 (15): 2781–2783
In Focus(焦点)
4
Charting New Paths in Cancer Research: Insights from the Frontiers in Cancer Science Conference 2024
绘制癌症研究的新路径：来自2024年癌症医学会议前沿的见解
Giang Le Minh; Sasidharan Swarnalatha Lucky; Shazib Pervaiz; Kristijan Ramadan; Joe Yeong; Sin Tiong Ong; Vaidehi Krishnan; Chit Fang Cheok; Wee Joo Chng; Sanjay De Mel; Xiaomeng Wang; Anand D. Jeyasekharan; Chartsiam Tipgomut; Li Ren Kong; Kanaga Sabapathy; Cheng Ean Chee; Koji Itahana; Reshma Taneja; Soo-Chin Lee
Cancer Res (2025) 85 (15): 2784–2787
Cancer Biology(癌症生物学)
5
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
RSL3肿瘤抑制机制的重新表征确定硒蛋白组作为结直肠癌的可药物途径
Stephen L. DeAngelo; Liang Zhao; Sofia Dziechciarz; Myungsun Shin; Sumeet Solanki; Andrii Balia; Marwa O. El-Derany; Cristina Castillo; Yao Qin; Nupur K. Das; Hannah N. Bell; Joao A. Paulo; Yuezhong Zhang; Nicholas J. Rossiter; Elizabeth C. McCulla; Jianping He; Indrani Talukder; Billy Wai-Lung Ng; Zachary T. Schafer; Nouri Neamati; Joseph D. Mancias; Markos Koutmos; Yatrik M. Shah
Cancer Res (2025) 85 (15): 2788–2804
6
Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor–Stroma Ratio and Promote Cancer Progression
胰腺神经内分泌肿瘤分泌载脂蛋白E诱导尖端内皮细胞重塑肿瘤-间质比率并促进肿瘤进展
Xin Lou; Yihua Shi; Faming Zhao; Xiaowu Xu; Yan Wang; Yi Qin; Wuhu Zhang; Zeng Ye; Fei Wang; Tian Ding; Desheng Jing; Guixiong Fan; Yue Zhang; Xuemin Chen; Jie Chen; Xianjun Yu; Junfeng Xu; Shunrong Ji
Cancer Res (2025) 85 (15): 2805–2819
7
Modeling the PAX5P80R Mutation Reveals HIF2α Activation as a Common Feature and Therapeutic Target in B-cell Acute Lymphoblastic Leukemia
PAX5P80R突变建模揭示HIF2α激活是B细胞急性淋巴细胞白血病的共同特征和治疗靶点
Manon Bayet; Vincent Fregona; Mathieu Bouttier; Clémence Rouzier; Jérémy Bigot; Laura Jamrog; Sylvie Hebrard; Naïs Prade; Stéphanie Lagarde; Christine Didier; Stéphanie Gachet; Marie Passet; Laetitia Largeaud; Marlène Pasquet; Ahmed Amine Khamlichi; Emmanuelle Clappier; Eric Delabesse; Cyril Broccardo; Bastien Gerby
Cancer Res (2025) 85 (15): 2820–2837
8
Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression
吸烟通过诱导GAPDH琥珀酰化改变细胞代谢促进肺癌进展
Kun Wang; Jingzhuo Li; Hai Zhang; Hongyan Ma; Hong-Yong Cui; Huai-Qiang Ju; Jing Zhang; Qing-zhi Ma; Ming Zhao; Qing-mei Zeng; Jie Zou; Xiu-Xuan Sun; Gang Nan; Meirui Qian; Lin Jing; Yiming Li; Cai-feng Xiong; Qiu-zi Yang; Hao Wang; Jian-Li Jiang; Zhi-Nan Chen; Liang Chen; Wan Huang
Cancer Res (2025) 85 (15): 2838–2857
Cancer Immunology(癌症免疫学)
9
Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer
靶向先天免疫检查点TREX1是一种安全有效的癌症免疫治疗策略
Cong Xing; Xintao Tu; Wanwan Huai; Zhen Tang; Kun Song; Devon Jeltema; Kennady Knox; Nicole Dobbs; Kun Yang; Nan Yan
Cancer Res (2025) 85 (15): 2858–2875
10
Systemic Inactivation of TREX1 Induces Selective Inflammation of the Tumor Microenvironment and Invigorated T-cell–Mediated Tumor Control
TREX1的系统失活诱导肿瘤微环境的选择性炎症和活化T细胞介导的肿瘤控制
Emilija Marinkovic; Minyi Chen; Nadja Schubert; Elif Dogan Dar; Tanja Poth; Janet Y. Leung; Jack Lohre; Jennifer M. Sahni; Christine Tun; Pavithra Rajeswaran; Tanja Mehlo-Jensen; Olivia Perng; C. Mark Hill; Pallavur Sivakumar; Michael J. Barnes; Rohit Malik; Rayk Behrendt; Axel Roers
Cancer Res (2025) 85 (15): 2876–2889
Therapeutic Development and Chemical Biology(治疗学发展和生物化学)
11
Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
结合多重CRISPR/Cas9-Nickase和PARP抑制剂有效精确地靶向癌细胞
Soyoung Lee; Kyunghwan Kim; Hye-Jin Jeong; Subin Choi; Himchan Cheng; Dayoung Kim; Soomin Heo; Jinhee Mun; Minjong Kim; Eunjin Lee; Yoon Ji Choi; Seon-gyeong Lee; Eun A Lee; Yewon Jang; Kayeong Lim; Heon Seok Kim; Euihwan Jeong; Seung-Jae Myung; Deok-Beom Jung; Chang Sik Yu; In Ho Song; M. Ryan Corces; Joo H. Kang; Kyungjae Myung; Taejoon Kwon; Tae-Eun Park; Jinmyoung Joo; Seung Woo Cho
Cancer Res (2025) 85 (15): 2890–2904
Cancer Landscapes(癌症特征)
12
Comprehensive Characterization of Somatic Mutation Timing Reveals the Evolutionary Trajectory of Lung Adenocarcinoma in Chinese Patients
体细胞突变时间的综合表征揭示了中国患者肺腺癌的进化轨迹
Na Qin; Zhoufeng Wang; Xianfeng Xu; Yuan Xie; Yingjia Chen; Wenxin Luo; Pan Tang; Xin Wang; Lingfeng Bi; Linnan Gong; Zhe Li; Congcong Chen; Kai Wang; Songwei Guo; Zihuan Zhao; Jun Xiang; Meng Zhu; Yue Jiang; Yuanlin He; Juncheng Dai; Rong Yin; Cheng Wang; Zhibin Hu; Hongxia Ma; Weimin Li; Hongbing Shen
Cancer Res (2025) 85 (15): 2905–2920
Computational Cancer Biology and Technology(癌症计算生物学与技术)
13
Epigenetic Heritability of Cell Plasticity Drives Cancer Drug Resistance through a One-to-Many Genotype-to-Phenotype Paradigm
细胞可塑性的表观遗传力通过一对多基因型-表型范式驱动癌症耐药性
Erica A. Oliveira; Salvatore Milite; Javier Fernandez-Mateos; George D. Cresswell; Erika Yara-Romero; Georgios Vlachogiannis; Bingjie Chen; Chela T. James; Lucrezia Patruno; Gianluca Ascolani; Ahmet Acar; Timon Heide; Inmaculada Spiteri; Alex Graudenzi; Giulio Caravagna; Andrea Bertotti; Trevor A. Graham; Luca Magnani; Nicola Valeri; Andrea Sottoriva
Cancer Res (2025) 85 (15): 2921–2938
Convergence Science(融合医学)
14
Tumor Suppressor Genes with Segmental Duplications Are Prone to Somatic Deletions and Structural Variations
具有片段重复的肿瘤抑制基因容易发生体细胞缺失和结构变异
Ziheng Huang; Lin Zhang; Huarong Chen; Xiaodong Liu; Likai Tan; Dan Huang; Yingzhi Liu; Yushan Wang; Xinyi Zhang; Alfred Sze Lok Cheng; Maggie Haitian Wang; Wei Kang; Ka-Fai To; Jun Yu; Ho Ko; Le Yu; Sunny H. Wong; Tony Gin; Matthew Tak Vai Chan; Xiansong Wang; William Ka Kei Wu
Cancer Res (2025) 85 (15): 2939–2952
Corrections(更正)
15
Correction: N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression
更正：N6甲基腺苷受体YTHDF1通过增强NOTCH1表达促进肝细胞癌的恶性和治疗耐药性
Xinyue Zhang; Tianhong Su; Yifan Wu; Yuhong Cai; Lina Wang; Cong Liang; Lei Zhou; Shiyan Wang; Xiao-Xing Li; Sui Peng; Ming Kuang; Jun Yu; Lixia Xu
Cancer Res (2025) 85 (15): 2953
16
Correction: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma
更正：抑制NF-κB依赖的信号传导增强了葡萄膜黑色素瘤对BET抑制的敏感性并克服了抗性
Grazia Ambrosini; Catherine Do; Benjamin Tycko; Ronald B. Realubit; Charles Karan; Elgilda Musi; Richard D. Carvajal; Vivian Chua; Andrew E. Aplin; Gary K. Schwartz
Cancer Res (2025) 85 (15): 2954
Cancer Res[Jour] AND 85[volume] AND 15_Supplement[issue]
癌症研究85卷 15期增刊
https://aacrjournals.org/cancerres/issue/
Abstracts: Frontiers in Cancer Science 2024; November 13-15, 2024; Singapore
摘要：《2024年癌症医学前沿》；2024年11月13日至15日；新加坡
LIGHTNING TALK ABSTRACTS（闪电演讲摘要）
1
Abstract LT01: Identifying Optimal Tumour-specific Promoters for CRISPR/Cas9 Engineering of Armoured CAR T Cells with Enhanced Safety and Efficacy
摘要LT01：鉴定用于增强安全性和有效性的装甲CAR - T细胞CRISPR/Cas9工程的最佳肿瘤特异性启动子
Kah Min Yap; Amanda X. Y. Chen ...
Cancer Res (2025) 85 (15_Supplement): LT01
2
Abstract LT02: CRISPR-Cas9 as a Novel Cancer Gene Therapy Approach against Pancreatic Cancers
摘要LT02：CRISPR-Cas9作为一种新的癌症基因治疗胰腺癌的方法
Selina Shiqing K. Teh; Kirsten Bowland ...
Cancer Res (2025) 85 (15_Supplement): LT02
3
Abstract LT03: Cell confinement by micropatterning induces phenotypic changes in cancer-associated fibroblasts
摘要LT03：微模式诱导的细胞隔离可诱导癌症相关成纤维细胞的表型改变
Aleksandr Mitriashkin; Josephine Yu Yan Yap ...
Cancer Res (2025) 85 (15_Supplement): LT03
4
Abstract LT07: HEPATOCTYE-MACROPHAGE CROSSTALK VIA THE PGRN-EGFR AXIS MODULATES ADAR1-MEDIATED IMMUNITY IN THE LIVER
摘要LT07：通过PGRN-EGFR轴的肝-巨噬细胞交联调节肝脏中ADAR1介导的免疫
Wei Liang Gan; Xi Ren ...
Cancer Res (2025) 85 (15_Supplement): LT07
5
Abstract LT08: Advancing Targeted Gene Therapy: Leveraging Dumbbell-Shaped DNA for Cell-Specific Precision in Cancer, Virus Infection and Mitochondrial Disease
摘要LT08：推进靶向基因治疗：利用哑铃形DNA在癌症、病毒感染和线粒体疾病中实现细胞特异性精确性
Pei She Loh (Rachel); Sushmita Poddar ...
Cancer Res (2025) 85 (15_Supplement): LT08
6
Abstract LT10: Molecular mechanisms of SOCS1-mediated tumor suppression in prostate cancer
摘要LT10：SOCS1介导的前列腺癌症肿瘤抑制的分子机制
Awais Ullah Ihsan; Mozhdeh Namvarpour ...
Cancer Res (2025) 85 (15_Supplement): LT10
POSTER PRESENTATION ABSTRACTS(海报展示摘要)（略）
Cancer Res[Jour] AND 85[volume] AND 16[issue]
癌症研究 85卷 16期
https://aacrjournals.org/cancerres/issue/
In the Spotlightt(焦点)
1
A Spotlight on Oxidative Metabolism in Oncogenic Transformation and Cell Competition
氧化代谢在肿瘤转化和细胞竞争中的作用
Yogaspoorthi J. Subramaniam; Eugenia Piddini
Cancer Res (2025) 85 (16): 2961–2962
In Focus(焦点)
2
Tumor–Immune Cell Interactions in Cancer Progression
癌症进展中的肿瘤-免疫细胞相互作用
Xiaoxue Zhou; Feng Xie; Long Zhang
Cancer Res (2025) 85 (16): 2963–2966
Review(综述)
3
Informatics at the Frontier of Cancer Research
癌症研究前沿的信息学
Kathleen Noller; Taxiarchis Botsis; Pablo G. Camara; Lauren Ciotti; Lee A.D. Cooper; Jeremy Goecks; Malachi Griffith; Brian J. Haas; Trey Ideker; Rachel Karchin; Despina Kontos; Jiaying Lai; Daniel Marcus; Clifford A. Meyer; Kristen Naegle; Sarthak Pati; Bjoern Peters; Dexter Pratt; Benjamin J. Raphael; Michael Reich; Guergana K. Savova; Carrie Wright; Elana J. Fertig; Spyridon Bakas
Cancer Res (2025) 85 (16): 2967–2986
Priority Report(优先报告)
4
SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition
SMAD4缺乏促进胰腺癌进展并赋予TGFβ抑制的易感性
Gilbert Z. Murimwa; Natalie E. Williams; Dina Alzhanova; Amir Mohammadi; Jill M. Westcott; Francisca Beato; Ruifan Dai; Luis Nivelo; Francesca Rossi; Henry K. Fleming; Alexandra F. Tassielli; Zeynep Yazgan; Jason E. Toombs; Jason B. Fleming; Aatur D. Singhi; Cecilia G. Ethun; Huocong Huang; Rolf A. Brekken
Cancer Res (2025) 85 (16): 2987–2996
Cancer Biology(癌症生物学)
5
SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer
SMARCA4缺失会加剧RNA聚合酶II的转录暂停现象，并增加R环的形成，从而抑制卵巢癌中BRCA1介导的DNA损伤修复
Xianbing Zhu; Zheng Fu; Giulio Aceto; Jonathan St-Germain; Kexin Liu; Azadeh Arabzadeh; Yuxuan Qi; Yibo Xue; Leora Witkowski; Elise Graulich; Jutta Steinberger; Selim Misirlioglu; Nicklas Bassani; Racim Sansal; Amber Yasmeen; Geneviève Morin; Jingjie Guo; Anie Monast; Virginie Pilon; Alica Valachová; Kitty Pavlakis; Lili Fu; Walter H. Gotlieb; W. Glenn McCluggage; David Huntsman; Alexander J.R. Bishop; Douglas A. Levine; Morag Park; Yemin Wang; Brian Raught; William D. Foulkes; Sidong Huang
Cancer Res (2025) 85 (16): 2997–3014
Cancer Immunology(癌症免疫学)
6
Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
通过靶向 SOS1 重新激活 cGAS–STING信号传导在 NRAS突变肿瘤中增强抗肿瘤免疫力
Jia-Lu Shan; Kai-Ming Zhang; Wen-Qing Zhong; Xiao-Yu Yang; Zhi-Ling Li; Yun Huang; Tian Du; Dong Yang; Jia-Hong Tang; Yu-Hong Chen; Hai-Liang Zhang; Xiao-Feng Zhu; Rong Deng
Cancer Res (2025) 85 (16): 3015–3031
Cancer Metabolism and Molecular Mechanisms(癌症代谢与分子机制)
7
Genome-Wide CRISPR Screening Reveals That mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer
全基因组CRISPR筛选揭示mTOR抑制在头颈癌中启动铁蛋白自噬和铁凋亡
Keiichi Koshizuka; Xingyu Wu; Kuniaki Sato; Pham Thuy Tien Vo; Gosia M. Murawska; Tomohiko Ishikawa; Zhiyong Wang; Alfredo A. Molinolo; Edward A. Dennis; Cherie-Ann O. Nathan; Prashant Mali; J. Silvio Gutkind
Cancer Res (2025) 85 (16): 3032–3051
8
MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer
MYLK-AS1 通过增强谷氨酰胺代谢促进 EGFR 抑制剂耐药性在非小细胞肺癌中的作用
Tianyu Qu; Lei Song; Jiali Xu; Xiyi Lu; Dandan Yin; Jiali Dai; Chen Zhang; Renhua Guo; Erbao Zhang
Cancer Res (2025) 85 (16): 3052–3071
Translational Cancer Biology(转化癌症生物学)
9
CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer
CARM1介导的MAP2K4甲基化增强MAP2K4的致癌功能，并在三阴性乳腺癌中构成可靶向的依赖性
Eui-Jun Kim; Yidan Wang; Yu-Lin Chen; Min Ma; Peng Liu; Megan S. Bacabac; Jingjing Zhou; Christopher J. Fry; Jordan R. Hoffman; Menggang Yu; Lingjun Li; Aussie Suzuki; Shulin Li; Wei Xu
Cancer Res (2025) 85 (16): 3072–3088
10
Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma
开发一种抗CD99抗体使弥漫性中线胶质瘤能够被靶向治疗
Ilango Balakrishnan; Krishna Madhavan; Angela Pierce; Joshua Michlin; Breauna Brunt; Senthilnath Lakshmanachetty; Dong Wang; John DeSisto; Zachary James Nuss; Nathan Davidson; Faye Walker; Ammu Suresh; Andrew Donson; Bridget Sanford; Kenneth L. Jones; Etienne P. Danis; Siddhartha S. Mitra; Adam L. Green; Nathan Dahl; Rajeev Vibhakar; Sujatha Venkataraman
Cancer Res (2025) 85 (16): 3089–3110
11
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
AREG和EREG是胃食管癌对EGFR抑制反应的预测性生物标志物
Daniela Conticelli; Marco Volante; Filippo Pietrantonio; Claudia Orrù; Martina Olivero; Alessia Nottegar; Felice Borghi; Gian L. Baiocchi; Giovanni Crotti; Uberto Fumagalli Romario; Giovanni De Manzoni; Rossella Reddavid; Roberta Porporato; Dinçer Kılıç; Rebecca Ghione; Erika Calabrò; Russell Petty; Simona Corso; Silvia Giordano; Cristina Migliore
Cancer Res (2025) 85 (16): 3111–3122
Cancer Landscapes（癌症特征）
12
Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
基因组分析揭示肠化生和胃癌的进化特征
Xianfeng Xu; Caiwang Yan; Lijun Bian; Zhe Li; Yuhui Yu; Xia Zhu; Yun Gao; Hao Xu; Fengyuan Li; Yao Liu; Ping Sun; Zheng Wang; Yao Fu; Yue Jiang; Juncheng Dai; Hongxia Ma; Zhibin Hu; Hongbing Shen; Gang Li; Cheng Wang; Guangfu Jin
Cancer Res (2025) 85 (16): 3123–3138
Convergence Science(融合医学)
13
Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy
数学建模和关联分析解读肠道微生物组对癌症免疫治疗的影响
Andreas G. Hadjigeorgiou; Constantinos Harkos; Aditya K. Mishra; Golnaz Morad; Sarah B. Johnson; Nadim J. Ajami; Jennifer A. Wargo; Lance L. Munn; Triantafyllos Stylianopoulos; Rakesh K. Jain
Cancer Res (2025) 85 (16): 3139–3155
14
Adaptation to Volumetric Compression Drives an Apoptosis-Resistant and Invasive Phenotype in Liver Cancer
适应体积压缩驱动肝癌细胞抗凋亡和侵袭性表型
Xiangyu Gong; Noriyoshi Ogino; M. Fátima Leite; Dingyao Zhang; Zehua Chen; Ryan Y. Nguyen; Raymond Liu; Emma Kruglov; Kaitlin Flores; Aidan T. Cabral; Gabriel Moreira de M. Mendes; Barbara E. Ehrlich; Michael Mak
Cancer Res (2025) 85 (16): 3156–3175
Editor’s Notes(编辑注)
15
Editor’s Note: A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression
编辑注：一种靶向TRIP13的小分子抑制剂抑制多发性骨髓瘤进展
Yingcong Wang; Jing Huang; Bo Li; Han Xue; Guido Tricot; Liangning Hu; Zhijian Xu; Xiaoxiang Sun; Shuaikang Chang; Lu Gao; Yi Tao; Hongwei Xu; Yongsheng Xie; Wenqin Xiao; Dandan Yu; Yuanyuan Kong; Gege Chen; Xi Sun; Fulin Lian; Naixia Zhang; Xiaosong Wu; Zhiyong Mao; Fenghuang Zhan; Weiliang Zhu; Jumei Shi
Cancer Res (2025) 85 (16): 3176
16
Editor’s Note: Cell Surface Tetraspanin Tspan8 Contributes to Molecular Pathways of Exosome-Induced Endothelial Cell Activation
编者注：细胞表面四跨膜蛋白Tspan8参与了外泌体诱导的内皮细胞活化的分子途径
Irina Nazarenko; Sanyukta Rana; Alexandra Baumann; Jessica McAlear; Andrea Hellwig; Michael Trendelenburg; Günter Lochnit; Klaus T. Preissner; Margot Zöller
Cancer Res (2025) 85 (16): 3177
Cancer Res[Jour] AND 85[volume] AND 17[issue]
癌症研究 85卷 17期
https://aacrjournals.org/cancerres/issue/
Obituary（讣告）
1
Eva Klein, MD, PhD, FAACR: In Memoriam (1925–2025)
伊娃·克莱因（Eva Klein）医学博士、哲学博士、美国癌症研究学会会士：缅怀（1925-2025）
Maria Teresa Bejarano; Marie Arsenian Henriksson
Cancer Res (2025) 85 (17): 3185.
In the Spotlight（亮点）
2
Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non–Small Cell Lung Cancer
又一块“蛋糕”被揭开：RIT1M90I是非小细胞肺癌中的可干预驱动因素
Cheng Pei Wu; Aria Vaishnavi
Cancer Res (2025) 85 (17): 3186–3188.
3
Bone Voyage: OPN's Path from Skeleton to Systemic Immunosuppression
骨之旅：骨桥蛋白（OPN）从骨骼到全身免疫抑制的路径
Kyoko Hashimoto; Kazuo Okamoto; Hiroshi Takayanagi
Cancer Res (2025) 85 (17): 3189–3191.
In Focus（聚焦）
4
Lactylation in Cancer: Advances, Challenges, and Future Perspectives
癌症中的乳酸化：进展、挑战与未来展望
Zhi Zong; Long Zhang; Fangfang Zhou
Cancer Res (2025) 85 (17): 3192–3195.
Priority Report（重点研究简报）
5
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma
RIT1驱动肺腺癌的致癌性转化，是可干预的靶点
Alessandro M. Mozzarelli; Antonio Cuevas-Navarro; Emily G. Shuldiner; Martha Vega; Walid K. Chatila; Jierui Xu; Henry S. Walch; Yuzhe Niu; Dmitri A. Petrov; Nikolaus Schultz; Anatoly Urisman; Charles M. Rudin; Monte M. Winslow; Pau Castel
Cancer Res (2025) 85 (17): 3196–3206.
Cancer Biology（癌症生物学）
6
RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy
RIT1M90I是肺腺癌发生和靶向治疗耐药的驱动因素
Ashley V. DiMarco; Mirunalini Ravichandran; Jeff Lau; Anthony Lima; Jennifer Lacap; Pablo Saenz-Lopez Larrocha; Eva Lin; Julie Weng; Luca Gerosa; Thomas Hunsaker; Yang Xiao; Monika Miś; Charles Havnar; Wennie Chen; Kai H. Barck; Klara Totpal; Oded Foreman; Nicole M. Sodir; Mark Merchant; Danilo Maddalo
Cancer Res (2025) 85 (17): 3207–3218.
7
XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance
XPO1R749Q突变与癌症中的POLE突变共存，可成为克服化疗耐药性的靶点
Tulasigeri M. Totiger; Wannasiri Chiraphapphaiboon; Yasmine Baca; Sana Chaudhry; Ryan Q. Notti; Skye Montoya; Monika Chojnacka; Gabriel Gaidosh; Jumana Afaghani; Maurizio Affer; Christopher Armstrong; Paul M. Kavanaugh; Efe Karaca; Jenna Zabroski; Michael Lewis; Alyssa Maye; Jacob Jahn; Rajesh K. Soni; Daniel Bilbao; Phil Walker; Andrew Elliott; Emil Lou; Wafik S. El-Deiry; Jose Antonio Rodriguez; Hai Dang Nguyen; Justin Taylor
Cancer Res (2025) 85 (17): 3219–3233.
8
The C-Terminal Kinase Domain–Binding and Suppression Motif Prevents Constitutive Activation of FGFR2
C端激酶结构域结合与抑制基序可防止成纤维细胞生长因子受体2（FGFR2）的组成性激活
Daniel Zingg; Chi-Chuan Lin; Julia Yemelyanenko; Lukasz Wieteska; Sjors M. Kas; Onno B. Bleijerveld; Xue Chao; Jinhyuk Bhin; Catrin Lutz; Ellen Wientjens; Sjoerd Klarenbeek; Giulia Zanetti; Stefano Annunziato; Bjørn Siteur; Eline van der Burg; Anne Paulien Drenth; Marieke van de Ven; Lodewyk F.A. Wessels; Maarten Altelaar; John E. Ladbury; Jos Jonkers
Cancer Res (2025) 85 (17): 3234–3257.
Cancer Immunology（癌症免疫学）
9
Tumor-Specific MHC-II Activates CD4+ and CD8+ T Cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy
头颈部鳞状细胞癌中肿瘤特异性主要组织相容性复合体II类分子（MHC-II）激活CD4+和CD8+T细胞，增强免疫治疗疗效
Yuying Zhang; Jinbang Li; Xiaoyu Guo; Zhao Gao; Junchen Pan; Sheng Nong; Jiyuan Ma; Gang Chen; Jiali Zhang
Cancer Res (2025) 85 (17): 3258–3274.
Cancer Metabolism and Molecular Mechanisms（癌症代谢与分子机制）
10
PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer
过氧化物酶体增殖物激活受体δ（PPARδ）协调胰腺癌对微环境信号的促转移代谢反应
Beatriz Parejo-Alonso; David Barneda; Sara Maria David Trabulo; Sarah Courtois; Sara Compte-Sancerni; Jelena Zurkovic; Laura Ruiz-Cañas; Quan Zheng; Jiajia Tang; Matthias M. Gaida; Ulf Schmitz; Pilar Irun; Laure Penin-Peyta; Shanthini Mary Crusz; Petra Jagušt; Pilar Espiau-Romera; Alba Royo-García; Andrés Gordo-Ortiz; Mariia Yuneva; Meng-Lay Lin; Shenghui Huang; Ming-Hsin Yang; Angel Lanas; Bruno Sainz, Jr; Christoph Thiele; Christopher Heeschen; Patricia Sancho
Cancer Res (2025) 85 (17): 3275–3291.
11
TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis
TRAF3IP2-AS1缺乏诱导坏死性凋亡，促进胰腺癌肝转移
Yong-Ding Wu; Xiao-Xiao Huang; Hao-Xiang Zhang; Yu Pan; Cheng-Ke Xie; Ge Li; Cai-Feng Lin; Xin-Quan Lin; Zhi-Yuan Li; Yin-Hao Chen; Jian-Fei Hu; Hong-Yi Lin; Shun-Cang Zhu; Zu-Wei Wang; Yi-Feng Tian; Qiao-Wei Li; Cheng-Yu Liao; Shi Chen
Cancer Res (2025) 85 (17): 3292–3312.
12
Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression
神经酰胺诱导的代谢应激耗竭延胡索酸，驱动线粒体自噬以介导肿瘤抑制
Natalia V. Oleinik; Firdevs Cansu Atilgan; Mohamed Faisal Kassir; Han Gyul Lee; Alhaji H. Janneh; Wyatt Wofford; Chase Walton; Zdzislaw M. Szulc; Elizabeth G. Hill; Alexander V. Alekseyenko; Huseyin Cimen; Jessica H. Hartman; Christina Voelkel-Johnson; Michael B. Lilly; John J. Lemasters; Norma Frizzell; Xue-Zhong Yu; Shikhar Mehrotra; Besim Ogretmen
Cancer Res (2025) 85 (17): 3313–3334.
Translational Cancer Biology（癌症转化生物学）
13
Dietary Fiber Lacks a Consistent Effect on Immune Checkpoint Blockade Efficacy Across Diverse Murine Tumor Models
在不同的小鼠肿瘤模型中，膳食纤维对免疫检查点阻断疗效的影响不一致
Asael Roichman; Gabriela Reyes-Castellanos; Ziqing Chen; Zihong Chen; Sarah J. Mitchell; Michael R. MacArthur; Akshada Sawant; Llewelyn Levett; Jesse R. Powers; Victoria Burgo; Maria Gomez-Jenkins; Maria Ibrahim; Xincheng Xu; Beianka Tomlinson; Xiang Hang; Eric G. Pamer; Yong Wei; Yibin Kang; Eileen P. White; Joshua D. Rabinowitz
Cancer Res (2025) 85 (17): 3335–3347.
14
NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma
神经纤维蛋白1（NF1）缺失促进表皮生长因子受体（EGFR）激活，使NF1突变型黑色素瘤对EGFR抑制敏感
Milad Ibrahim; Irineu Illa-Bochaca; George Jour; Eleazar Vega-Saenz de Miera; Joseph Fracasso; Kelly Ruggles; Iman Osman; Markus Schober
Cancer Res (2025) 85 (17): 3348–3364.
Cancer Res[Jour] AND 85[volume] AND 18[issue]
癌症研究 85卷 18期
https://aacrjournals.org/cancerres/issue/
In the Spotlight（聚焦）
1
A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer
三阴性乳腺癌细胞内检查点信号传导的新“VISTA”
Jacqueline J. Tao; Neil Vasan
Cancer Res (2025) 85 (18): 3371–3372.
2
The Approaching Darwinian Era in Oncology
肿瘤学中达尔文时代的来临
Robert A. Gatenby
Cancer Res (2025) 85 (18): 3373–3375.
3
Catch Me If You Can: Could Y Chromosome Loss Spread in Cancer?
想抓我？没那么容易：Y染色体缺失会在癌症中传播吗？
Zihai Li
Cancer Res (2025) 85 (18): 3376–3377.
Review（综述）
4
Plasticity and Functional Heterogeneity of Cancer-Associated Fibroblasts
癌症相关成纤维细胞的可塑性与功能异质性
Jacqueline M. Flynn; Nikita Thadani; Erin E. Gallagher; Isabella Azzaro; Cameron M. Bodnar; Colin P. McCarty; Gabriele Romano; Marie R. Webster; Claudia Capparelli
Cancer Res (2025) 85 (18): 3378–3398.
Cancer Biology（癌症生物学）
5
A Four Amino Acid Intracellular Motif of VISTA Blocks Growth Receptor Signaling in Cancer Cells to Induce Tumor Suppression
VISTA的四个氨基酸细胞内基序可阻断癌细胞中的生长受体信号传导以诱导肿瘤抑制
Yan Zhao; Tina Andoh; Fatima Charles; Priyanka Reddy; Kristina Paul; Harsh Goar; Ishrat Durdana; Caiden J. Golder; Ashley N. Hardy; Marisa M. Juntilla; Soo-Ryum Yang; Chien-Yu Lin; Idit Sagiv-Barfi; Benjamin S. Geller; Stephen Moore; Dipti Thakkar; Jerome D. Boyd-Kirkup; Yan Peng; James M. Ford; Melinda L. Telli; Song Zhang; Allison W. Kurian; Robert B. West; Tao Yue; Andrew M. Lipchik; Michael P. Snyder; Joshua J. Gruber
Cancer Res (2025) 85 (18): 3399–3415.
6
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells
线粒体钙单向转运体将乙酰辅酶A代谢和H3K27乙酰化联系起来以维持胶质母细胞瘤干细胞
Guangqin Liu; Haoqian Zhang; Siqi Chen; Jun Gao; Haixin Zhao; Yan Dong; Changwei Liu; Xuechen Wei; Ting Li; Chang Lu; Haizhen Zhu; Dingyi Lu; Shiyu Feng; Teng Li; Weina Zhang; Qing Xia; Jianghong Man; Tao Zhou; Jiayi Chen; Ailing Li; Xin Pan
Cancer Res (2025) 85 (18): 3416–3434.
Cancer Immunology（癌症免疫学）
7
Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion
前列腺癌细胞在外泌体中分泌PD-1以增强髓源性抑制细胞活性并促进肿瘤免疫逃逸
Jie Zhang; Weiwu Chen; Chen Zhang; Qian He; Xudong Wang; Jiayu Han; Peng Gao; Kunyu Wang; Haoze Xie; Feng Gao; Yining Guo; Wenhao Guo; Haofei Jiang; Jing Le; Ruichen Zang; Sisi Mo; Haobo Fan; Xiaoxiao Zhu; Xinrong Jiang; Fengbin Gao; Yanlan Yu; Guoqing Ding; Yicheng Chen
Cancer Res (2025) 85 (18): 3435–3453.
8
FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
肝细胞癌中FADD的激活可增强CD8+ T细胞反应并增强对免疫检查点抑制剂的敏感性
Jiahuan Lu; Thomas Ting-Hei Chan; Yun Wang; Jingya Wang; Zhewen Xiong; Jingqing Li; Yixuan Zhang; Huanyu Wang; Jintian Chen; Weiqin Yang; Jing Wang; Yalin Tu; Howard H.W. Leung; Raymond Wai Ming Lung; Wei Kang; Man Tong; Dan Michelle Wang; Qi-Nian Wu; Zhao-Lei Zeng; Alfred Sze-Lok Cheng; Ka-Fai To; Anthony W.H. Chan; Jingying Zhou
Cancer Res (2025) 85 (18): 3454–3470.
Cancer Metabolism and Molecular Mechanisms（癌症代谢与分子机制）
9
Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer
选择性利用丙氨酸转运体是ARID1A突变型卵巢癌的治疗弱点
Hao Nie; Liping Liao; Rafal J. Zielinski; Javier A. Gomez; Akshay V. Basi; Erin H. Seeley; Lin Tan; Agnes Julia Bilecz; Wei Zhou; Heng Liu; Chen Wang; Shuai Wu; Yuan Qi; Taito Miyamoto; Federica Severi; Aaron R. Goldman; Shengqing Gu; Anil K. Sood; Amir A. Jazaeri; Ronny Drapkin; Daniel T. Claiborne; Nan Zhang; Philip L. Lorenzi; Jared K. Burks; Ernst Lengyel; Eyal Gottlieb; Rugang Zhang
Cancer Res (2025) 85 (18): 3471–3489.
Therapeutic Development and Chemical Biology（治疗开发与生物化学）
10
A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition
一种基于肽的BRCA2 PROTAC降解剂可使转移性去势抵抗性前列腺癌对PARP抑制剂敏感
Qi Ye; Bohan Ma; Lei Li; Zixi Wang; Mingming Lu; Jialu Kang; Yuzeshi Lei; Shan Xu; Ke Wang; Yanlin Jian; Yizeng Fan; Bin Wang; Jing Liu; Yang Gao; Jian Ma; Lei Li
Cancer Res (2025) 85 (18): 3490–3502.
Translational Cancer Biology（癌症转化生物学）
11
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
适应性治疗利用化疗耐药性卵巢癌的适应性缺陷实现长期肿瘤控制
Helen Hockings; Eszter Lakatos; Weini Huang; Maximilian Mossner; Mohammed A. Khan; Nikolina Bakali; Jacqueline McDermott; Kane Smith; Ann‐Marie Baker; Trevor A. Graham; Michelle Lockley
Cancer Res (2025) 85 (18): 3503–3517.
12
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer
CRISPR-药物组合筛选确定了针对MTAP缺失型癌症的有效联合治疗方案
Nikola Knoll; Sarah Masser; Blanka Bordas; Richard Y. Ebright; Guangyan Li; Devishi Kesar; Eliana Destefanis; Nicholas Kania; Diego J. Rodriguez; Jayu Jen; Sydney E. Zagar; Caleb Mensah; Zixin Chen; Samuel J. Moffitt; Erhumuoghene M. Enakireru; Yao He; Baomou Feng; Mira K. Chokshi; Cyrus Y. Jin; Srivatsan Raghavan; William R. Sellers; Kathleen M. Mulvaney
Cancer Res (2025) 85 (18): 3518–3539.
13
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
MTA协同PRMT5抑制剂BMS-986504与KRAS抑制剂联合是治疗MTAP缺失型KRAS突变胰腺癌的有效治疗策略
Kristina Drizyte-Miller; Lars D. Engstrom; Jeffrey A. Klomp; Clint A. Stalnecker; Addison G. Stamey; Khalilah E. Taylor; Mallory K. Roach; Ryan Robb; Laura M. Waters; Andrew Calinisan; Seamus Degan; Wen-Hsuan Chang; Xousaen M. Helu; David Nguyen; Elisa Baldelli; Mariaelena Pierobon; Emanuel F. Petricoin; David M. Briere; Jill Hallin; James G. Christensen; Kirsten L. Bryant; Adrienne D. Cox; Peter Olson; Channing J. Der
Cancer Res (2025) 85 (18): 3540–3557.
Cancer Landscapes（癌症特征）
14
Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
对新辅助化疗治疗前后的卵巢癌进行多组学分析揭示了肿瘤发生和化疗反应的介导因子
Mark C. Valentine; Mary M. Mullen; Emilee N. Kotnik; Matthew A. Powell; Premal H. Thaker; Carolyn K. McCourt; Lindsay M. Kuroki; Andrea R. Hagemann; Rebecca C. Arend; Alex S. Holehouse; Robi Mitra; David G. Mutch; Katherine C. Fuh
Cancer Res (2025) 85 (18): 3558–3570.
Editor’s Note（编者按）
15
Editor’s Note: Nuclear-Cytoplasmic Partitioning of Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Differentially Regulates the Cell Cycle and Apoptosis
编者按：第10号染色体缺失的磷酸酶和张力蛋白同源物（PTEN）的核质分布差异调控细胞周期和细胞凋亡
Ji-Hyun Chung; Charis Eng
Cancer Res (2025) 85 (18): 3571.
Retraction（撤稿声明）
16
Retraction: Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Has Nuclear Localization Signal-Like Sequences for Nuclear Import Mediated by Major Vault Protein
撤稿声明：第10号染色体缺失的磷酸酶和张力蛋白同源物（PTEN）具有由主要穹窿蛋白介导的核定位信号样序列以实现核输入
Ji-Hyun Chung; Margaret E. Ginn-Pease; Charis Eng
Cancer Res (2025) 85 (18): 3572.
Cancer Res[Jour] AND 85[volume] AND 18_Supplement[issue]
癌症研究 85卷 18期增刊
https://aacrjournals.org/cancerres/issue/85/18_Supplement
Abstracts: AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research; September 19-21, 2025; Denver, CO
摘要：美国癌症研究协会（AACR）癌症研究特别会议：卵巢癌研究进展；2025年9月19 - 21日；美国科罗拉多州丹佛市
GENOMICS
基因组学
KEYNOTE LECTURE
主题演讲
PATHOLOGY
病理学
PATIENT ADVOCACY: CLINICAL TRIALS AND SURVIVORSHIP
患者权益倡导：临床试验与生存者关怀
PRECISION THERAPY
精准治疗
TUMOR HETEROGENEITY
肿瘤异质性
TUMOR IMMUNOLOGY
肿瘤免疫学
TUMOR IMMUNOLOGY (BIOLOGY)
肿瘤免疫学（生物学方向）
TUMOR INITIATION
肿瘤发生起始
OTHER TOPICS
其他主题
Cancer Res[Jour] AND 85[volume] AND 18_Supplement_2[issue]
癌症研究 85卷 18期增刊2期
https://aacrjournals.org/cancerres/issue/85/18_Supplement_2
Abstracts: AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology to Breakthrough Therapies; September 25-28, 2025; Boston, MA
摘要：美国癌症研究协会（AACR）癌症研究特别会议：儿童癌症领域的发现与创新——从生物学研究到突破性疗法；2025年9月25 - 28日；美国马萨诸塞州波士顿市
BIOMARKERS AND INTEGRATION OF MOLECULAR APPROACHES INTO DIAGNOSTICS
生物标志物及分子方法在诊断中的应用整合
CANCER BIOLOGY, TUMOR HETEROGENEITY, EARLY DETECTION AND CTDNA
癌症生物学、肿瘤异质性、早期检测与循环肿瘤DNA（ctDNA）
CLINICAL TRIALS
临床试验
DEVELOPMENT IN CANCER AND CANCER EPIGENETICS
癌症发生发展及癌症表观遗传学研究
DISCOVERY AND TRANSLATION OF TARGETS
靶点发现与转化应用
IMMUNOLOGY AND IMMUNO-ONCOLOGY IN CHILDHOOD CANCERS
儿童癌症的免疫学与免疫肿瘤学
MECHANISMS UNDERLYING CHILDHOOD CANCER
儿童癌症的潜在发生机制
OTHER TOPICS
其他主题
Cancer Res[Jour] AND 85[volume] AND 18_Supplement_3[issue]
癌症研究 85卷 18期增刊3期
https://aacrjournals.org/cancerres/issue/85/18_Supplement_3
Abstracts: AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; September 28 - October 1, 2025; Boston, MA
摘要：美国癌症研究协会（AACR）癌症研究特别会议：胰腺癌研究进展——新兴科学推动变革性解决方案；2025年9月28日 - 10月1日；马萨诸塞州波士顿市
BIOLOGY OF PANCREATIC CANCER PROGRESSION
胰腺癌进展生物学
CLINICAL TRIALS (INCLUDING TRIALS IN PROGRESS)
临床试验（含进行中的试验）
HARNESSING THE IMMUNE SYSTEM TO TREAT PANCREATIC CANCER
利用免疫系统治疗胰腺癌
NEW THERAPEUTIC STRATEGIES
新型治疗策略
REVOLUTIONIZING EARLY DIAGNOSIS AND PREVENTION
革新早期诊断与预防手段
SPOTLIGHT ON NEW DRUG DEVELOPMENT
聚焦新药研发
TRANSLATIONAL ADVANCES TO DISSECT PANCREATIC CANCER TREATMENT RESPONSE
转化研究进展：解析胰腺癌治疗反应
TUMOR HETEROGENEITY AND EVOLUTION
肿瘤异质性与演进
OTHER TOPICS
其他主题
Cancer Res[Jour] AND 85[volume] AND 19[issue]
癌症研究 85卷 19期
https://aacrjournals.org/cancerres/issue/
In the Spotlight（焦点）
1
Ceramide Links Alzheimer’s Disease to Decreased Cancer Risk: A Lipid Behind the Enigma of Inverse Comorbidity
神经酰胺：连接阿尔茨海默病与癌症风险降低的纽带——逆共病现象背后的脂质奥秘
Erhard Bieberich
Cancer Res (2025) 85 (19): 3579–3581.
2
Generations in Flux: Tracking the Birth of Cellular Heterogeneity in Cancer
代际更迭：追踪癌症细胞异质性的起源
Aaron McKenna
Cancer Res (2025) 85 (19): 3582–3583.
Review（综述）
3
Challenges and Opportunities in Analyzing Cancer-Associated Microbiomes
分析癌症相关微生物组的挑战与机遇
Minghao Chia; Mihai Pop; Steven L. Salzberg; Niranjan Nagarajan
Cancer Res (2025) 85 (19): 3584–3595.
Resource Report（资源报告）
4
Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells
泛癌症分析完善肿瘤浸润树突状细胞的单细胞图谱
Tianyi Ma; Xiaojing Chu; Jinyu Wang; Xiangjie Li; Yu Zhang; Dan Tong; Wenbin Xu; Guohui Dang; Lu Qi; Yuhui Miao; Zemin Zhang; Sijin Cheng
Cancer Res (2025) 85 (19): 3596–3613.
Cancer Biology（癌症生物学）
5
Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells
SOX10缺陷型黑色素瘤中转谷氨酰胺酶-2升高促进肿瘤发生并减少肿瘤内CD4+ T细胞
Signe Caksa; Timothy J. Purwin; Dan A. Erkes; Kristen M. DeRosa; Erica Kitterman; Samantha M. Barnada; Casey D. Stefanski; Haley P. Wilson; Glenn L. Mersky; McKenna Q. Glasheen; Jacob S. Heilizer; Namra Ajmal; Yunguang Sun; Joanna S.Y. Chan; Hallgeir Rui; Inna Chervoneva; Claudia Capparelli; Andrew E. Aplin
Cancer Res (2025) 85 (19): 3614–3632.
6
Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma
肿瘤来源的CCL16通过巨噬细胞ICAM-1受体使肿瘤血管正常化并增强肝细胞癌免疫治疗疗效
Kunling Chen; Huolun Feng; Yujie Zhang; Jingyuan Pei; Yuyan Xu; Xiangxu Wei; Zhuohao Chen; Zhoubin Feng; Lei Cai; Yong Li; Liang Zhao; Mingxin Pan
Cancer Res (2025) 85 (19): 3633–3650.
Cancer Metabolism and Molecular Mechanisms（癌症代谢与分子机制）
7
BBOX1 Is a Metabolic Checkpoint That Mediates Metastatic Cancer Cell Evasion from Immunosurveillance by NK Cells
BBOX1是代谢检查点，介导转移性癌细胞逃逸自然杀伤（NK）细胞的免疫监视
Chuanjie Zhang; Hongchao He; Yi Gao; Jiawei Ding; Hai Huang; Yixun Liu; Hanqing Liu; Jun Xiao; Dan-feng Xu; Zunguo Du; Zhenbo Zhang; Lechi Ye
Cancer Res (2025) 85 (19): 3651–3670.
8
Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma
缺氧诱导的肌酸摄取重编程代谢，对抗PARP1介导的细胞死亡并促进肝细胞癌进展
Rui-Zhe Li; Guo-Qiang Pan; Chen Xiong; Zi-Niu Ding; Tuan-Song Zhang; Lun-Jie Yan; Dongxu Wang; Xiaolu Zhang; Xiao-Feng Dong; Yu-Chuan Yan; Yu Zhou; Rui Dong; Zhao-Ru Dong; Tao Li
Cancer Res (2025) 85 (19): 3671–3688.
9
TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression
TERC刺激脂肪酸代谢以促进膀胱癌进展
Chen Chen; Yuting Gao; Renquan Lu; Ying Wu; Yiwen Yao; Ruixin Sun; Junlu Wu; Ping Ji; Wenqiang Quan; Denglong Wu; Zujun Sun; Dong Li
Cancer Res (2025) 85 (19): 3689–3705.
Therapeutic Development and Chemical Biology（治疗开发与生物化学）
10
Lipid Nanoparticle–Encapsulated mRNAs Encoding Tumor-Specific Toxin Proteins Selectively Target Cancer Cells and Stimulate T-cell Infiltration
脂质纳米颗粒包裹的编码肿瘤特异性毒素蛋白的mRNA选择性靶向癌细胞并刺激T细胞浸润
Rui Zhou; Lu Han; Jing Wang; Ling Ma; Tingting Zhang; Tianming Qi; Meichen Liu; Yijie Dong; Weiguo Zhang; Shan Cen
Cancer Res (2025) 85 (19): 3706–3716.
Translational Cancer Biology（癌症转化生物学）
11
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy
通过抑制帽子依赖性起始来阻断NRF2翻译，使淋巴瘤细胞对铁死亡和嵌合抗原受体（CAR）T细胞免疫治疗敏感
Paola Manara; Austin D. Newsam; Venu Venkatarame Gowda Saralamma; Tyler Andrew Cunningham; Drew Lazenby; J.J.David Ho; Marco Vincenzo Russo; Abdessamad Youssfi Alaoui; Dhanvantri Chahar; Alicia Bilbao Martinez; Nikolai Fattakhov; Alexandra Marie Carbone; Olivia Barbara Farag; Alexa Marie Barroso; Kyle Hoffman; Francesco Maura; Daniel Bilbao; Jonathan H. Schatz
Cancer Res (2025) 85 (19): 3717–3736.
12
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy
碳酸酐酶抑制使3组髓母细胞瘤对放疗敏感
Cory M. Richman; Alexandra Rasnitsyn; Borja L. Holgado; Maria Vladoiu; Namal Abeysundara; Sandra Majo; Sara Chabi; Lucie J. Taunay; Hiromichi Suzuki; Ichiyo Shibahara; Joonas Haapasalo; Jonelle G. Pallotta; Tajana Douglas; Kaitlin Kharas; Kyle Juraschka; Oliver Ocsenas; Sachin A. Kumar; Kristiina Nordfors; Ana Guerreiro Stücklin; Raul A. Suarez; Jiao Zhang; Xiaochong Wu; Craig Daniels; Livia Garzia; Jüri Reimand; Olivier Saulnier; Thomas E. Merchant; Celio Pouponnot; David R. Raleigh; Michael D. Taylor; Pasqualino De Antonellis
Cancer Res (2025) 85 (19): 3737–3751.
13
Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis
催产素受体调控Hippo/YAP轴以驱动肝细胞癌发生
Huijie Yang; Jiayao Cui; Peng Su; Xiujie Cui; Haojie Guo; Penghe Yang; Shuqing Zhang; Chenmiao Zhang; Mingxi Fu; Zhongbo Li; Yinlu Ding; Ting Zhuang; Jian Zhu; Xiaodong Tan
Cancer Res (2025) 85 (19): 3752–3770.
Cancer Landscapes（癌症特征）
14
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
整合组学和多队列分析确定一个增强子变异，将铁死亡与前列腺癌精准治疗联系起来
Sheng Ma; Yue Ge; Zequn Lu; Junbiao Zhang; Qin Zhang; Yuzheng Peng; Zirui Xi; Hao Peng; Meng-Yao Xu; Zezhong Xiong; Yuan Gao; Yanan Wang; Le Li; Chunyu Zhang; Zheng Chao; Tengfei Li; Ruiyun Zhang; Qiang Zhang; David A. Horne; Baojun Wang; Xu Gao; Xu Zhang; Jianbo Tian; Jing Li; Meng Jin; Gong-Hong Wei; Zhihua Wang
Cancer Res (2025) 85 (19): 3771–3790.
Convergence Science（互动医学）
15
Alzheimer's Disease–Associated Amyloid-βPrecursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity
阿尔茨海默病相关淀粉样蛋白-β前体蛋白可防止衰老应激诱导的线粒体自噬和富马酸盐耗竭，从而改善抗肿瘤免疫
Mohamed Faisal Kassir; Han Gyul Lee; Natalia V. Oleinik; Wyatt Wofford; Chase Walton; Firdevs Cansu Atilgan; Alhaji H. Janneh; Paramita Chakraborty; Kubra Calisir; Elif Percin; Silvia G. Vaena; Kalyani Sonawane; Ashish Deshmukh; Narayan R. Bhat; Kumar Sambamurti; Onder Albayram; Ozgur Sahin; Shikhar Mehrotra; Besim Ogretmen
Cancer Res (2025) 85 (19): 3791–3811.
Editor’s Notes（编者按）
16
Editor’s Note: A Novel L-Asparaginase with low L-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo
编者按：一种低L-谷氨酰胺酶共活性的新型L-天冬酰胺酶对体内T细胞和B细胞急性淋巴细胞白血病均具有高效治疗作用
Hien Anh Nguyen; Ying Su; Jenny Y. Zhang; Aleksandar Antanasijevic; Michael Caffrey; Amanda M. Schalk; Li Liu; Damiano Rondelli; Annie Oh; Dolores L. Mahmud; Maarten C. Bosland; Andre Kajdacsy-Balla; Sofie Peirs; Tim Lammens; Veerle Mondelaers; Barbara De Moerloose; Steven Goossens; Michael J. Schlicht; Kasim K. Kabirov; Alexander V. Lyubimov; Bradley J. Merrill; Yogen Sauntharajah; Pieter Van Vlierberghe; Arnon Lavie
Cancer Res (2025) 85 (19): 3812.
17
Editor’s Note: Werner Syndrome Helicase Has a Critical Role in DNA Damage Responses in the Absence of a Functional Fanconi Anemia Pathway
编者按：沃纳综合征解旋酶在无功能性范可尼贫血通路时对DNA损伤反应起关键作用
Monika Aggarwal; Taraswi Banerjee; Joshua A. Sommers; Chiara Iannascoli; Pietro Pichierri; Robert H. Shoemaker; Robert M. Brosh, Jr.
Cancer Res (2025) 85 (19): 3813.
Cancer Res[Jour] AND 85[volume] AND 20[issue]
癌症研究 85卷 20期
https://aacrjournals.org/cancerres/issue/
In the Spotlight（聚焦热点）
1
Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade Therapy
精准表观遗传重编码：抑制CoREST使STK11突变肿瘤对免疫检查点阻断疗法敏感
De-Chen Lin; Keyue Shen
Cancer Res (2025) 85 (20): 3821–3822.
2
From Harmony to Discord: Multicellular Coordination in Tissues and Its Rewiring in Cancer
从和谐到失调：组织中多细胞协调及其在癌症中的重编码
Merve Dede; Vakul Mohanty; Ken Chen
Cancer Res (2025) 85 (20): 3823–3825.
Review（综述）
3
P2 Purinergic Receptors in Tumor Immunity
肿瘤免疫中的P2嘌呤能受体
Xin Wang; Shu-Heng Jiang; Mingyue Ma; Shuqi Cai; Dong Song; Bing Han
Cancer Res (2025) 85 (20): 3826–3841.
Priority Report（优先报道）
4
Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
PROX1的表观遗传去抑制促进神经内分泌前列腺癌进展
Varadha Balaji Venkadakrishnan; Adam Presser; Nathaniel C.E. Voss; James Neiswender; Lisa Brenan; Keira Prenza Sosa; Kenny Weng; Andres M. Acosta; Francisca Vazquez; Himisha Beltran
Cancer Res (2025) 85 (20): 3842–3854.
Resource Report（资源报道）
5
Genetic Control of tRNA-Derived Fragments Contributes to Cancer Risk
tRNA衍生片段的遗传调控对癌症风险的影响
Bin Li; Hanting Li; Yan Li; Zhirui Chen; Danyi Zou; Chunyi He; Songqiang Li; Kexin Hu; Caibo Ning; Yanmin Li; Hui Geng; Shuhui Yang; Chaoqun Huang; Xiaojun Yang; Qiuhong Wang; Xu Zhu; Xiangpan Li; Ying Zhu; Meng Jin; Xiaoping Miao; Jianbo Tian
Cancer Res (2025) 85 (20): 3855–3874.
Cancer Biology（癌症生物学）
6
HPV E5 Mediates Resistance to Chemotherapy and Radiation by Promoting a Stem Cell–Like Phenotype in Head and Neck Squamous Cell Carcinoma
HPV E5通过促进头颈部鳞状细胞癌的干细胞样表型，介导对化疗和放疗的耐药性
Souvick Roy; Sayuri Miyauchi; Riley N. Jones; Sangwoo S. Kim; Aldo Venuti; Angad S. Boparai; Loren K. Mell; Theresa Guo; Joseph A. Califano; Andrew B. Sharabi
Cancer Res (2025) 85 (20): 3875–3893.
7
SRSF9 Forms Phase-Separated Condensates to Promote Ovarian Cancer Progression by Inducing RNA Alternative Splicing That Is Inhibited by m6A Modification
SRSF9形成相分离凝聚物，通过诱导RNA选择性剪接促进卵巢癌进展，而该过程受m6A修饰抑制
Xinzhao Zuo; Jie Xu; Dan Yang; Chenyue Yang; Xiaoyi Liu; Ningxuan Chen; Haocheng Wang; Xin Luo; Qingya Luo; Yuan Wang; Qinglv Wei; Yu Yang; Hongyan Zhao; Jing Xu; Wei Wang; Tao Liu; Ping Yi
Cancer Res (2025) 85 (20): 3894–3909.
Cancer Immunology（癌症免疫学）
8
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy
达沙替尼重塑肿瘤微环境，使小细胞肺癌对免疫治疗敏感
Esther Redin; Nerea Otegui; Mirentxu Santos; Sergio Leon; Miriam Redrado; Diego Serrano; Eva Fernandez de Pierola; Joan Salvador Russo-Cabrera; Irene Ferrer; Maria Olmedo; Angel Diaz-Lagares; Maeva Houry; Silve Vicent; Anna Vilalta; Patricia Mondelo-Macía; Jorge García-González; Luis León-Mateos; Alvaro Gonzalez; Luis Paz-Ares; Rafael López; Miguel F. Sanmamed; Luis Montuenga; Alfonso Calvo
Cancer Res (2025) 85 (20): 3910–3929.
Cancer Metabolism and Molecular Mechanisms（癌症代谢与分子机制）
9
Exon Skipping of Ste20-Like Kinase Enhances Glycolysis and Tumor Progression by Activating Enolase 1–Mediated Phosphoenolpyruvate Production
Ste20样激酶的外显子跳跃通过激活烯醇化酶1介导的磷酸烯醇式丙酮酸生成，增强糖酵解和肿瘤进展
Zeyu Chen; Jingyu Liao; Chang Zhu; Ruizhi Chang; Huifang Liang; Zeyang Ding; Zhao Huang; Xiaoping Chen; Junnan Liang; Bixiang Zhang
Cancer Res (2025) 85 (20): 3930–3948.
10
PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA
PCBP2通过抑制m6A甲基化稳定PARP1 mRNA，介导乳腺癌对奥拉帕利的耐药性
Zhaochang Qi; Lifang He; Zemei Xu; Xi Luo; Likeng Ji; Chenting Lin; Armando E. Giuliano; Xiaojiang Cui; Zihao Deng; Jundong Wu; Stanley Li Lin; Yukun Cui
Cancer Res (2025) 85 (20): 3949–3965.
Therapeutic Development and Chemical Biology（治疗方法开发与生物化学）
11
TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti–PD-1 Immunotherapy
TNG260是一种小分子CoREST抑制剂，可使STK11突变肿瘤对抗PD-1免疫治疗敏感
Leanne G. Ahronian; Soumyadip Sahu; Minjie Zhang; Ayushi S. Patel; Ke Geng; Reshmee Bhattacharya; Gerald S. Falchook; Jonathan W. Goldman; Alexander I. Spira; Salman R. Punekar; David R. Spigel; Judy S. Wang; Ferdinandos Skoulidis; Janaye Stephens; Mary Meynardie; Jaylen M. Powell; Alfonso Lopez; Michela Ranieri; Magdalena A. Ploszaj; Yi Jer Tan; Yeuan Ting Lee; Yi Yu; Jiehui Deng; Ting Chen; Patrick McCarren; Alice Tsai; Suleman S. Hussain; Brian Doyon; Kenjie Amemiya; Jacques Ermolieff; Preksha Shahagadkar; Nikitha M. Das; Lauren R. Flynn; Julie A. Shields; Laney Danielczyk; Brian J. McMillan; Andre Mignault; Samuel R. Meier; Hsin-Jung Wu; David J. Guerin; Douglas A. Whittington; Chengyin Min; Iga Sienczylo; John P. Maxwell; Heather J. DiBenedetto; Hideo Watanabe; Brian B. Haines; Alan Huang; Adam Crystal; Jannik N. Andersen; Xinyuan Wu; Kwok-Kin Wong
Cancer Res (2025) 85 (20): 3966–3982.
Translational Cancer Biology（癌症转化生物学）
12
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2−Breast Cancer
基于分型的精准治疗优化HR+/HER2−乳腺癌的传统“一刀切”疗法
Xiu-Zhi Zhu; Hu-Yun-Long Zhang; Yi-Fan Zhou; Yi-Yu Chen; Tong Fu; Ming-Liang Jin; Ya-Xin Zhao; Yi-Fan Xie; Xiaohua Zeng; Xi Jin; Yi-Zhou Jiang; Zhi-Ming Shao
Cancer Res (2025) 85 (20): 3983–3998.
13
Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer
靶向ATP7A依赖的铜代谢稳态诱导铜死亡，抑制突变KRAS驱动的肺癌进展
Jian Zhao; Weijie Zhang; Yuanyuan Zeng; Di Lu; Chenkang Ma; Mengzhu Zhang; Xin Cai; Zhifan Huang; Hongli Yang; Jianjun Li; Jianjie Zhu; Jian-An Huang; Zeyi Liu
Cancer Res (2025) 85 (20): 3999–4017.
Computational Cancer Biology and Technology（癌症计算生物学与技术）
14
Heterogeneous Driving Effects Guide Personalized Tumor Treatments Targeting N6-Methyladenosine
异质性驱动效应指导针对N6-甲基腺苷的个性化肿瘤治疗
Xudong Mao; Zhehao Xu; Xingbo Yang; Shihan Chen; Liyang Li; Zeyi Lu; Haohua Lu; Yudong Lin; Ruyue Wang; Yang Li; Fan Li; Lifeng Ding; Wenqin Luo; Xianjiong Chen; Yi Lu; Ziwei Zhu; Xinyu Zhao; Zhifan Ding; Liqun Xia; Qi Liu; Gonghui Li
Cancer Res (2025) 85 (20): 4018–4035.
Editor’s Notes（主编评注）
15
Editor’s Note: Circadian Clock Gene Bmal1 Inhibits Tumorigenesis and Increases Paclitaxel Sensitivity in Tongue Squamous Cell Carcinoma
主编评注：昼夜节律基因Bmal1抑制舌鳞状细胞癌的肿瘤发生并增加对紫杉醇的敏感性
Qingming Tang; Bo Cheng; Mengru Xie; Yatao Chen; Jiajia Zhao; Xin Zhou; Lili Chen
Cancer Res (2025) 85 (20): 4036.
16
Editor’s Note: MDR1 Synonymous Polymorphisms Alter Transporter Specificity and Protein Stability in a Stable Epithelial Monolayer
主编评注：MDR1同义多态性改变稳定上皮单层中转运蛋白的特异性和蛋白稳定性
King Leung Fung; James Pan; Shinobu Ohnuma; Paul E. Lund; Jessica N. Pixley; Chava Kimchi-Sarfaty; Suresh V. Ambudkar; Michael M. Gottesman
Cancer Res (2025) 85 (20): 4037.
Cancer Res[Jour] AND 85[volume] AND 21[issue]
癌症研究 85卷 21期
https://aacrjournals.org/cancerres/issue/
In the Spotlight（聚焦热点）
1
Exploiting AR-Synergistic Metabolic Vulnerabilities in Prostate Cancer
利用前列腺癌中雄激素受体协同的代谢弱点
Jonathan M. Anzules; Mark Sayegh; Yun Rose Li
Cancer Res (2025) 85 (21): 4045–4046.
2
Transient Nutrient Sensing Shapes T-cell Exhaustion
瞬时营养感应塑造T细胞耗竭状态
Julian J. Lum
Cancer Res (2025) 85 (21): 4047–4048.
Review（综述）
3
The Multifaceted Role of Osteopontin in Modulating the Tumor Microenvironment
骨桥蛋白在调节肿瘤微环境中的多面作用
Yu Gu; William J. Muller
Cancer Res (2025) 85 (21): 4049–4061.
Resource Report（资源报告）
4
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy
一个注释完备的三阴性乳腺癌患者来源异种移植生物样本库，包含新辅助化疗期间未经治疗和纵向采集的样本
Amanda L. Rinkenbaugh; Yuan Qi; Shirong Cai; Jiansu Shao; Faiza Baameur Hancock; Sabrina L. Jeter-Jones; Xiaomei Zhang; Emily Powell; Lei Huo; Rosanna Lau; Chunxiao Fu; Rebekah Gould; Petra den Hollander; Elizabeth E. Ravenberg; Jason B. White; Gaiane M. Rauch; Banu Arun; Clinton Yam; Alastair M. Thompson; Gloria V. Echeverria; Stacy L. Moulder; W. Fraser Symmans; Jeffrey T. Chang; Helen Piwnica-Worms
Cancer Res (2025) 85 (21): 4062–4080.
Cancer Biology（癌症生物学）
5
Gut Microbiota–Mediated Bile Acid Metabolism Regulates Colorectal Cancer Liver Metastasis by Altering Neutrophil Recruitment
肠道微生物群介导的胆汁酸代谢通过改变中性粒细胞招募调节结直肠癌肝转移
Zongmei Zheng; Fuwen Yuan; Jinming Li; Xiangxiang Zhu; Ru Jia; Jiao Wei; Fengjing Jia; Xinxin Hou; Zhaozhou Zhang; Yan Wang; Yanlei Ma; Wei Jia; Ling Zhao
Cancer Res (2025) 85 (21): 4081–4098.
6
MYADM Activates RhoA-Mediated Ameboid Migration to Drive Metastasis
MYADM激活RhoA介导的变形虫样迁移以驱动肿瘤转移
Yi-Ta Tsai; En-Ting Liu; Ming-Hsin Yang; Chien Chang Kao; Sheue-Fen Tzeng; Yu-Chi Chen; Pei-Wen Hsiao; An-Chieh Feng; Grace S. Shieh; Mong-Hsun Tsai; Shau-Kwaun Chen; Yi-Lin Chiu; Chin Li Chen; Sheng-Tang Wu; En Meng; Wen-Chiuan Tsai; Tai-Kuang Chao; Guang-Huan Sun; Sun-Yran Chang; Mien-Chie Hung; Tai-Lung Cha
Cancer Res (2025) 85 (21): 4099–4121.
7
Loss of SETD8 Impairs Mitochondrial Homeostasis to Suppress Leukemia Stem Cell Function in t(8;21) Acute Myeloid Leukemia
SETD8缺失损害线粒体稳态，抑制t(8;21)急性髓系白血病中白血病干细胞的功能
Yongwei Su; Shuyi Li; Lei Wang; Yiran Wang; Shujiao He; Xiaotong Li; Jingqiao Qiao; Jingfeng Zhou; Li Yu
Cancer Res (2025) 85 (21): 4122–4138.
Cancer Immunology（癌症免疫学）
8
Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma That Drives Antitumor Immunity
细胞毒性CD8+ T细胞下调GPX4以促进黑色素瘤中的铁死亡，进而驱动抗肿瘤免疫
Karine Flem-Karlsen; Ronan Talty; Meaghan K. McGeary; Koonam Park; Durga Thakral; Veronica T. Brooks; Andrew J. Daniels; William Damsky; Simon F. Roy; Goran Micevic; Marcus Bosenberg
Cancer Res (2025) 85 (21): 4139–4150.
9
METTL14 Enhances Antitumor Immunity through m6A-Dependent Loss of PD-1
METTL14通过m6A依赖性的PD-1缺失增强抗肿瘤免疫
Chang Huang; Xiaodong Wang; Yinmin Gu; Ke Ren; Haojing Zang; Yibi Zhang; Yongbo Pan; Shuwen Cheng; Xiaofeng Zhu; Songzhe Wu; Liqiang Duan; Xiaojun Xu; Qinong Ye; Jian Zeng; Hongbo Hu; Shan Gao
Cancer Res (2025) 85 (21): 4151–4163.
10
Intracellular IL1αin Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma
肿瘤周围单核细胞内的IL1α诱导IL8产生并抑制线粒体自噬，促进肝细胞癌的干性和转移
Yong-Hao Ruan et al.
Cancer Res (2025) 85 (21): 4164–4181.
Cancer Metabolism and Molecular Mechanisms（癌症代谢与分子机制）
11
Caloric Restriction Enhances the Efficacy of Antiandrogen Therapy in Prostate Cancer by Inhibiting Androgen Receptor Translation
热量限制通过抑制雄激素受体转化增强前列腺癌抗雄激素治疗的疗效
Ricardo A. Cordova; May Elbanna; Christopher Rupert; Sabrina A. Orsi; Noah R. Sommers; Angela J. Klunk; Li Shen; Jagannath Misra; Jocelyne N. Hanquier; Maria Tsompana; Yanqing Wang; David W. Goodrich; Ronald C. Wek; Luigi Fontana; Kirk A. Staschke; Roberto Pili
Cancer Res (2025) 85 (21): 4182–4197.
12
PRODH2-Mediated Metabolism in the Bone Microenvironment Promotes Breast Cancer Metastasis
骨微环境中PRODH2介导的代谢促进乳腺癌转移
Hui Gong; Yixuan Li; Wen Yang; Zishan Xie; Jiahao Hu; Peihang Li; Rou Xu; Yifan Li; Tianyu Tao; Riqing Li; Shuguang Liu; Yefeng Zhu; Libing Song; Lishan Fang
Cancer Res (2025) 85 (21): 4198–4211.
13
The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma
乙酰转移酶ARD1诱导谷胱甘肽合成，以促进肝细胞癌逃逸铁死亡
Yingyi Liu; Fusheng Liu; Jie Liu; Dongzhi Cairang; Xiaomian Li; Peng Xia; Weijie Ma; Tiangen Wu; Xiangdong Gongye; Zhonglin Zhang; Xi Chen; Wenzhi He; Yufeng Yuan
Cancer Res (2025) 85 (21): 4212–4232.
Cancer Landscapes（癌症特征）
14
Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
空间多组学定义高级别胶质瘤切除边缘的共享肿瘤浸润特征
Balagopal Pai; Susana Isabel Ramos; Wan Sze Cheng; Tanvi Joshi; Emine Özen; Lakshmi Shree Kulumani Mahadevan; Thenzing J. Silva-Hurtado; Gabrielle A. Price; Jessica Tome-Garcia; German Nudelman; Sanjana Shroff; Kristin G. Beaumont; Raymund L. Yong; Robert P. Sebra; Elena Zaslavsky; Nadejda M. Tsankova
Cancer Res (2025) 85 (21): 4233–4250.
15
Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer
不同克隆进化与早期播散促进去势抵抗性前列腺癌转移灶的遗传异质性
Noshad Hosseini; Rahul Mannan; Ryan J. Rebernick; Fengyun Su; Rui Wang; Xuhong Cao; Ana Lako; Dattatreya Mellacheruvu; Jing Hu; Joshi J. Alumkal; Zachery R. Reichert; Rohit Malik; Rohit Mehra; Arul M. Chinnaiyan; Marcin P. Cieslik
Cancer Res (2025) 85 (21): 4251–4268.
Computational Cancer Biology and Technology（癌症计算生物学与技术）
16
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response
骨转移的计算机数字孪生模型助力肿瘤进展和治疗反应研究
Luca Marsilio; Sergio Barrios; Stefan Maksimovic; Alice Maccarini; Elisa Serafini; Michele Grimaldi; Thomas J. Heyman; Pietro Cerveri; Stefano Casarin; Eleonora Dondossola
Cancer Res (2025) 85 (21): 4269–4284.
Correction（更正）
17
Correction: Tumor Suppressor Genes with Segmental Duplications Are Prone to Somatic Deletions and Structural Variations
更正：具有片段重复的肿瘤抑制基因易发生体细胞缺失和结构变异
Ziheng Huang; Lin Zhang; Huarong Chen; Xiaodong Liu; Likai Tan; Dan Huang; Yingzhi Liu; Yushan Wang; Xinyi Zhang; Alfred Sze Lok Cheng; Maggie Haitian Wang; Wei Kang; Ka-Fai To; Jun Yu; Ho Ko; Le Yu; Sunny H. Wong; Tony Gin; Matthew Tak Vai Chan; Xiansong Wang; William Ka Kei Wu
Cancer Res (2025) 85 (21): 4285.
Editor’s Note（编者注）
18
Editor’s Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
编者注：MDM2/MDMX-p53拮抗剂PM2增加野生型p53肿瘤对放疗的敏感性
Diana Spiegelberg; Anja C. Mortensen; Sara Lundsten; Christopher J. Brown; David P. Lane; Marika Nestor
Cancer Res (2025) 85 (21): 4286.
Cancer Res[Jour] AND 85[volume] AND 22[issue]
癌症研究 85卷 22期
https://aacrjournals.org/cancerres/issue/
In the Spotlight(焦点)
1
Alternatively Spliced Citrate Synthase Supports Colorectal Cancer
选择性剪接的柠檬酸合酶促进结直肠癌发展
Désirée Schatton; Christian Frezza
Cancer Res (2025) 85 (22): 4293–4295
2
White Matter Injury Fuels Early Progression of Glioblastoma
白质损伤推动胶质母细胞瘤早期进展
Keon Woo Kim; Hyun Jin Choi; Jeong Ho Lee
Cancer Res (2025) 85 (22): 4296–4298
Review(综述)
3
Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in Cancer
错配修复作为癌症中动态且临床可干预的薄弱环节
Eleonora Piumatti; Pietro Paolo Vitiello; Vito Amodio; Alberto Bardelli; Giovanni Germano
Cancer Res (2025) 85 (22): 4299–4314
Resource Reports（资源报告）
4
An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
优化平台克服CRISPR/Cas9 慢病毒系统诱导的过度肿瘤免疫排斥反应
Yan Shang; Shuaihu Li; Tian Xu; Yihua Sun; Fei Li
Cancer Res (2025) 85 (22): 4315–4328
5
Wide-Field Optical Redox Imaging with Leading-Edge Detection Enables Assessment of Treatment Response and Heterogeneity in Patient-Derived Cancer Organoids
具有领先科技检测的宽视野光学氧化还原成像可评估患者来源的癌症类器官的治疗反应和异质性
Amani Gillette; Shirsa Udgata; Alexa E. Schmitz; Jordan N. Stoecker; Jeremy D. Kratz; Dustin A. Deming; Melissa C. Skala
Cancer Res (2025) 85 (22): 4329–4340
Cancer Biology(癌症生物学)
6
Metastasis-Initiating Osteosarcoma Subpopulations Establish Paracrine Interactions with Lung and Tumor Cells to Create a Metastatic Niche
转移起始的骨肉瘤亚群与肺细胞和肿瘤细胞建立旁分泌相互作用以创建转移微环境
James B. Reinecke; Leyre Jimenez Garcia; Amanda J. Saraf; John Hinckley; Amy C. Gross; Helene Le Pommellet; Kelly M. Gutpell; Maren Cam; Matthew V. Cannon; Matthew J. Gust; Sophia Vatelle; Berkley E. Gryder; Ruben Dries; Ryan D. Roberts
Cancer Res (2025) 85 (22): 4341–4358
7
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer
MYC 和 p53 改变通过 VEGF 信号通路协同抑制前列腺癌中的细胞毒性 T 细胞和免疫治疗反应
Katherine C. Murphy; Kelly D. DeMarco; Lin Zhou; Jessica Peura; Hadiya K. Giwa; Yvette Lopez-Diaz; Yu-Jui Ho; Junhui Li; Shi Bai; Karl Simin; Lihua J. Zhu; Jason R. Pitarresi; Arthur M. Mercurio; Marcus Ruscetti
Cancer Res (2025) 85 (22): 4359–4379
8
Lipid Composition Alters Ferroptosis Sensitivity
脂质组成改变铁死亡敏感性
Vivian S. Park; Lauren E. Pope; Justin P. Ingram; Grace A. Alchemy; Julie J. Purkal; Magdalena B. Murray; Sha Jin; Eli Y. Andino-Frydman; Sanjana Singh; Anlu Chen; Priya Narayanan; Sarah Kongpachith; Darren C. Phillips; Scott J. Dixon; Relja Popovic
Cancer Res (2025) 85 (22): 4380–4397
9
Condensation of the Golgi Apparatus Activates YAP1 to Promote Gastric Cancer Progression
高尔基体凝聚激活YAP1 以促进胃癌进展
Jinyoung Kim; Chandani Shrestha; Gwangbin Lee; Dasom Jung; Annie Zhao; Junyoung Cho; Ji Hae Nahm; Shinwon Kang; Jung Hwan Yoon; Bum-Ho Bin; Dongwoo Chae; Seung Min Jeong; Eun Kyung Lee; Jiyoon Kim
Cancer Res (2025) 85 (22): 4398–4414
Cancer Immunology(癌症免疫学)
10
Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
表型分析揭示多模式 γδ T 细胞细胞毒性作为克服癌细胞介导的免疫调节的策略
Callum Baird Nattress; Rhianna O’Sullivan; Daniel Fowler; Colin Hutton; Petra Vlckova; Jahangir Sufi; Magdalena Buschhaus; Ewa Basiarz; Maria Ramos Zapatero; Ferran Cardoso Rodriguez; Xiao Qin; Ashley Campbell; Angeliki Kanouta; Vivian S.W. Li; Kerry Chester; John Anderson; Marta Barisa; Jonathan P.H. Fisher; Christopher J. Tape
Cancer Res (2025) 85 (22): 4415–4432
11
SPP1+Neutrophils Mediate Resistance to Immune Checkpoint Blockade in BAP1-Inactivated Tumors
SPP1+中性粒细胞介导 BAP1 失活肿瘤对免疫检查点阻断的耐药性
Jiahao Shi; Shiyun Huang; Yixiong Zhou; Guopei Zheng; Zhe Zhang; Xianqun Fan; Jianfeng Shen
Cancer Res (2025) 85 (22): 4433–4449
Cancer Metabolism and Molecular Mechanisms(癌症代谢与分子机制)
12
A Citrate Synthase Splice Variant Rewires the TCA Cycle to Promote Colorectal Cancer Progression
一种柠檬酸合酶剪接变体重编码三羧酸循环以促进结直肠癌进展
Justin Chak Ting Cheung; Lok Wan Ng; Zhongxu Zhu; Bonan Chen; Stephen Li; Mingjing Xu; Xiaofan Ding; Dandan Pu; Yi Hu; Yuqing Ren; Wei Kang; Ming Li; Jason Wing Hon Wong; Xin Wang; Yuen Kit Cheng; Wei Shen Aik; Ka Leung Wong; Simon Siu Man Ng; Nathalie Wong; Yujuan Dong
Cancer Res (2025) 85 (22): 4450–4468
13
Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer
神经肽前体VGF 促进小细胞肺癌的神经内分泌分化和癌症相关成纤维细胞活化
Wen Ding; Jianzheng Zhu; Jianshan Mo; Shumin Ouyang; Guopin Liu; Yingxue Su; Danyuan Sun; Jiangling Ye; Yanle Wu; Jiayu Yan; Menghan Xue; Peibin Yue; Jin-jian Lu; Libin Wang; Yandong Wang; Xiaolei Zhang
Cancer Res (2025) 85 (22): 4469–4484
14
KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma
KDM6 去甲基化酶促进 EWSR1::FLI1 驱动的尤文肉瘤致癌重编码
Elisabet Figuerola-Bou; Carla Ríos-Astorch; Enrique Blanco; María Sánchez-Jiménez; Pablo Táboas; Guerau Fernández; Soledad Gómez-González; Oscar Muñoz; Pol Castellano-Escuder; Sara Perez-Jaume; Marta Garcia; Estela Prada; Silvia Mateo-Lozano; Nicolo Riggi; Alexandra Avgustinova; Cinzia Lavarino; Luciano Di Croce; Sara Sánchez-Molina; Jaume Mora
Cancer Res (2025) 85 (22): 4485–4503
15
Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation
丙二酰辅酶 A 通过增强脂肪生成和 Ran 激活促进前列腺癌进展及去势抵抗
Yiheng Dai; Lilong Liu; Yongbo Luo; Cai Zhang; Sayu Xiao; Kaixuan Du; Yuanhao Liu; Youmiao Zeng; Zhengfeng Wang; Zhaohui Chen; Ke Chen; Lijie Zhou
Cancer Res (2025) 85 (22): 4504–4520
Therapeutic Development and Chemical Biology(治疗学新进展与生物化学)
16
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer
一种 Fc工程改造的糖基化修饰抗体支持免疫效应细胞的促炎激活并抑制乳腺癌进展
Alicia M. Chenoweth; Anthony Cheung; Jitesh Chauhan; Rebecca Adams; Gabriel Osborn; Katie Stoker; Melanie Grandits; Roman Laddach; Jennifer Trendell; Blanca Navarro-Llinas; Erin Suriawinata; Amanda Gross; Amanda Clarke; Lev Brown; Judit Cserny; Lenny Moise; Shashi Jatiani; Alexandra McCraw; Benjamina Esapa; Syed Haider; Jelmar Quist; Kristina M. Ilieva; Anna M. Davies; Pablo Romero-Clavijo; Thomas Sénard; Jack Cheeseman; Richard A. Gardner; Daniel I.R. Spencer; Sophia Tsoka; Sheeba Irshad; James M. McDonnell; Anita Grigoriadis; Andrew N.J. Tutt; Sophia N. Karagiannis
Cancer Res (2025) 85 (22): 4521–4540
Translational Cancer Biology(癌症转化生物学)
17
Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12DInhibitor Treatment
锌分泌失调的分子磁共振成像可检测胰腺导管腺癌及对 KRASG12D 抑制剂治疗的反应
Veronica Clavijo Jordan; Mozhdeh Sojoodi; Farzad Moloudi; Patricia Gonzalez Pagan; Manyu Jin; Pamela Pantazopoulos; Ethan French; Ibrahim Eissa; Jonah Weigand-Whittier; Nicholas Rotile; Mehrad Tavallai; Jill Hallin; Ian Ramsay; Eric M. Gale; Stephen C. Barrett; Nabeel El-Bardeesy; Stuti Shroff; Motaz Qadan; Kenneth K. Tanabe; Peter Caravan
Cancer Res (2025) 85 (22): 4541–4557
Convergence Science(融合医学)
18
Modeling Early-Onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening
早期发病癌症动力学建模揭示潜在风险变化及人群筛查的影响
Navid Mohammad Mirzaei; Chin Hur; Mary Beth Terry; Piero Dalerba; Wan Yang
Cancer Res (2025) 85 (22): 4558–4570
Correction(更正)
19
Correction: Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype
更正：骨髓瘤修饰的脂肪细胞表现出代谢功能障碍和衰老相关分泌表型
Heather Fairfield; Amel Dudakovic; Casper M. Khatib; Mariah Farrell; Samantha Costa; Carolyne Falank; Maja Hinge; Connor S. Murphy; Victoria DeMambro; Jessica A. Pettitt; Christine W. Lary; Heather E. Driscoll; Michelle M. McDonald; Moustapha Kassem; Clifford Rosen; Thomas L. Andersen; Andre J. van Wijnen; Abbas Jafari; Michaela R. Reagan
Cancer Res (2025) 85 (22): 4571
Editor’s Note(编辑注)
20
Editor’s Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer
编者按：硫氧还蛋白是 Smad7 下游通路中的成分，该通路促进胰腺癌生长并抑制顺铂诱导的细胞凋亡
Nicole Boyer Arnold; Knut Ketterer; Jörg Kleeff; Hellmut Friess; Markus W. Büchler; Murray Korc
Cancer Res (2025) 85 (22):4572.
Cancer Res[Jour] AND 85[volume] AND 23[issue]
癌症研究 85卷 23期
https://aacrjournals.org/cancerres/issue/
In the Spotlight(焦点)
1
Gut Check: Lactobacillus johnsonii Harnesses Bile Acids and Reactive Oxygen Species to Suppress High-Fat Diet–Induced Colorectal Cancer
肠道检查：约翰逊乳杆菌利用胆汁酸和活性氧抑制高脂饮食诱导的结直肠癌
Prarthana J. Dalal; Yatrik M. Shah
Cancer Res (2025) 85 (23): 4579–4581
2
Can’t KEEP Up: UXS1 Dependency Exposes a Pyrimidine Vulnerability in KEAP1-Mutant Lung Cancer
难以维持：UXS1依赖性暴露了KEAP1突变型肺癌中嘧啶的薄弱环节
Basma A. Yasseen; Gina M. DeNicola
Cancer Res (2025) 85 (23): 4582–4584
Review(综述)
3
From Worms to Tumors: Conserved Strategies of Cellular Arrest and Survival Governing Dormancy
从蠕虫到肿瘤：调控细胞停滞与存活的保守策略主导休眠状态
Veena Prahlad; Irwin H. Gelman
Cancer Res (2025) 85 (23): 4585–4599
Cancer Biology(癌症生物学)
4
Lactobacillus johnsonii Synthesizes Chenodeoxycholic Acid to Reduce Susceptibility to High-Fat Diet–Induced Colorectal Cancer
约翰逊乳杆菌合成鹅脱氧胆酸以降低对高脂饮食诱导的结直肠癌的易感性
Chen Liu; Peng Lai; Jiancong Hu; Shengmei Yin; Shuang Guo; Danling Liu; Jing Yu; Dayi Liang; Guangyuan Chen; Mengze Xing; Zhanhao Luo; Xiaosheng He; Junli Gong; Ping Lan; Zhen He
Cancer Res (2025) 85 (23): 4600–4615
5
A Multipotent PROX1+ Tumor Stem/Progenitor Cell Population Emerges during Intestinal Tumorigenesis and Mediates Radioresistance in Colorectal Cancer
在肠道肿瘤发生过程中出现一种多能PROX1+肿瘤干细胞/祖细胞群体，并介导结直肠癌的放疗抵抗
Pauliina Kallio; Cinzia Bessone; Fatemeh Seyednasrollah; Jefim Brodkin; Marika Lassila; Jenny Högström; Alejandra González-Loyola; Tatiana V. Petrova; Caj Haglund; Kari Alitalo
Cancer Res (2025) 85 (23): 4616–4631
6
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate Cancer Metastasis
TROP2细胞外结构域脱落激活EGFR信号传导，驱动前列腺癌转移
Shiqin Liu; En-Chi Hsu; Merve Aslan; Fernando Garcia-Marques; Michelle Shen; Alifiani B. Hartono; Francisco Solano; Kewei Le; Hyeonji Hwang; Chung S. Lee; Abel Bermudez; Rosalie Nolley; Donna M. Peehl; James D. Brooks; Michael A. Liss; Sharon J. Pitteri; Tanya Stoyanova
Cancer Res (2025) 85 (23): 4632–4647
7
SWI/SNF Functions as a Gatekeeper of Enhancer Chromatin Access to Control Progression of Mesenchymal Triple-Negative Breast Cancer
SWI/SNF作为增强子染色质可及性的守门人，控制间充质三阴性乳腺癌的进展
Rikkemaja Isahbell J. Møldrup; Mikkel G. Terp; Simon T. Jakobsen; Tina Ravnsborg; Maria S. Madsen; Daniel D. Brown; Laurits R. Sloth; Michael C. Gorry; Steffi Oesterreich; Adrian V. Lee; Henrik J. Ditzel; Ole N. Jensen; Rasmus Siersbæk
Cancer Res (2025) 85 (23): 4648–4663
Cancer Immunology(癌症免疫学)
8
Hypoxia Induces Immunosuppression by Silencing STING in Cancer
缺氧通过沉默癌症中的STING诱导免疫抑制
Yuhong Lu; Annali M. Yurkevicz; Yanfeng Liu; Peter M. Glazer
Cancer Res (2025) 85 (23): 4664–4680
9
Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti–PD-1 Immunotherapy
使用一种易发生抗体依赖性细胞介导的细胞毒性作用的纳米抗体构建体耗竭IL1R2+肿瘤浸润调节性T细胞，增强抗PD-1免疫疗法的疗效
Sana M. Arnouk; Daliya Kancheva; Helena Van Damme; Guillaume E. Courtoy; Romina Mora Barthelmess; Jolien Van Craenenbroeck; Els Lebegge; Yvon Elkrim; Naela Assaf; Yves Heremans; Aleksandar Murgaski; Timo W.M. De Groof; Emile Clappaert; Ayla Debraekeleer; Jan Brughmans; Gillian Blancke; Máté Kiss; Ramses Forsyth; Wim Waelput; Louis Boon; Nick Devoogdt; Catelijne Stortelers; Nadja van Boxel; Bruno Dombrecht; Lars Vereecke; Cécile Vincke; Geert Raes; Damya Laoui; Jo A. Van Ginderachter
Cancer Res (2025) 85 (23): 4681–4700
10
ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP介导的胆碱剥夺和趋化因子分泌塑造肿瘤相关巨噬细胞，促进免疫逃逸
Jianhong Zhao; Baoxiang Chen; Yanrong Deng; Lifang Fan; Siyuan Yin; Haisheng Yu; Yongchang Wei; Jing Dai; Qun Qian; Quanjiao Chen; Xianghai Ren; Xiaoyu Xie; Wenyi Wei; Jinfang Zhang; Congqing Jiang
Cancer Res (2025) 85 (23): 4701–4717
Cancer Metabolism and Molecular Mechanisms(癌症代谢与分子机制)
11
PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
PAX3-FOXO1驱动横纹肌肉瘤中可靶向的细胞状态依赖性代谢薄弱环节
Katrina I. Paras; Julia S. Brunner; Angela M. Montero; Jacob A. Boyer; Benjamin T. Jackson; Sangita Chakraborty; Abigail Xie; Kristina Guillan; Armaan Siddiquee; Lourdes Pajuelo Torres; Joshua D. Rabinowitz; Andrew L. Kung; Daoqi You; Filemon S. Dela Cruz; Lydia W.S. Finley
Cancer Res (2025) 85 (23): 4718–4733
12
CLK2 Regulates the KEAP1/NRF2 and p53 Pathways to Suppress Ferroptosis in Colorectal Cancer
CLK2调节KEAP1/NRF2和p53通路以抑制结直肠癌中的铁死亡
Hai-Meng Zhou; Yi Liu; Feng Shi; Hao-Wen Qiu; Le Li; Qi-Peng Shu; Yu-Ying Liu; Bai-Qi Wang; Meng Gao; Run-Lei Du; Shao-Bo Ke; Xiao-Dong Zhang
Cancer Res (2025) 85 (23): 4734–4750
13
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer
LHX2重塑代谢和表观遗传格局以驱动前列腺癌的肿瘤进展
Jun Jiang; Shaojie Liu; Chao Xu; Limin He; Hongji Li; Yike Zhou; Zhengxuan Li; Yu Li; Fa Yang; Yuchen Wei; Tong Lu; Keying Zhang; Jingliang Zhang; Pang Wang; Li Guo; Changhong Shi; Weihong Wen; Rui Zhang; Donghui Han; Weijun Qin
Cancer Res (2025) 85 (23): 4751–4768
14
Long-Chain Fatty Acid Redistribution Induced by SLC27A2 Deficiency Facilitates Hypoxic Adaptation and Immunosuppression in Hepatocellular Carcinoma
SLC27A2缺乏诱导的长链脂肪酸重新分布促进肝细胞癌的缺氧适应和免疫抑制
Chuli Fu; Wenyun Fu; Zuotian Huang; Xiaoyan He; Teng Wei; Wen Jin; Geyan Wu; Zhengwei Zhao; Kunxiong Guo; Jincui Yang; Jing Li; Shuhui Xu; Xuelong Zheng; Xiaoqiang Chen; Ling Ran; Xiaoli Pan; Kezhen Zong; Zhongjun Wu; Junyao Xu; Guang-Rong Yan; Qiangnu Zhang
Cancer Res (2025) 85 (23): 4769–4786
15
tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression
tRF-21LeuTAA通过改变谷胱甘肽代谢酶促进氧化应激，以支持前列腺癌进展
Xiaoyu Guo; Jinjing Zhong; Jingyu Qian; Xiuyi Pan; Xinyue Zhang; Xueqin Chen; Hao Zeng; Ni Chen; Ling Nie; Ting Yu; Qiao Zhou
Cancer Res (2025) 85 (23): 4787–4805
Translational Cancer Biology(癌症转化生物学)
16
Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer
UXS1缺失选择性地耗竭嘧啶，并在KEAP1突变型肺癌中诱导复制压力
Melat T. Gebru; Timothy E. Hoffman; Aaron Boudreau; Ngoc Vu; Fei Han; Putianqi Wang; Eddie Folk; Xiumin Wu; James Newton; Kelly D. Foster-Duke; Jessica Gajda; Sammy Villa; Nianxin Yang; Celeste M. Sandoval; Christian Grant; Samatha E. Wildeboer; Wayne R. Buck; Jonathan A. Hickson; Ari J. Firestone; Michael Kort; Bryson D. Bennett; J. Brad Shotwell; Noel S. Wilson; David Stokoe
Cancer Res (2025) 85 (23): 4806–4824
17
KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
KRAS抑制在胰腺癌中激活可操作的CD24“不要吃我”信号
Yongkun Wei; Minghui Liu; Er-Yen Yen; Jun Yao; Zhenzhen Xun; Phuoc T. Nguyen; Xiaofei Wang; Zecheng Yang; Abdelrahman Yousef; Dean Pan; Yanqing Jin; Ching-Fei Li; Madelaine S. Theardy; Jangho Park; Yiming Cai; Mitsunobu Takeda; Matthew Vasquez; Elizabeth M. Park; David H. Peng; Yong Zhou; Hong Zhao; Timothy P. Heffernan; Andrea Viale; Huamin Wang; Stephanie S. Watowich; Han Liang; Dan Zhao; Ronald A. DePinho; Wantong Yao; Haoqiang Ying
Cancer Res (2025) 85 (23): 4825–4838
Convergence Science(融合医学)
18
Spatial Cross-talk Modeling of the Tumor Microenvironment Identifies CCR5-Mediated Glia-to-Glia Signaling as a Key Regulator of Brain Metastatic Progression
肿瘤微环境的空间交叉对话建模确定CCR5介导的神经胶质细胞-神经胶质细胞信号传导作为脑转移进展的关键调节因子
Ju Young Ahn; Wenjuan Dong; Akshjot Puri; Matthew Vasquez; Raksha Raghunathan; Li Yang; Jianting Sheng; Hong Zhao; Stephen T.C. Wong
Cancer Res (2025) 85 (23): 4839–4855
AACR会议临床结果
2025-12-01
点击蓝字，关注我们
Volume 15 · Issue 11 · November 2025
长按扫码
直接阅读
Review papers
Artificial intelligence guided Raman spectroscopy in biomedicine: Applications and prospects
Yuan Liu, Sitong Chen, Xiaomin Xiong, Zhenguo Wen, Long Zhao, Bo Xu, Qianjin Guo, Jianye Xia, Jianfeng Pei
J. Pharm. Anal. 2025. 15(11) 101271
https://doi.org/10.1016/j.jpha.2025.101271
拉曼光谱凭借其高灵敏度、非破坏性等优势，已成为生物制药分析与药物研发中不可或缺的重要工具。随着人工智能，特别是深度学习算法的快速发展，拉曼光谱在数据处理、特征提取和模型优化方面实现了质的飞跃，进一步拓展了其在生物医学领域的应用范围。人工智能引导的拉曼光谱技术广泛应用于药物结构表征、剂型分析、质量控制、成分鉴定及药物-生物分子相互作用研究等多个环节。此外，该技术也深刻改变了生物医学研究与临床诊断的模式，尤其在疾病早期诊断与治疗优化方面展现出巨大潜力。本文系统综述了多种人工智能方法——包括半监督学习、强化学习、迁移学习以及Transformer模型——在拉曼光谱解析中的关键作用。这些方法不仅推动了生物制药过程监控与临床诊断的智能化进程，也为疾病治疗策略和药品生产控制提供了全新的研究视角与技术支持。人工智能与拉曼光谱的深度融合，正持续为生物医学领域注入创新动力，具有广阔的发展前景。
Highlights
Raman's non-destructive, high-sensitivity drives biomedical/biopharmaceutical applications.
PLS/SVM remain key chemometric tools; ML/DL enhance analysis complexity & efficiency.
DL models (CNN, LSTM, GAN) improve pattern recognition & predictive accuracy.
Transformers enable big data processing/feature extraction, rising in Raman spectroscopy.
Mitochondrial membrane chromatography: Discovery of mitochondrial targeting modulators
Wu Su, Yu Kong, Hua Li, Yongyao Wang, Lizhuo Wang, Le Shi, Huaizhen He, Shengli Han, Hui Guo, Jiankang Liu, Jiangang Long
J. Pharm. Anal. 2025. 15(11) 101272
https://doi.org/10.1016/j.jpha.2025.101272
线粒体功能异常与衰老、神经退行性疾病、代谢综合征等密切相关，筛选线粒体靶向活性分子是相关疾病防治的关键。本文系统阐述线粒体膜色谱（MMC）技术的核心价值与应用进展：该技术通过将线粒体蛋白（含膜蛋白与基质蛋白）固定于载体制备固定相，无需纯化蛋白即可保留其天然构象与活性，整合高效液相色谱与受体药理学优势，解决传统方法靶向性差、效率低的难题。文中介绍MMC技术发展历程（物理吸附、化学键合、蛋白标签修饰等固定相制备方法），展示其在受体-配体相互作用研究、中药活性成分筛选等领域的应用，提出未来向多靶点、微型化发展及拓展至其他细胞器膜色谱技术的方向，为线粒体及其他细胞器靶向药物研发及中药现代化提供关键技术支撑。
Highlights
Proposed strategies for preventing and treating major chronic diseases through mitochondrial-targeted regulation.
Defined the concept of mitochondrial membrane chromography and detailed the protocol.
Summarized the applications of mitochondrial membrane chromatography.
Regulated cell death in age-related macular degeneration: Regulatory mechanisms and therapeutic potential
Le-Le Zhang, Jia-Mei Yu, Zhong-Xi Fan, Wen-Qi Xie, Liang Zou, Feiya Sheng
J. Pharm. Anal. 2025. 15(11) 101285
https://doi.org/10.1016/j.jpha.2025.101285
年龄相关性黄斑变性（AMD）是导致老年人不可逆视力丧失的主要疾病之一，目前临床治疗手段仍较为有限。研究表明，氧化应激、炎症反应及视网膜色素上皮损伤是推动AMD发生发展的关键病理因素。程序性细胞死亡在介导细胞应激、维持组织稳态以及促进疾病进展方面发挥核心作用，且与AMD的发生发展密切相关。本文系统综述了AMD中多种程序性细胞死亡的机制及其治疗潜力，涵盖凋亡、铁死亡、焦亡、坏死性凋亡等不同形式，详细阐述了各类细胞死亡调控通路在AMD病理进程中的作用，并探讨了针对这些通路的治疗策略，包括生物制剂、化学药物及天然产物等。文章进一步强调，靶向程序性细胞死亡具有显著的治疗潜力，有望为AMD的防治提供新的思路与药物靶点，具备重要的研究价值与应用前景。
Highlights
Age-related macular degeneration (AMD) has currently limited therapeutic options.
So far, the role of regulated cell death in AMD pathology has been neglected.
Apoptosis, ferroptosis, pyroptosis, necroptosis, and autophagy contribute to AMD.
Key elements in their pathways are promising therapeutic targets in AMD.
Recent advances in mass spectrometry-based bioanalytical methods for endogenous biomarkers analysis in transporter-mediated drug-drug interactions
Dang-Khoa Vo, Han-Joo Maeng
J. Pharm. Anal. 2025. 15(11) 101289
https://doi.org/10.1016/j.jpha.2025.101289
Highlights
Overview of potential endogenous transporters biomarkers and supporting evidence.
Summary of LC-MS(/MS) bioanalytical methods for quantifying endogenous biomarkers.
Selection of appropriate approaches for calibration curves and QC samples in biomarker quantification.
Summary of individual baseline levels of endogenous transporters biomarkers in biological fluids.
Small-molecule probes based on natural products: Elucidation of drug-target mechanisms in stroke
Xingyue Jin, Suyi Liu, Shujing Chen, Rui Han, Xingyi Sun, Mingyan Wei, Yanxu Chang, Lin Li, Han Zhang
J. Pharm. Anal. 2025. 15(11) 101290
https://doi.org/10.1016/j.jpha.2025.101290
本文聚焦天然产物（NPs）在卒中治疗新药研发中的重要作用。针对卒中药物开发中作用靶点识别这一关键挑战，基于NPs的小分子探针展现出独特优势。与传统探针相比，NPs探针凭借其丰富的结构多样性、良好的生物相容性及独特生物活性，克服了传统探针非特异性强、稳定性差与合成困难等不足，能够精确直接地探寻NPs活性小分子的相互作用蛋白靶点。本综述系统介绍了NPs小分子探针的特性，并详细探讨了其在卒中及其他疾病机制研究中的前沿应用。研究者期望这项工作能为揭示NPs活性小分子的作用机制提供新视角，进而加速其向卒中治疗候选药物的转化进程。
Highlights
Small-molecule probes based on natural products possess clear therapeutic efficacy and natural source properties.
Small molecule probes based on NPs can accurately and directly identify the interacting proteins of NPs.
Small-molecule probes based on NPs have been used for the discovery of therapeutic targets for a variety of diseases.
NPs-based small-molecule probes applied in stroke treatment offer insights into novel drug discovery.
Targeting proteostasis pathways for cancer therapy
Xiaofeng Dai, Ruohan Lyu, Guanqun Ge
J. Pharm. Anal. 2025. 15(11) 101287
https://doi.org/10.1016/j.jpha.2025.101287
蛋白质稳态失衡是驱动肿瘤发生的一个关键因素。虽然许多热休克蛋白家族成员抑制剂已进入临床试验阶段，但由于毒性等问题至今尚无获准临床应用的相关药物。本文通过分析HSP90抑制剂阻断肿瘤特征的分子机制，发现抑制HSP90可通过调节细胞蛋白质稳态，同时靶向癌症的多个关键特征。此外，本文通过建立蛋白质稳态与氧化还原稳态之间的内在关联提出低温常压等离子体（CAP）可以作为一种新型HSP90抑制剂治疗癌症并具有温和无毒副作用等优势的创新观点。最后，本文将HSP90抑制剂和CAP的治疗范围从癌症延伸至自身免疫病等其他炎症驱动性疾病。这些创新观点有助于推动现有疾病治疗模式的范式转移。
Highlights
Emphasizes the role of proteostasis in preventing carcinogenesis.
Attributes the cause of cancers to chronic inflammation.
Identifies intrinsic connections between proteostasis and redox homeostasis.
Proposes cold atmospheric plasma as a tool for maintaining proteostasis.
Extends the treatment spectrum of cold atmospheric plasma to autoimmune diseases.
Structure-based design of anticancer drugs based on β-elemene: Research foundations and development potential
Haiyi Chen, Yuntao Yu, Chenghong Hu, Lehuang Zhou, Zhe Wang, Odin Zhang, Yi Wang, Tian Xie
J. Pharm. Anal. 2025. 15(11) 101325
https://doi.org/10.1016/j.jpha.2025.101325
β-榄香烯是中药来源的重要抗癌活性成分，仅由碳氢元素构成，已被应用于多种癌症的临床治疗中。然而，β-榄香烯的理化性质和生物利用度较差，同时学界对于β-榄香烯发挥抗癌活性的具体靶标在结构层面仍无定论。本综述汇总并整理了已有的β-榄香烯抗癌机制研究，指出甲基转移酶样3蛋白（METTL3）有可能是β-榄香烯的抗癌靶点。以此蛋白作为案例，需要阐明β-榄香烯的受体-配体互作机制，并设计性质更为优良的衍生物。本文讨论了将基于结构的现代药物设计策略（SBDD）引入的可能性，涉及到传统的计算机辅助药物设计（CADD）技术如传统的基于分子对接的虚拟筛选和分子动力学模拟，及基于人工智能的药物设计（AIDD）技术如分子生成等。
Highlights
First systematic study of β-elemene’s anticancer mechanism via ligand-protein interactions.
Docking reveals novel insights for β-elemene modifications, proposed for the first time in academia.
AI-based molecular generation of β-elemene derivatives introduced, with preliminary examples provided.
CADD-driven optimization strategy for β-elemene remains applicable beyond METTL3 for other anticancer targets.
Recent trends in mesoporous carbon-based nanoplatforms for biomedical application
Wei Yang, Jinnian Ge, Mohan Jiang, Nan Zhang, Qinghe Yang, Kaisheng Nan, Qinfu Zhao, Long Wan, Xiaofan Wang
J. Pharm. Anal. 2025. 15(11) 101383
https://doi.org/10.1016/j.jpha.2025.101383
Highlights
Classification, synthesis methods and modification strategies of MCNs were expounded.
The physicochemical properties of MCNs and design strategies were highlighted.
MCNs-based nanoplatforms for tumor therapy and tumor theranostics were presented.
Antibacterial, biological detection and delivery of insoluble drugs were reviewed.
The challenges, prospects and clinical future development of MCNs were prospected.
Original articles
Revolutionizing antibiotic therapy: Polymyxin B and Fe2+-enriched liposomal carrier harness novel bacterial ferroptosis mechanism to combat resistant infections
Xiangrong Wei, Xinhui Cao, Chengyi Xu, Guangwei Shi, Hong Wang, Jinming Liu, Huiyang Li, Bingmei Yao, Yudong Zhang, Liqun Jiang
J. Pharm. Anal. 2025. 15(11) 101293
https://doi.org/10.1016/j.jpha.2025.101293
本研究针对当前日益严峻的细菌耐药性难题，提出一种“旧药新用”的创新策略，通过构建同时递送多黏菌素B（PMB）与Fe²⁺的脂质体载体（P/Fe@L-P），实现对多黏菌素耐药鲍曼不动杆菌的高效杀灭。与传统依赖LPS作用位点的抗菌机制不同，P/Fe@L-P在进入细菌后可协同促进Fenton反应，显著升高细菌内ROS与MDA水平，并下调Nrf2、GPX4等关键抗氧化蛋白，从而诱导铁死亡（ferroptosis）。研究显示，P/Fe@L-P对耐药菌株的MIC和MBC分别为54μM和192μM，较游离PMB（72μM和768μM）具有更强抑菌和杀菌能力。小鼠肺炎模型进一步验证了P/Fe@L-P在体内可显著降低肺部细菌负荷、改善组织损伤并提高存活率，治疗效果明显优于PMB。该工作不仅提供了一种突破耐药屏障的新型抗菌机制，也展示了通过递药系统激活传统抗生素潜力的可行路径，为抗生素创新研发与临床耐药感染治疗提供了新的重要思路。
Highlights
Liposomal co-delivery of polymyxin B & Fe2+ altered polymyxin B's bacterial interaction.
This liposome triggered ferroptosis, a novel bactericidal mode, in Acinetobacter baumannii.
The novel bactericidal mechanism enhanced efficacy against PMB-resistant Acinetobacter baumannii.
Caffeic acid alleviates myocardial ischemia-reperfusion injury by directly targeting Keap1N532/M550 and promoting its degradation
Ying Zhang, Huan Lan, Wenjuan Zhai, Lin Jiang, Xiaotong Xia, Fang Liu, Lin Zhang, Jinjun Wu, Zhongqiu Liu, Caiyan Wang
J. Pharm. Anal. 2025. 15(11) 101219
https://doi.org/10.1016/j.jpha.2025.101219
本研究首次揭示天然多酚化合物咖啡酸（CA）通过直接靶向并结合Keap1蛋白的N532和M550位点，促进其经p62依赖性自噬途径降解，进而激活Keap1/Nrf2信号通路，缓解心肌缺血再灌注损伤。研究利用细胞与动物模型证实，CA能显著减少氧化应激与炎症反应，增强抗氧化酶表达，改善心功能。通过晶体结构解析、分子动力学模拟及多种生物物理技术，明确了CA与Keap1的直接相互作用机制。此外，咖啡酸类似物绿原酸（CGA）也表现出类似的Keap1靶向降解能力。该研究为咖啡酸及其衍生物在心血管保护方面的临床应用提供了新的分子机制与结构基础。
Highlights
The complex structure of caffeic acid and Keap1Kelch domain was analyzed.
Caffeic acid directly targets Keap1 using multiple target confirmation techniques.
Caffeic acid promotes Keap1 degradation and inhibits myocardial ischemia-reperfusion injury.
Sulfonylation sites for adenine and its nucleosides/nucleotides
Xiaoyue Cheng, Pengcheng Li, Li Xu, Congcong Zhang, Qi Wang, Huiru Tang
J. Pharm. Anal. 2025. 15(11) 101258
https://doi.org/10.1016/j.jpha.2025.101258
磺酰化技术在生物化学研究中有着广泛的应用，但关于腺嘌呤及其核苷、核苷酸的磺酰化位点，学界却始终存在着诸多不一致和争议。本研究利用高分辨率质谱以及核磁共振波谱，对腺嘌呤及其甲基化衍生物、核苷、核苷酸与5-(N,N-二甲基氨基)萘-1-磺酰氯（DNS-Cl）和5-(N,N-二乙基氨基)萘-1-磺酰氯（DEANS-Cl）的磺酰化产物进行了全面而细致的分析。通过借助磺酰化诱导的化学位移变化以及二级质谱特征碎片离子，清晰地揭示了磺酰化位点。此外，研究者还合成了一种新型的磺酰化试剂——5-(N,N-二乙基亮氨酸氨基)萘-1-磺酰氯(DELANS-Cl)，进一步探究了改变萘氨基团对磺酰化位点的潜在影响。经过一系列严谨的实验和分析发现：对于腺嘌呤，磺酰化试剂优先与N9H发生反应；对于核苷、AMP、ADP和ATP，磺酰化试剂优先与2'-OH发生反应；而对于那些2'-OH不存在的分子，如脱氧腺苷、dAMP，磺酰化试剂则优先与3'-OH发生反应。这一系列发现不仅为解决磺酰化位点的争议提供了明确的答案，也为未来相关领域的研究和应用奠定了坚实的基础。
Highlights
The sulfonylation sites were defined for adenine and its nucleosides/nucleotides.
N9H on imidazole ring was the major sulfonylation site for adenine.
2′-OH of ribose was main sulfonylation site for adenosine and its nucleotides.
3′-OH of deoxyribose was main sulfonylation site for 2′-deoxynucleosides/nucleotides.
Screening of glycan biomarkers for early detection of colorectal cancer based on novel isotope labeling relative quantitative method
Yuxuan Li, Zhenggen Piao, Songze Wang, Longhai Cui, Xinyan Li, Jinlong Ma, Chengqiang Han, Xi-Ling Li, Toufeng Jin, Jun Zhe Min
J. Pharm. Anal. 2025. 15(11) 101262
https://doi.org/10.1016/j.jpha.2025.101262
聚糖异常表达与疾病发生和发展密切相关，因此监测聚糖水平的变化对于阐明疾病机制和开发新的治疗策略至关重要。结直肠癌（CRC）是一种常见的胃肠道恶性肿瘤。然而，传统临床血清生物标志物的诊断准确性不足，导致患者在病情晚期才被确诊。鉴于此，本研究基于同位素质谱探针d0/d5-BOTC标记构建了聚糖相对定量分析新方法，并筛选了CRC患者血清和组织样本中差异性聚糖。结果发现CRC患者血清和组织样本中新型聚糖生物标志物H4N5F1SA、H5N4F、H5N4F3SA 和H5N4SA2在诊断CRC的阳性检测率高达90%以上。本研究为CRC的临床诊断提供了新的潜在生物标志物和策略。
Highlights
A novel method for differential glycans in CRC patients' serum and tissue was developed.
Seven glycans had a significant difference in the serum and tissue of CRC patients.
The sensitivity of H4N5F1SA, H5N4F, H5N4F3SA, and H5N4SA2 exceeds CEA for CRC diagnosis.
A novel strategy for early warning of CRC stages II and III was provided.
Obtain substance of anti-glioblastoma from Erigeron breviscapus through fragment-based target research (FBTR): An efficient strategy for pharmacology investigation and optimization of natural products
Chunguo Wang, Jinli Shi, Qinling Rao, Bingqing Shen, Canyu Su, Heng Chen, Zhixing Huang, Shuwei Jiang, Rongge He, Luni Xu, Muxuan Li, Yonggang Liu, Tao Ma, Yantong Xu, Xinqi Deng
J. Pharm. Anal. 2025. 15(11) 101366
https://doi.org/10.1016/j.jpha.2025.101366
天然产物（NPs）是创新药物研发的重要源泉。单体成分的靶标研究模式已经成熟，但是针对NPs复杂体系的靶标作用模式与机制解析研究，仍是亟待突破的关键科学问题。本研究建立了基于片段的靶标研究（FBTR）新策略，实现了NPs复杂体系中成分的共有靶标鉴定和药物优化研究。以灯盏细辛提取物（EBP）治疗胶质母细胞瘤（GBM）为范例，通过FBTR策略，最终获得了具有明确靶点的有效组分（EBPP）。EBPP不仅能通过靶向Fas相关死亡结构域蛋白（FADD）第105位半胱氨酸位点，高效诱导GBM免疫原性细胞死亡（ICD），还能显著延长GBM模型小鼠中位生存期。本研究证实了FBTR在NPs复杂体系的靶标作用模式和机制解析中的价值，并在推进NPs药物优化实现临床转化方面具有实用性。
Highlights
The FBTR approach was introduced in this study.
FBTR can be applied in exploring the function of natural products, revealing the target, and advancing drug optimization.
With FBTR, an optimized NPs named EBPP with definite target was obtained for glioblastoma treatment.
Signatures of proteomics and glycoproteomics revealed liraglutide ameliorates MASLD by regulating specific metabolic homeostasis in mice
Yuxuan Chen, Chendong Liu, Qian Yang, Jingtao Yang, He Zhang, Yong Zhang, Yanruyu Feng, Jiaqi Liu, Lian Li, Dapeng Li
J. Pharm. Anal. 2025. 15(11) 101273
https://doi.org/10.1016/j.jpha.2025.101273
代谢相关性脂肪性肝病（MASLD）与肥胖、2型糖尿病风险升高密切相关。利拉鲁肽（Lira）作为胰高血糖素样肽-1受体激动剂，已获FDA批准用于治疗糖尿病和肥胖症。尽管Lira具备明确的肝脏代谢改善作用，但其在MASLD中的深层机制，尤其是对关键糖基化病理轴的调控方式仍未明确。本研究利用定量蛋白质组学与位点分辨N-糖蛋白质组学揭示，Lira除调控蛋白表达外，在糖基化层面呈现更强且独立的效应，其对特定N-糖基化位点的影响显著高于对蛋白丰度的调节，并主要关联于氨基酸和碳水化合物代谢。结果表明，Lira通过重塑“代谢–糖基化”网络发挥作用，而蛋白变化则聚焦脂质代谢和纤维化，与糖基化形成互补机制。此外，本研究进一步设计了可延长给药间隔的Lira缓释水凝胶制剂，为提高依从性和优化临床应用提供了新的给药策略。本研究系统描绘了Lira的调控网络与作用靶标，为理解GLP-1RA类药物的肝脏作用提供新的视角，并为MASLD精准治疗策略提供关键科学依据。
Highlights
Comprehensive proteomics and glycoproteomics revealed MASLD mechanisms in HFD mice.
Liraglutide increased glycosylation, identifying 255 independent and impactful sites.
Liraglutide regulated amino acid and lipid metabolism, ferroptosis, and fibrosis.
Identified 21 signature molecules offered potential therapeutic targets.
Lira@Fib Gel improved delivery and efficacy for chronic metabolic disease management.
Dexamethasone palmitate-loaded sHDL nanodiscs: Enhanced efficacy and safety in allergic conjunctivitis
Jiawei Li, Pengyue Liu, Yue Zhang, Fan Yang
J. Pharm. Anal. 2025. 15(11) 101276
https://doi.org/10.1016/j.jpha.2025.101276
本研究开发了用于变应性结膜炎的sHDL纳米盘激素滴眼剂（DXP-sHDL）。地塞米松棕榈酸酯被稳定装载于约10nm的合成HDL盘状纳米结构中，形成澄清透明、可过滤灭菌、无需防腐剂且在低温长期稳定的滴眼剂，兼具安全性与产业化潜力。在小鼠过敏性结膜炎模型中，DXP-sHDL 显著延长眼表滞留时间、提升角膜渗透，并在远低于传统剂量下有效缓解红肿、瘙痒和分泌物。其作用机制包括抑制Th2型细胞因子与IgE，减少嗜酸性粒细胞浸润和肥大细胞脱颗粒，从而实现强效抗炎抗过敏。安全性优于市售激素滴眼液，显示出作为前节眼病创新递药平台的突出应用价值。
Highlights
The residence time of synthetic high-density lipoprotein nanodisc eye drops on the ocular surface of mice is prolonged.
The synthetic high-density lipoprotein nanodisc eye drops exhibit superior permeability performance in vitro.
The synthetic high-density lipoprotein nanodisc eye drops reduce the concentration of corticosteroids during administration.
The synthetic lipoprotein nanodisc eye drops are free of preservatives, exhibiting high safety and minimal side effects.
USP50-mediated NLRP3 deubiquitination enhances NLRP3 inflammasome activation to suppress HCC metastasis
Zhengyan Gong, Yuhong Li, Yixuan Nie, Shenhao Zhang, Xiaoyu Tang, Yu Hu, Tianfeng Yang, Man Zhu, Wenjuan Tang, Qi Su, Yingzhuan Zhan, Dongdong Zhang, Bingling Dai, Yanmin Zhang
J. Pharm. Anal. 2025. 15(11) 101380
https://doi.org/10.1016/j.jpha.2025.101380
本研究证实了NOD样受体热蛋白结构域蛋白3（NLRP3）具有抑制肝癌增殖转移的生物学功能。机制层面阐明，NLRP3通过与GSK3β结合,负向调控β-catenin信号通路，进而逆转上皮-间质转化（EMT）进程，最终发挥抗肝癌效应；β-catenin补救实验进一步验证，明确了NLRP3/GSK3β/β-catenin调控轴在肝癌发生发展中的作用。同时发现，泛素特异性肽酶50（USP50）在肝癌中低表达，其表达水平与患者不良预后显著相关。深入机制研究表明，USP50可通过特异性去除NLRP3蛋白K48位的多聚泛素链，提高其蛋白稳定性并增强其功能活化，进而正向调控NLRP3炎症小体的激活过程。本研究不仅系统揭示了NLRP3与USP50在肝癌中的关键调控作用及分子网络，为肝癌治疗提供了潜在新型靶点，更为临床开发针对性抗癌策略提供了重要的理论支撑与实验依据。
Highlights
USP50 interacts with NLRP3 at the PYD domain.
USP50 increases NLRP3 expression depending on its deubiquitinase activity.
NLRP3 negatively regulates β-catenin by binding with GSK3β in HCC.
USP50 inhibits HCC metastasis by activating NLRP3 inflammasome.
Ursolic acid ameliorates ocular surface dysfunction in dry eye via targeting EGFR/RAS/RAF/MAP2K1/MAPK1 pathway
Qinghe Zhang, Ke Yan, Yufei Lv, Qiuping Liu, Yi Han, Zuguo Liu
J. Pharm. Anal. 2025. 15(11) 101294
https://doi.org/10.1016/j.jpha.2025.101294
干眼（DE）是一种由多种因素引起、以眼表炎症为主要病理特征的疾病。熊果酸（UA）是一种具有显著抗炎特性的五环三萜类化合物。本研究评估了UA对干眼相关眼表功能障碍的治疗效果及其潜在机制。通过高渗应激模型和干眼动物模型，发现UA对细胞和动物整体水平具有保护作用。通过数据库挖掘和网络药理学分析，揭示了UA作用于干眼的核心靶点和信号通路，分子对接模拟进一步阐明了UA与其靶点之间的相互作用模式。进一步研究表明，UA通过调节EGFR/RAS/RAF/MAP2K1/MAPK1信号通路发挥治疗作用，其能改善炎症，有效修复角膜上皮，减轻干眼相关的眼表损伤。
Highlights
UA, a natural small molecule compound, is therapeutic potential for DE.
UA maintains homeostasis in HCEs under hyperosmotic stress.
UA promotes recovery of damaged ocular surfaces, alleviating DE in vivo.
UA mitigates lacrimal and meibomian gland dysfunction associated with DE.
UA exerts therapeutic effects on DE via modulation of the EGFR/RAS/RAF/MAP2K1/MAPK1 signaling pathway.
Gut microbiota-bile acid metabolic disorder involved in the cognitive impairments in epilepsy through HO-1 dependent ferroptosis
Xinyu Li, Jia Ji, Jing Li, Saisai Li, Qiang Luo, Maosheng Gu, Xin Yin, Meng Zhang, Hongbin Fan, Ruiqin Yao
J. Pharm. Anal. 2025. 15(11) 101291
https://doi.org/10.1016/j.jpha.2025.101291
本研究系统阐明了肠道菌群-胆汁酸代谢紊乱在癫痫及其认知障碍中的重要作用。靶向代谢组学分析显示，癫痫患者血清与脑脊液中的脱氧胆酸（DCA）显著升高，并与认知受损密切相关。结合16S核糖体RNA（16S rRNA）测序及小鼠模型，研究者证实癫痫诱导的肠道菌群失衡会加重包括DCA在内的次级胆汁酸（SBAs）代谢紊乱。来自健康小鼠的粪菌移植（FMT）能够纠正菌群和胆汁酸失衡，明显降低癫痫发作强度并改善认知表现。机制研究显示，DCA激活法尼醇X受体（FXR），上调血红素加氧酶1（HO-1）表达，从而诱导海马神经元铁死亡，加重癫痫病理过程。本研究首次从“肠道菌群-胆汁酸-神经元铁死亡”视角阐明了癫痫进展机制，并提出了“DCA-FXR-HO-1”轴作为潜在治疗靶点，为癫痫精准干预提供了全新思路。
Highlights
DCA is elevated in serum and CSF of epilepsy patients and correlates with cognitive impairment.
Gut microbiota dysbiosis links bile acid metabolism to ferroptotic neuronal death in epilepsy.
DCA activates FXR/Nrf2-HO-1 signaling to promote ferroptosis and neuronal injury.
Targeting the DCA-FXR pathway may help treat epilepsy and cognitive deficits.
Short communications
Time-specific study on the efficacy of stems and leaves of Arachis hypogaea L. targeting glycine/serine metabolism for insomnia treatment
Yin Wang, Yuling Huang, Guohua Wang, Ting Jiang, Shuwen Geng, Hongzhan Xu, Tingting Zhou, Wenjing Zhang
J. Pharm. Anal. 2025. 15(11) 101288
https://doi.org/10.1016/j.jpha.2025.101288
失眠症发病率高，危害性强，已成为全球重要的公共卫生问题，亟需安全有效的治疗手段。在自然界中一些植物具有“昼开夜合”的特性，这与人类的昼夜节律相一致。根据中医“天人相应”理论，这些“昼开夜合”的植物可能可以治疗失眠。本研究对具有“昼开夜合”特性的花生枝叶（PSL）开展一系列实验，采用UPLC-Q-TOF/MS对PSL成分进行了定性定量分析，并通过腹腔注射对氯苯丙氨酸（PCPA）建立了失眠大鼠模型，研究了PSL抗失眠疗效的时间特异性。代谢组学和转录组学分析显示甘氨酸/丝氨酸代谢与失眠症密切相关，且不同时间点服用PSL对失眠症的疗效以及甘氨酸/丝氨酸代谢水平存在显著差异——睡前服用抗失眠疗效最佳。本研究对失眠的病理生理特点具有重要意义，为优化“昼开夜合”植物（如PSL）在失眠治疗中的给药时间提供了科学依据。
Highlights
The timing of administration affects the hypnotic efficacy of Arachis hypogaea L., which exhibits diurnal opening and nocturnal closing characteristics.
Glycine and serine are potential insomnia biomarkers, showing similar trends across species and samples.
Arachis hypogaea L. time-specific regulation of glycine metabolism in the treatment of insomnia provides new ideas for the use of similar traditional Chinese tranquillizing medicine.
A DPAL method for the identification of the synergistic target of drugs
Dongyao Wang, Yuxiao Tang, Na Li, Chenghua Wu, Jianxin Yang, Mengpu Wu, Feng Lu, Yifeng Chai, Chenqi Li, Hui Shen, Xin Dong, Changquan Ling
J. Pharm. Anal. 2025. 15(11) 101351
https://doi.org/10.1016/j.jpha.2025.101351
华蟾素注射液是治疗肝癌的常用中药提取物，其主要有效成分蟾毒灵（Bufalin,B）、华蟾酥毒基（Cinobufagin,C）与脂蟾毒配基（Resibufogenin,R）组成的BCR组合，展现出显著的协同抗肝癌效应。然而，这一协同作用的分子靶点长期不明。本研究创新性运用DNA编程亲和标记（DPAL）技术，通过多组学分析与功能验证，成功锁定磷脂酰肌醇5-磷酸4-激酶2A（PIP4K2A）为BCR组合的特异性协同靶点。研究证实，BCR组合可通过结合PIP4K2A抑制其酶活性，调控脂质代谢通路，进而诱导肝癌细胞凋亡；而敲除PIP4K2A后，BCR的协同抗癌效应完全消失。该成果不仅揭示了华蟾素注射液协同抗癌的核心机制，更为中药复方协同靶点的筛选提供了高灵敏度、低干扰的DPAL技术方案，为中西医结合抗癌药物的研发提供了重要理论支撑与技术借鉴。
Highlights
A highly sensitive, low interference DPAL method for identifying the synergistic targets of drugs.
PIP4K2A is the synergistic target of the combination of Bufalin, Cinobufagin, and Resibufogenin.
PIP4K2A mediates the anti-HCC effects of Bufalin, Cinobufagin, and Resibufogenin synergism.
Butyrate-based ionic liquid for improved oral bioavailability and synergistic anti-colorectal cancer activity of glycyrol
Ziyu Wang, Xingyue Shi, Yikang Shu, Ran Gao, Ting Sun, Mingyue Wu, Mingxin Dong, Weiguo Wu, Ruili Ma, Daoquan Tang, Min Ye, Shuai Ji
J. Pharm. Anal. 2025. 15(11) 101359
https://doi.org/10.1016/j.jpha.2025.101359
甘草酚具有显著的抗结肠癌活性，但由于溶解度差，其口服生物利用度较低。本研究报道了一种用于口服递送甘草酚且具有抗结肠癌活性的离子液体，旨在提高其生物利用度并实现协同抗癌效果。首先，以具有抗结肠癌活性的丁酸为阴离子合成了四种离子液体，通过筛选发现其中的甜菜碱丁酸盐（[BE][BA]）能够显著提高甘草酚的口服生物利用度。机理研究表明，[BE][BA]能够增加甘草酚的溶解度，同时通过抑制MRP2来降低甘草酚的外排，从而促进其跨细胞吸收转运。另一方面，甘草酚与[BE][BA]在体外协同促进结肠癌细胞的凋亡，同时在裸鼠移植瘤模型中也展现出协同抗结肠癌效果。本研究为难溶性药物或天然产物的口服递送提供了新思路。
Highlights
Four new edible ionic liquids using butyrate as the anion were synthesized.
[BE][BA] increased oral bioavailability of glycyrol and other same type of compounds.
[BE][BA] enhanced solubility of glycyrol.
[BE][BA] promoted glycyrol absorption transport by inhibiting MRP2-mediated efflux.
Glycyrol and [BE][BA] had synergetic anti-colorectal cancer effect in vitro/in vivo.
近期阅读：
Journal of Pharmaceutical Analysis 2025年第10期
文章推荐｜伦敦大学学院冯德超团队联合四川省人民医院熊玮教授发表综述文章：晚期前列腺癌的新型内分泌治疗：耐药机制解析与应对策略
期刊简介
Journal of Pharmaceutical Analysis（JPA,《药物分析学报（英文）》）创刊于2011年，由教育部主管，西安交通大学主办，是国内第一本有关药物分析的专业英文学术期刊，JPA 始终秉承服务国家重大战略需求、建设世界一流科技期刊的办刊宗旨，重点报道药物发现与药品全生命周期质量控制的新理论、新技术、新方法，临床精准用药，以及药物与生物、人工智能等交叉领域的技术方法方面的最新研究成果，为全球药物研发和药品质量控制提供高水平的国际学术交流平台，持续推动药物分析学科以及药学领域的快速发展。
JPA目前已组建一支以主编贺浪冲教授为核心的国际化的学术团队和专业的编辑出版团队，已实现编委国际化、稿源国际化、同行评议国际化、读者国际化和出版国际化。已被SCIE、PubMed、Scopus、DOAJ、中国科学引文数据库（CSCD）等多种重要国际和国内数据库和评价体系定为刊源。JPA连续7年入选“中国最具国际影响力学术期刊”。2019年入选“中国科技期刊卓越行动计划”重点期刊，2024年入选“中国科技期刊卓越行动计划二期”英文领军期刊。2024年影响因子 8.9，位于全球药理学和药学类学术期刊第14位（14/352），进入药学与药理学前4%，继续稳居于Q1区前列。2025年中科院1区，Top期刊。
收稿范围
药物分析新技术、新方法，分析药理学，药物代谢与递送，中药与天然药物，生物传感，可视化分析，生物功能分析，生物技术药物，药物分析装备，人工智能应用
收稿栏目
原创论文、综述、快报、展望、观点、新闻、社评等
期刊官网
https://www.journals.elsevier.com/journal-of-pharmaceutical-analysis
投稿网址
https://www.editorialmanager.com/jpa/Default.aspx
编辑 | 李 蕾
校对 | 朱丹丹
审核 | 王梦杰、马维娜
阅读原文
了解更多
100 项与 复方氨基酸 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 极低出生体重婴儿 | 美国 | 1984-07-20 | |
| 肝性脑病 | 美国 | 1982-08-03 | |
| 尿毒症 | 美国 | 1978-02-24 | |
| 营养紊乱 | 美国 | 1971-09-24 | |
| 营养不良 | 中国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 慢性肾病 estimated glomerular filtration rate | 812 | 鑰壓獵淵壓鑰蓋遞顧憲(簾襯淵鏇願醖願簾糧顧) = 襯廠膚選積網顧壓鹹襯 獵淵鏇鑰醖鑰蓋選壓鬱 (鬱醖膚選積鬱艱膚築鬱 ) 更多 | 积极 | 2025-05-01 | ||
(Placebo) | 鑰壓獵淵壓鑰蓋遞顧憲(簾襯淵鏇願醖願簾糧顧) = 窪淵憲襯糧淵遞鹽餘襯 獵淵鏇鑰醖鑰蓋選壓鬱 (鬱醖膚選積鬱艱膚築鬱 ) 更多 | ||||||
临床2期 | 39 | 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan+Amino Acids | 積觸淵醖範膚廠鏇製積 = 積壓願製獵艱襯簾範艱 鑰膚憲窪鏇網繭獵衊積 (鬱觸積構蓋襯遞膚衊鏇, 願遞遞顧醖願繭構膚遞 ~ 醖壓築淵遞艱構觸鑰鏇) 更多 | - | 2023-02-09 | ||
N/A | 168 | (Standard Amino Acids) | 範壓醖鑰壓壓觸願觸壓 = 鹹積選醖範艱襯鹹繭廠 鬱獵窪醖鹹製糧構襯選 (築製鏇遞蓋繭艱網淵糧, 鏇醖構醖顧鹹窪遞鑰遞 ~ 獵夢憲積顧鹽構廠壓鏇) 更多 | - | 2017-04-10 | ||
(High Amino Acids) | 範壓醖鑰壓壓觸願觸壓 = 顧顧顧壓鏇鏇鹽鏇鹹壓 鬱獵窪醖鹹製糧構襯選 (築製鏇遞蓋繭艱網淵糧, 遞範鹽鏇壓願齋選窪憲 ~ 築觸淵壓鑰願觸夢衊廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用